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                                                                                    Abstract 
The biopharmaceutical industry is a multi-billion dollar global market with projections that within the 
next 5 to 10 years, up to 50% of all drugs in development will be biopharmaceuticals. The majority of 
these drugs are recombinantly produced protein based therapeutics with the demand for such new 
therapeutic products continuing to increase, broadening the range of medical conditions that they 
are being used to treat. Chinese hamster ovary (CHO) cells are the preferred and most commonly 
used system for large scale production of recombinant glycoproteins for therapeutic use due to their 
ability to perform complex human-like post-translational modifications required for biological 
activity. CHO cells also display robust growth, high productivity and stability, attributes that have 
enabled them to become widely used. Whilst there have been large increases in the yield and quality 
of recombinant protein that can be obtained from mammalian expression systems over the years, 
particularly CHO cells, many recombinant proteins remain difficult to express in CHO cells or any 
other system. Many of these proteins are highly complex, highly glycosylated, large and unstable 
proteins. As such, there remains a need to develop CHO cell systems that are able to produce such 
difficult to express proteins rapidly in higher yield and quality. The endoplasmic reticulum (ER) is a 
key compartment in the secretory pathway of mammalian cells and during the production of 
recombinant proteins in CHO cells this has reportedly been a potential bottleneck and site of 
perceived cellular stress as a result of the load imposed on the cell by the recombinant protein.  
This study has investigated two sterol reductases; Transmembrane 7 Superfamily member 2 
(TM7SF2) and 7-dehydrocholesterol reductase (DHCR7). ER resident proteins involved in the 
biosynthesis of  cholesterol that have been reported to influence endoplasmic reticulum (ER) and 
nuclear envelope (NE) expansion when over-expressed in mammalian cell lines. The work described 
here therefore set out to determine whether overexpression of these sterol reductases could 
enhance the secretory capacity of CHO cells by expansion of the ER and hence lead to increased yields 
of difficult to express recombinant proteins compared to those cells where these were not over-
expressed. The TM7SF2 and DHCR7 genes were cloned into a mammalian expression vector with a 
hygromycin selection marker to allow for the selection of stable cell lines where the genes had been 
integrated into the genome. Stable CHO cells overexpressing TM7SF2 and DHCR7 were generated to 
assess the impact on cell growth and stable and transient recombinant protein expression, monitored 
using western blot techniques and microscopy analysis. Control cell lines over-expressing GFP (but 




expression levels of the sterol reductases were determined in heterogeneous pools and then used 
for limited dilution cloning to isolate clonal cell lines with differing sterol reductase expression which 
were further investigated. Growth profile assays were undertaken to monitor any toxicity effect of 
over-expression of TM7SF2 and DHCR7 on CHO cells. Transient expression studies of the recombinant 
bio therapeutic protein etanercept, a 150 kDa biomolecule and erythropoietin (EPO), a 36 kDa 
recombinant protein, were carried out to investigate the production capacity of lipid engineered CHO 
cells with reference to controls. Immunocytolocalisation studies were also undertaken to investigate 
pools and clones of lipid targets predicted to be ER-localized or associated. A YFP tag was present on 
the N-terminal of TM7SF2 and DHCR7 molecules and was used to monitor expression by fluorescence 
in stable CHO cells. 
The data from these experiments show that both TM7SF2 and DHCR7 engineered CHO cells had 
improved cell growth and culture viability over the course of 10-day experimental study compared 
to the control cells. Western blot studies showed that both TM7SF2 and DHCR7 could be stably over-
expressed in CHO cells and the amount of expression varied among the generated clones. Further, 
the high expressers of TM7SF2 and DHCR7 were identified and investigated for EPO and etanercept 
production and expression levels of these recombinant biomolecules were observed to be 
proportional to the levels of TM7SF2 and DHCR7 expressions in CHO cells. More importantly, TM7SF2 
and DHCR7 engineered cells showed increased expression levels of these recombinant products 
when compared with pcDNA3.1Hygro controls as determined by western blot analysis of the amount 
of secreted recombinant target protein in the cell culture supernatant.  Confocal images also showed 
clones expressed different levels of YFP signal which related to expression levels observed when 
western blot techniques were used.  In summary, the data presented here shows that the 
manipulation of cellular circuits such as cholesterol biosynthesis has the potential to enhance cellular 
growth and recombinant protein yield. By designing new hosts and cellular circuits to reprogramme 
the CHO cell ER there is the potential of expanding the secretory capacity and/or subsequent 











1.0     Introduction 
 
1.1       Recombinant Bio therapeutic Proteins and the Biopharmaceutical Industry 
According to Allied Market Research, 2018, the sales of US $186 billion worth of biopharmaceuticals 
as at 2017 following an approximate 10% annual growth rate (CAGR) having been valued at US $162 
billion in 2014 shows a continuous impressive growth that reflects new opportunities in 
biopharmaceuticals over the past decade. The global biopharmaceuticals market is projected to 
reach US $526 billion by 2025, growing at a CAGR of 13.8% from 2018 to 2025 (Owczarek & 
Gerszberg, 2019). The discovery of recombinant DNA and monoclonal antibody technologies in the 
1970s marked the birth of the biopharmaceutical industry by production of recombinant proteins.  
The term biopharmaceuticals was coined in the 1980s and refers to pharmaceuticals of a protein 
based nature produced in living cells utilising biotechnological processes and when recombinantly 
produced using molecular biology methods. These protein-based drugs are increasingly being used 
in practically all branches of medicine and have become one of the most effective clinical treatment 
modalities for a broad range of diseases, including cancers and metabolic disorders (Kesik-
brodacka, 2017). Biopharmaceuticals are mostly therapeutic recombinant proteins obtained by 
biotechnological processes, termed bioprocessing.  
According to Faustino et al., (2016)  it is predicted that within the next 5 to 10 years up to 50% of 
all drugs in development will be biopharmaceuticals. So far, recombinant proteins, including 
monoclonal antibodies (mAbs) have been the top targets and low hanging fruit for 
biopharmaceutical drug production. The market continues to grow (Figure 1.1). Biopharmaceuticals 
are derived from biological sources such as organs and tissues, microorganisms, animal fluids, or 
genetically modified cells and organisms (Faustino et al., 2016) with an ongoing increase in the 
number of the recombinant proteins produced in mammalian expression platforms (Lalonde & 
Durocher, 2017). In essence, the biopharmaceutical industry is by far the fastest-growing sector of 














Figure 1.1   The progression rate for recombinant protein and monoclonal antibody production 
from 1995 till 2016. There continues to be a notable increase in demand and production. 
Advances in genetic information and associated technologies make it possible for 
interdisciplinary start-up companies to perform effective bio drug discovery activities. 
Monoclonal antibodies have constituted an ever increasing proportion of biopharmaceutical 
drug sales since the year 2000. Source: Evaluate Pharma and Gene Techno Science. 
 
1.1.1      Protein-Based Therapeutics   
As described in the section above, the demand for new therapeutic products is continuously 
increasing in order to broaden the range of medical conditions that are being treated (Marie, 2018). 
Protein therapeutics (including monoclonal antibodies, peptides and recombinant proteins) 
represent the largest group of new products in development by the biopharmaceutical industry 
(Dumont et al., 2016).  
 
Biologics are a rapidly growing segment of the pharmaceutical market with a steady entry of 
traditional large pharmaceutical companies into this space. Generally, biologics are considered as 
substances that are derived from living organisms (such as humans, animals). However, they are 
carefully defined as substances produced in cell culture using recombinant technologies including 





Common examples of biologics include proteins; fusion proteins and monoclonal antibodies as well 
as conjugated proteins. Others include altered proteins while antibody–drug conjugates are  recent 
additions to this group (Kishnani & Squibb 2012). Without doubt, therapeutic proteins are 
becoming increasingly important as they typically possess low adverse effects and higher specificity 
compared to the traditional, small molecule drugs. Unfortunately, the high costs of therapeutic 
protein place a heavy financial burden on the healthcare system and limit the number of patients 
that are able to be covered (Kaida-Yip et al., 2018). The World Health Organization (WHO), in part 
of its guidelines, on the evaluation of similar bio therapeutic products, defines a biosimilar as a bio 
therapeutic product that is similar in terms of quality, safety and efficacy to an already licensed 
reference product. Such biosimilars include growth hormone, erythropoietin, etanercept and 
monoclonal antibodies for the treatment of several diseases.  
 
Many of these bio therapeutic products are complex and involve different intricate and expensive 
development (Lundqvist & Högskolan, 2018). This is so, as most of the established blockbusters face 
stiff competition from biosimilars, which put more pressure on cost effectiveness in manufacturing 
processes (Zobel-Roos et al., 2019) as modern industrial production of recombinant proteins in 
mammalian hosts is challenged by technology, regulatory and market changes and these revolve 
around factors such as productivity efficiency, quality of bio therapeutics and the resulting cost of 
production (Figure 1.2)  (Bielser et al., 2018).   
 
There is a strong relationship between the manufacturing process and characteristics of the final 
biosimilar (Mellstedt et al., 2008). According to Amgen Biosimilars, 2017, a small change in 
manufacturing can result in altered protein stability as well as impact post-translational 
modifications such as glycosylation hence it is therefore critical that appropriate safeguards be 
established to protect patients. Process Analytical Technology (PAT) is a key-enabling technology 
for quality-by-design (QbD) process development approaches  such as bioprocess monitoring for 
product safety and this entails process variables such as (viable) cell, substrate, metabolite, and 
product concentration, as well as product quality and impurities (Kornecki et al., 2019). However, 
the main concerns raised regarding biosimilars are immunogenicity, efficacy, adverse effects when 






                          Figure 1.2 Presentation showing successful continuous bio therapeutic protein production 
revolves around productivity capacity, bio therapeutic protein quality and price of 
production. Some of the critical parameters to consider for continuous processing as a 
method of choice for sensitive and complex biologicals. S. R. Schmidt (2017)  
 
As evidenced in the number of successful treatments which have been documented over the years, 
bio therapeutic proteins have become an important area of pharmaceutical research with several 
advantages over small biomolecule drugs which include their higher specificity as well as limited 
adverse effects. The technologies behind their production have changed substantially since bio 
therapeutic proteins were first approved in the 1980s (Dumont et al., 2016).  
 
The advancement through the establishment of recombinant production for therapeutic proteins 
was a ground-breaking achievement in the field where living cells are utilised as host systems for 
protein production. This allows the production of large quantities of human proteins in a controlled 
environment. This has improved the ability to make such molecules and have helped gain access to 
these life-changing treatments. However, the development and production of therapeutic proteins 
can be too expensive in many countries to offer access to such medicines. Perhaps, the 
heterogeneity of bio therapeutics from groups of proteins allows structures to be sensitive both to 
the inherent variability of the protein production or expression system, and ultimately to changes 
in manufacturing processes. Many of these protein products are relatively large, complex entities 
and therefore are more difficult to characterize than chemical drugs which are simpler (Kang & 




In the production of biopharmaceuticals, a traditional biopharmaceutical manufacturing system 
consists of a similar sequence of unit operations that are divided into two main parts: upstream and 
downstream. The upstream process (USP) is the entire process from early cell isolation and 
cultivation, to cell banking and culture expansion of the cells until final harvest whereas the 
downstream process (DSP) refers to the part where the cell mass from the upstream are processed 
to meet purity and quality requirements. The increasing productivity in cell culture of recombinant 
proteins has led to the investigation of alternate methodologies to boost downstream process 
productivity as the continuous increase of upstream process productivity continues to place 
bottlenecks in downstream production processing (Shukla et al., 2017).   
 
Although downstream steps might reach 50  – 80% of the total production costs of proteins, the 
best step combination can result in significant enhancement in terms of purification and process 
economy (Lopes et al., 2017) more so, as process development for protein therapeutics is 
increasingly dependent on high-throughput (HT) technologies to accelerate the screening of many 
conditions and the optimisation of cell culture process outputs (Rouiller et al., 2013).  However, 
there has been a conscious effort to understand the relationship between the upstream and 
downstream production processes of recombinant proteins as Upstream processes at low 
productivity is more costly than downstream processes (Gupta et al., 2017). Stages involved in 
upstream scale processes include cell culturing, process optimisation, recovery purification, 
formulation delivery while scale-up, manufacturing/ process monitoring, quality control/ analytical 
(Figure 1.3).  
 
The inherent complexity of biological molecules and processes has been reported to create 
challenges for the application of process analytical technology (PAT) to biopharmaceutical 
manufacturing (Hong et al., 2018) which in turn affects the production processes of bio 
therapeutics, however, the availability of various expression systems such as Chinese Hamster 
Ovary cells (CHO) as appropriate host may aid high level of protein expression (Gupta et al., 2017). 
Process analytical technology is the development of instrumentation for real-time, continuous 
analysis of manufacturing processes and involves use of mathematical modelling (chemometrics) 





Figure 1.3   Schematics showing processes involved in upstream and downstream -
processing. The bottleneck in downstream processing requires new optimisation, technology 
and development approaches. The optimisation and adaptation vary with every new 
separation task as development focuses on yield and productivity as well as on purity and 
process capacities. The various optimisation areas are shown and these are optimised 
individually with the aim of producing a robust generation of a high product titre, high 
productivity and defined quality. Source: Emzo Life Sciences. 
 
Demands for biologics will continue to increase in the coming decades and in identifying the 
challenges of downstream and upstream production processes, bottlenecks involved with 
innovative technologies must be addressed. According to a review by (Strube et al., 2014), 
engineering concepts like modularisation and standardisation methods for speeding up process 
design and filing for regulatory approval must be investigated in an attempt to address the 
challenges of efficient engineering and production and this is applicable for therapeutic drug 
production. Some of the strategies proposed for optimisation processes in order to address 
improved capacity therapeutic drug production include: modelling with a Quality by Design (QbD) 
approach for a successful and economical process development, advancement of process 
automation for formulation, continuous production processing with intensification so as to reduce 
economical production and the use of single-use systems in upstream and downstream processes 
(Gronemeyer et al., 2014). The QbD approach is recent trend in analytical method development 
and its helps a lot if properly implemented as the approach suggests looking into the quality of 
analytical process during the development stage itself rather than testing into final results of 
analytical process (Pande et al., 2017) and for an efficient QbD, processes such as quality target 
product information, product and process design, control strategy and continuous improvement 


















1.2 Host cell physiology and its engineering for therapeutic protein production 
The knowledge of the physiology of the host cell is very important and complementary to the genetic 
engineering for increasing the specific production rates of a desired product. It should also be closely 
relevant to the bioprocess design and bioprocess engineering which requires a deep understanding 
of the host cell physiology (Xavier Garcia, 2015).  Due to the advances in protein engineering and cell 
line development, recombinant proteins can be produced in different living standard systems and 
the type of cell that is best suited as factory depends on the complexity of the protein that will be 
produced (Lundqvist & Högskolan, 2018). Expression systems such as mammalian cells, Pichia 
pastoris, Aspergillus niger, and Escherichia coli have been widely used to express recombinant bio 
therapeutic proteins (Peña et al., 2018), whilst other alternatives such as plant and insect cells have 
also been investigated or used (Dumont et al., 2016). 
 
Figure 1.4 Systematics showing the Implementation of Quality by design (QbD) approach for 
the production of therapeutic drugs.  The production of therapeutic protein drugs occurs in a 
systematic manner which allows both upstream and downstream processes to be optimised 
for desired production capacity. Such optimisation involves an implementation of the Quality 
by design (QbD) approach in both the processes for consistency in the continuous process 
involving high through-put technology for analytical techniques involving production as well 




1.2.1    E. coli cells 
E. coli has been a lab-favourite for expression of recombinant proteins for decades. It became popular 
because it was easy to work with and as a consequence, it is now possibly the most well-understood 
organism on the planet (Lundqvist & Högskolan, 2018). Without a doubt, E. coli is the most widely 
used host for heterologous gene expression across all scales and uses. It has been used for this 
purpose for more than 40 years, so there is much accumulated knowledge about its advantages and 
disadvantages as an expression platform (Rosano & Ceccarelli, 2014). However, there are limitations 
to the use of E.coli for recombinant protein production destined as a biological therapeutic drug in 
humans. For proteins used in treatment, it is often not the best choice.  
 
Large and complex proteins, such as the commonly used monoclonal antibodies, require the 
appropriate environment and enzymes to be correctly folded and receive the necessary post-
translational modifications (PTMs) (Dalton & Barton, 2014). E.coli cells do not have the cellular 
machinery for undertaking many of the required functional post-translational protein modifications 
on bio therapeutic protein drugs, such as glycosylation or phosphorylation. Again, the problem of 
insolubility when using proteins expressed within E.coli, because proteins are not folded correctly, 
remains a challenge. While eukaryotic expression systems favour these needs, E.coli remains most 
suitable for the production of small and less complicated proteins such as insulin (Lundqvist & 
Högskolan, 2018). 
 
1.2.2   Yeast cells 
Yeasts are inexpensive systems to culture with qualities such as easy manipulation and cultivation. 
They share many biological processes with mammalian cells such as the ability to perform various 
PTMs, and are therefore more capable when it comes to correctly folding and secreting complex 
proteins (Wells & Robinson, 2017). However, the glycosylations that occur in yeasts are quite 
different from those that are carried out in mammalian cells. Saccharomyces cerevisiae (baker’s 
yeast) has traditionally been the most commonly used yeast for recombinant protein production, but 
strains from the Pichia genus have recently seen an increase in popularity (Mattanovich et al., 2014). 
As a host organism, yeast has been used to produce a wide variety of products including sterols, 
terpenoids, lactic acid, citric acid, alcohols, sugar derivatives, organic and fatty acids, terpenes, 




However, the major limiting factors of yeasts on protein processing such as folding, assembly, 
performance of PTMs and secretions are well documented.  
 
1.2.3 Mammalian cells as the preferred expression system 
The most preferred platform for expression of the widest range of biopharmaceuticals, including 
antibodies, has been mammalian cells. This is largely attributed to their ability to produce large 
volumes of therapeutic antibodies with the required folding, assembly and PTMs and adaptability in 
large-scale production systems (Kunert & Reinhart, 2016). Mammalian cells from various species such 
as human, hamster, monkey and mouse have been well studied. Further, advances in cell engineering 
make it more convenient to engineer the mammalian cells (Dangi et al., 2018). Of these, the most 
commonly used cell lines for the production of therapeutic proteins are Chinese hamster ovary cells 
(CHO) and murine myeloma cells, and these rodent cell lines have glycosylation patterns that are 
similar to humans (Wells & Robinson, 2017).  
 
Close to 70 % of all therapeutic proteins are produced in CHO cells (Kim et al., 2012) and these cells 
provide high protein yields and are tolerant to changes and fluctuations (e.g. pH, oxygen, pressure, 
and temperature) during the manufacturing process. Additionally, by becoming a choice of 
expression system early on, CHO cell lines is now benefitting from a notable knowledge base. One 
might expect that human cell lines should be the preferred choice of expression system as these 
would provide true human PTMs (Lundqvist & Högskolan, 2018) and although, HEK cells (human 
embryonic kidney cells) are the most widely used system, as these cells have shown efficient 
production in laboratory scale, the application of human cell lines for commercial manufacturing, 
however, remains limited. This is not without the regulatory hurdles, such as the lack of species 
barrier which allows easier transfer of adventitious agents making conferring a major limitation on 
human cell lines. As such, infections with full-blown pathogenic effect in human cells will be easy to 
detect, whereas such agent may be dormant in rodent cells (Swiech et al., 2012). However, CHO cells 
have been demonstrated to display reduced susceptibility to human viral infections which represent 
an additional advantage over other cell lines of human origin (Dumont et al., 2016).  
 
Table 1.1 presents some properties of different mammalian cell lines as reported in literature and 




therapeutic drug production. Human Embryonic Kidney (HEK) cells, originate from neuronal fetal 
kidney cell as against the initial report that it originated from an endothelial, epithelial or fibroblastic 
cell of the fetal kidney have proven to be popular and easy to culture and sequencing studies have 
shown that these cells have a very complicated karyotype with multiple copies of chromosomes as 
they have four copies of chromosome 17 with no single Y chromosome (Simmons, 2019). With the 
rising demand for bio therapeutics as many biopharmaceutical drugs are reaching later stage clinical 
trials, most bio therapeutic drugs which are widely produced in mammalian cell lines for improved 
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Table 1.1   General characteristics and genomic information of some mammalian 




1.3 Chinese Hamster Ovary Cells as an Expression System 
Chinese hamsters (scientific name, Cricetulus griseus) belong to a family of rodents that are native to 
the desert of northern China and Mongolia and have been used in life-saving biomedical research 
ever since they were first introduced in the laboratory in 1919 for typing pneumococci (Jayapal et al., 
2007). The original Chinese Hamster Ovary Cell line was derived from a female Chinese hamster by 
Theodore Puck in 1957 which he obtained from Dr. George Yerganian's laboratory at the Boston 
Cancer Research Foundation. Theodore Puck first found that a cell line of near diploid karyotype 
could be generated with relative ease, from a trypsinised sample of ovarian tissue from Chinese 
hamsters and also that this cell line was able to grow for months without showing signs of 
senescence, which are normally seen in cell lines derived from humans (Kaas, 2015). With a  culture 
history of more than 60 years,  CHO cell populations have been handled by a number of laboratories 
and have therefore been passed to many researchers in the field with many names generated that 
are not popular anymore   (Wurm & Wurm, 2017). Hence, different lineages of CHO cell line from the 
original (CHO-ori) have been derived such as the pro3-, K1, DX B11, DG 44, CHO variant (from which 
the CHO-S is derived) amongst others, always with the prefix CHO.  
 
Literature studies have reported how that Scientists did not give up trying to domesticate and breed 
Chinese hamsters as they recognized that the hamster was an exceptionally useful animal model for 
genetic research and that although the CHO-ori cells, described as hardy, very well growing and fast 
in adherent culture had a high cloning efficiency, even at very low fetal bovine serum concentrations 
in the culture media there was a need for the addition of proline to the culture media at that time, a 
nutritional requirement for all CHO cell lines in use today as the loss or inactivation of proline 
synthesis was an early event in the history of these cells (Wurm, 2013).  Figure 1.5 shows the pattern 
of consistent derivation of variants from the original CHO cell line. Nearly ten years after the CHO-K1 
(first derivative) cell line was generated from this ancestral host (CHO-ori), many others have also 
been derived based on requirement needed in such cell lines.  
 
For instance, to facilitate the creation of stable cell lines producing a gene of interest, a selection 
system was needed thus resulting in the creation of CHO DXB11 cell line with a DHFR negative 
phenotype as Dihydrofolate reductase (DHFR) can catalyse the conversion of dihydrofolic acid to 
tetrahydrofolic acid – an essential cofactor carrier (Kaas et al., 2015), these needs have continued to 




cells were passed on from Thompson and/or Gottesman, to Dr R. A. Tobey’s laboratory at the Los 
Alamos National Laboratory, New Mexico and then to a company interested in growing and 
eventually commercially using such cells, a major advantage in the use of these cells is their capacity 





Figure 1.5   Representation showing the lineage of CHO. With a culture history of more 
than 50 years, CHO cell populations have been handled by a number of laboratories and 
passed to many researchers in the field. While some names may not be popular 
anymore, others are still in use today. These include; K1, DXB11, S, DG 44 cells named 
with prefix CHO. Adapted from Wurm & Wurm (2017).   
 
The approval of CHO-derived tissue plasminogen activator (tPA) in 1986 led to an era of 
revolutionized medicine which subsequently promoted the possibility of using mammalian cell 
culture for the manufacturing of protein therapeutic products (Lai et al., 2013). As the preferred 




to be readily transfected and perform complex human-like post-translational modifications. These 
cells have several other major advantages over other cell expression systems. For instance, CHO 
cells are able to grow in suspension culture (which enables large-scale production), they exhibit 
robust growth, high productivity and stability which allows for consistency in the bioprocesses 
during the production of biologic drugs (Roy et al., 2018). Also, an optimised CHO host cell could 
include features such as better growth, no cell aggregation, more efficient metabolism like reduced 
lactate production, increased tolerance to culture (Gadgil, 2017). Hence, they have become the 
primary production host for therapeutic proteins, producing seven out of the top ten bestselling 
therapeutic proteins from 2016 (Kesik-Brodacka, 2017). 
 
Recombinant glycosylated proteins, particularly monoclonal antibodies, hormones, blood-related 
proteins have been produced in Chinese hamster ovary (CHO) cells. Examples of products expressed 
in CHO cells include erythropoietin (EPO), indicated for the treatment of severe anaemia, 
coagulation factors as Factor IX, used as a therapeutic in haemophilia, interferon used for treating 
multiple sclerosis and monoclonal antibodies (mABs) for treating Crohn’s disease, different 
lymphomas and cancers (Pereira et al., 2018). Generally, there has been tremendous and steady 
improvement since the first use of CHO cells for recombinant protein expression areas such as 
production processes, optimisation of basal media, screening and isolation as well as enhanced 
monitoring and control of processes including feed supplements. 
 
One limitation of the Chinese hamster ovary system until recently was the lack of a Chinese hamster 
genome. Hammond et al., 2011 had reported that there was little genomic sequence data available 
for CHO cells and that it limited the application of high throughput molecular tools in gene discovery 
and cell line engineering. Recently the CHO genome was elucidated, providing high-level 
information about cell function (Heffner 2017) and this has secured the CHO cell as a tool for 
industrial applications and manipulations with the potential to develop new CHO cell hosts that 
could be tailored for the synthesis of specific protein needs, in particular difficult to express 
proteins. Hence, the publication of the Chinese Hamster (CH) genome (and that of various CHO cell 
lines), ushered scientists into a new era for the production of biopharmaceuticals (Hefzi et al., 2016). 
For example, it is now known that the genomes of some cell lines derived from CHO-K1 over the 
past few decades contain large-scale rearrangements and that even clonal populations are known 




1.3.1.       Recombinant Protein Production in Mammalian Cells 
The ability to produce recombinant proteins by utilising different cell factories revolutionised the bio 
therapeutic and pharmaceutical industry, and consequently influenced health care operations 
worldwide (Owczarek & Gerszberg, 2019).  As there is a continuous increase in the number of 
biologics entering the development pipelines of pharmaceutical companies, CHO cells have been the 
preferred production host for therapeutic proteins (Sou et al., 2018).  Indeed, recombinant protein 
therapeutics have become important components of the modern medicine (Bandaranayake & Almo, 
2014).   
 
With the multiple expression host system generated from mammalian cells of different species, there 
is therefore the capacity to function in a reliable and predictable expression system of large numbers 
of transgenes for a wide range of scientific, industrial and therapeutic applications through improved 
recombinant protein production for prevailing health issues such as cancer and autoimmune 
diseases. As hundreds of recombinant protein therapeutics have been approved by the United States 
Food and Drug Administration (FDA), there is a rapid increase over the last 10 – 15 years in the 
production of recombinant protein with a total of around 90 now in use for treatment and diagnostic 
purposes (Kinch, 2015). Production of these proteins have involved several approaches such as 
improving metabolism, glycosylation, anti-apoptosis and pro-proliferation, molecular chaperones, 
and protein folding have been successfully implemented (Inwood et al., 2018).  
 
Aside diagnostic and therapeutic applications (Jozala et al., 2016), the use of mammalian cells for 
smart materials that have also been reported (Hollingshead et al., 2017). Smart materials have 
properties that react to changes in their environment. This means that one of their properties can be 
changed in a controlled fashion by external way stimuli or condition such as stress, temperature, 
moisture, pH, light, pressure or electricity. This change is reversible and therefore can be repeated 
many times. Improving recombinant protein expression from CHO cells remains a priority in the area 
and continuing efforts are being devoted to this since the first therapeutic protein, human tissue 








1.3.2       Difficult-to-Express Recombinant Proteins 
 
Despite the increased yield of recombinant proteins produced from mammalian expression systems, 
particularly CHO cells, many recombinant proteins remain difficult to express in CHO cells or other 
systems. The term “Difficult-to-express” is used to refer to recombinant proteins generally 
considered to be expressed at low titres or quality from mammalian or other expression systems. 
Many of these difficult to express‘‘ (DTE) engineered proteins, such as fusion proteins and bispecific 
antibodies, have begun to fill the development pipelines of many biopharmaceutical companies 
compared to natural protein formats (Johari 2015). As many of these include the highly complex, 
highly glycosylated, large and unstable proteins, many difficult-to-express proteins require a 
consistent, homeostatic environment for maximised productivity.  
 
Cell lines producing low protein titres can require long-term production to express enough product 
to reach required yields. These proteins cover various types of membrane proteins, including ion 
channels, multi-pass membrane proteins as well as proteins that exhibit cytotoxic effects on the host 
cell during overexpression (Thoring et al., 2016). They do not emerge in fully soluble, well-folded, and 
active form in a heterologous expression system and cell culture processes can also affect product 
quality, especially in the area of glycosylation and post-translational modifications. More relevant for 
the work here, many of the antibody inspired molecules such as bispecifics and antibody fragments, 
fusion proteins containing section of antibodies and domain antibodies that are in development as 
therapeutic molecules are proving difficult to express in CHO expression systems optimised for 
antibody expression. In order for such molecules to be tested in the clinic and be evaluated it will 
therefore be necessary to further develop expression systems that can provide the required amounts 
of these molecules, at a suitable quality.  
 
With regard to bio therapeutic proteins, new formats or novel proteins that could be very beneficial 
for the treatment of diseases, often diseases with no current treatment options, are also proving 
difficult to express. These include; TNF Fusion Proteins, Mut-F Recombinant Protein, GM-CSF Fusion 
Protein, HC3 Recombinant Protein and others. For the scope of this project however, we have used 






1.3.2.1    TNF Fusion Proteins 
Both the Tumor necrosis factor superfamily (TNFSF) proteins and their receptors (TNFRSF) play 
critical roles in mammalian biology, including cell growth, survival, and apoptosis, immune responses, 
and organogenesis of the immune, ectodermal, and nervous systems as the binding of the tumor 
necrosis factor α (TNFα) to its cognate receptor initiates many immune and inflammatory processes 
(Lim & Lee, 2018). The focus on developments that will enhance recombinant proteins and 
monoclonal antibodies (mAbs) in mammalian cells in the recent years, has been on three broad areas: 
cancer, infectious diseases and immunological disorders. TNF as a signalling molecule controls 
intercellular communication that mediates inflammation, apoptosis, immunoregulation, and cellular 
proliferation/differentiation as its  main role is in the induction of inflammation and immunity 
through activating immune cells in reaction to infections and tissue injury (Korani et al., 2019,).  
 
 It also functions in many normal physiological functions that cut across antimicrobial immunity as 
well as in homeostasis and health. Fc-fusion proteins are one of the most intensively investigated, of 
the proteins that target TNF. The fused partners attached to an Fc-domain have significant 
therapeutic potential, and the Fc domain contributes additional beneficial pharmacological 
properties (Chiang et al., 2014).  As at 2017, there were five TNF-α antibodies approved by the US 
Food and Drug Administration (FDA) for clinical applications on the market either chimeric, 
humanized, or fully human (i.e., etanercept, infliximab, adalimumab, certolizumab and golimumab) 
(Iz et al., 2018). Many of the commercial TNF antagonists comprise of engineered monoclonal 
antibodies and fusion proteins reported to have successfully been used for the treatment of a 
number of chronic inflammatory diseases including psoriasis (Balabashin et al., 2015). 
 
However, TNF is not without its challenges for therapeutic intervention. These include the need to 
pre-identify anti-TNF treatment responders, the need to specifically target selected TNF producing 
cells or individual tissue targets, and also the need to discover and produce orally delivered small 
molecule TNF-inhibitors (Sedger & Mcdermott, 2014). In this project, focus was on etanercept, as 
model difficult to express molecule whereby difficulty of expression of the Fc-fusion protein impacts 






1.3.3    Etanercept as a model for expression studies 
In the early 1990s, Bruce A. Beutler, an academic researcher at the University of Texas South-western 
Medical Centre, Dallas and his colleagues first reported that the prototypic fusion protein, 
etanercept, produced by recombinant DNA, when synthesized was highly active and unusually stable 
as a modality for blockade of TNF in vivo. Etanercept is a soluble protein that binds to and specifically 
inhibits, tumor necrosis factor (TNF), a pro-inflammatory cytokine (Hassett et al., 2018). As the only 
TNF blocker commercially available consisting in a fusion protein combining two extracellular ligand-
binding portions of the human soluble TNF receptor p75 with the end Fc fragment of human 
immunoglobulin G1 (Figure 1.6) (Marotte & Cimaz, 2014), it was the first approved biologic disease-
modifying anti-rheumatic drug and allowed for a major advance in the treatment of rheumatoid 
arthritis (Emery et al., 2017) which is used in the treatment of medical conditions such as adult and 
juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis and spondylitis.  
 
The mechanism of action of etanercept is via binding to TNF, competitively inhibiting TNF from 
binding to cell receptors and preventing pathway activation. The dimeric structure allows the 
molecule to bind to two TNF molecules at an affinity more than 50 times that of naturally occurring 
monomeric forms (Chadwick et al., 2018). This fully human, soluble, dimeric fusion protein has a total 
of 934 amino acid residues with a molecular weight of 150 kDa (Hassett et al., 2018).  As such, this 
heavily glycosylated molecule with both N- and O-linked oligosaccharides, potentially influences the 
structure, activity, signalling, clearance and immunogenicity of such glycosylated proteins (Hassett et 
al., 2018) making the size and complexity of etanercept present an exceptional challenge for 
companies aiming to produce follow on biosimilar products, which must comprise highly similar 
structural and functional properties and exhibit no clinically meaningful differences to the original 












                                                                     






Figure 1.6    Structure of Etanercept. Etanercept is a fusion protein with the TNF receptor 
extracellular domain and the Fc portion of a human IgG1. Its dimeric structure allows it to 
bind up to two TNF molecules and functions as a TNF inhibitor by competitively binding 
to TNF and preventing its activation of the inflammatory cascade.  (A) Overview of the 
structure of Etanercept shows two naturally occurring soluble human 75-kilodalton TNF 
receptors linked to an Fc portion of an IgG1. (B) Chemical structure of Etanercept shows 
the linkage of the Fc portion of human immunoglobulin G1 (IgG1) by three pairs of 
disulfide bridges to the extracellular ligand-binding domains of the Receptor region. 
 
 
1.4       Erythropoietin (EPO) 
In 1948, haemopoietin was first discovered in patients with high red blood cell counts living at high 
altitudes. The name “erythropoietin” (first mentioned by Bonsdorff and Jalavisto) arose from its 
functional implication in the generation of red blood cells (erythrocytes) for improved tissue oxygen 
supply (Ostrowski & Heinrich, 2018). For over three decades, recombinant human erythropoietin 
(rhEPO) has been used in the treatment of anemia. EPO is mainly produced in the kidney that raises 
blood haemoglobin mass by anti-apoptotic effects on erythroid progenitor cells in the bone marrow 
(Aachmann-andersen et al., 2018). Therefore, the administration of EPO as a therapeutic is known to 
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EPO has three N-linked complex oligosaccharides attached to asparagine side chains at positions 24, 
38 and 83, and a short O-linked oligosaccharide at serine 126 (Lee et al., 2019). The human 
erythropoietin which are expressed in mammalian cells, contain substantial amounts of 
heterogeneous, complex-type oligosaccharide (Čaval et al., 2018), Figure 1.7. The present 
therapeutic recombinant EPO preparations are manufactured in mammalian host cells as EPO is a 
complex glycoprotein of 165 amino acids to which four glycans are attached.  
 
Advances in recombinant EPO (rhEPO) production are classified into three types: the development 
of improved rhEPO molecules by protein engineering; improvement of production host cells by 
genetic engineering; and culture condition optimisation by fine control of the production 
mode/system, process parameters and culture media (Lee et al., 2012). A publication comprising a 
list of over thirty erythropoietin based therapeutics approved in the US and EU for the treatment of 
anemia (see link; www.fda.com and www.ema.eu). With the approval of erythropoietin based 
therapeutics, rhEPO became a leading drug for treatment of anemia virtually abolishing the need for 
RBC transfusion in some types of anemia (Debeljak et al., 2014) and as EPO increases the number of 
peripheral red blood cells, there has been considerable interest in the therapeutic use of EPO for the 










Figure 1.7   Protein structure of Erythropoietin. The three-dimensional structure comprises two 
immunoglobulin-like domain. Also, erythropoietin has one binding interface of the ligand which 





1.5     Strategies for Mammalian Cell Engineering 
Recent advances in mammalian cell engineering have witnessed significant improvement in production 
of recombinant protein production and numerous strategies have been used and targeted to enhance 
cell engineering with growth-promoting and productivity-enhancing factors. These past few years 
particularly have witnessed reports of many strategies to improve the productivity of mammalian cell 
factories (Zucchelli et al., 2016) and these mammalian cell lines that support reliable and predictable 
expression of large numbers of transgenes are an enabling technology for a wide range of scientific, 
industrial and therapeutic applications such cell lines could be used to improve production of 
recombinant proteins that can treat autoimmune disorders, cancer and other diseases (Gaidukov et 
al., 2018).  
 
There are several methods used to select host cells that have attributes which further improve the 
efficiency or robustness of protein production and the economic footprint of the cell factories ranges 
in the hundreds of billions of USD/year on the global markets (Davy et al., 2017).  For over three 
decades, vast optimisations of cell productivity for recombinant protein production during bioprocess 
has yielded powerful clones for bio therapeutic production. While many of the processes used in these 
advancements are kept as commercial knowhow, there are reviews which detail cell line development 
technologies. With the fast rising advancement in technology, the next generation may, as well, come 
from genetic engineering approaches where approaches such as vector engineering and cell regulation 
through the use of endogenous promoters to overcome bottlenecks that limit increased protein 
production, a major focus in this work. 
 
1.5.1   Host cell line selection  
Every bioprocess design begins with the important step of choice of a suitable host as an expression 
system for the production of recombinant protein, decision of which may be challenging (Overton 
2014). Quite a number of mammalian systems are capable of yielding high-level expression of 
recombinant proteins that are suitable for use in the manufacture of protein pharmaceuticals. Some 
of the most commonly used cell lines used are rodent-derived such as Chinese hamster ovary (CHO) 
cells and baby hamster kidney (BHK) cells. Other examples of mammalian cells used for the production 
of approved bio therapeutics include human embryonic kidney cells 293 (HEK293) and HT-1080 human 




human mammalian expression systems, accounting for over 60% of currently approved bio-
therapeutics (Butler & Spearman 2014). 
 
1.5.2        Improved screening and selection methods 
Methods of screening for the selection of cell lines is critical due to the desire for high specific 
productivity of stable clone for recombinant protein production.  As it has become a valid requirement 
for commercial production of therapeutic proteins the selection procedures used to identify the 
desired cell line are often tedious time-consuming but remains an important requisite for the regulated 
expression or production.  A popular method of screening and selection is the limiting dilution of cells 
which is used to identify monoclonal cell lines, followed by other analysis that favour high production 
processes. While many screening methods are being developed in order to reduce the time in the 
generation and identification of high producer cell lines, there remains the challenge of identifying 
desirable high producers in a transfected pool as low producers are usually the majority of the cell pool 
whereas high producers often remain scarce. Antibiotics commonly used for selection include 
hygromycin, geneticin (also known as G418) and puromycin. Table 1.2 shows some examples of the 
selection methods popularly used to identify clonal cells and perhaps the pros and cons with their 

















Advantages Disadvantages  







Isolation not guaranteed 
 
Low level of successful outcome  
Fluorescent activated 
Cell sorting (FACS) 
High throughput Toxicity problems from fluorescent 
proteins 
 
Limited to cells with certain 
characteristics 
 
Expensive instruments  
Gel micro-drop 
technology 




Needs trained person 
Laser enabled analysis 
and processing (LEAP) 
Automated Expensive 
 
Potential Damage to Cells (irradiation) 
 
 
1.5.3        Cell line engineering 
Cell engineering is by far, one of the most effective and powerful ways to improve the production of 
therapeutic proteins. For two decades, efforts have been devoted to genetically engineer host cells or 
produce cells with enhanced growth characteristics or to modulate the glycosylation pattern of the 
product. There have also been efforts to genetically engineer host cells so that the same desirable 
traits would be carried to new cell lines for different products (Le et al., 2015). Further, advances in 
cell engineering make it more convenient to engineer mammalian cells (Dangi et al., 2018) as these 
have continued to enable techniques that cut across various fields of synthetic biology, molecular 
biology, genetic engineering and many other areas. Mammalian cell lines can be improved by genetic 
engineering of either enzymatic or regulatory activities for example. The benefits of cell line 




engineering are however not limited to antibody production only, but have also been explored in 
production of other biopharmaceutical products as are fast selling as well as highly effective products 
as other recombinant proteins, vaccines, fusion proteins and growth factors (Sandig et al., 2017). 
Applications of cell engineering have enabled manipulations which favour cell protein production. 
Various types of cellular and genetic engineering techniques are therefore directed at modifying 
features specific to the host cells (Dangi et al., 2018). There are approaches used to manipulate the 
delay of apoptosis (Pistritto et al., 2016), over-express anti-apoptotic genes (Zustiak et al., 2014), 
down-regulate pro-apoptosis genes (Zhang et al., 2018) in engineered cell lines, manipulate growth of 
the cell (Vergara et al., 2018), promote post-translational modifications (Alexandris et al., 2017) as well 
as other cell engineering processes.  
For instance, overexpression of the anti-apoptotic Bcl-X(L) gene was reported to improve cell 
productivity against breast cancer cells (Mimura et al., 2018). Along with these strategies, researchers 
have engineered cells in order to increase transcription rate, modulate specific posttranslational 
modifications and decrease protein misfolding, aggregation, and degradation such as the engineering 
of chaperone network of CHO cells which was reported to improve recombinant protein production 
(Jossé et al., 2012). The use of micro-RNAs in host-cell engineering is another important strategy used 
to improve recombinant therapeutic protein production as well as the regulation of apoptosis so as to 
promote cell-cycle progression for improved cell viability and overall improved cellular productivity  
(Fischer et al., 2017). 
 
1.5.3.1     Anti- Apoptosis engineering in CHO cells 
Anti-apoptosis engineering is an established technique to prolong the viability of mammalian cell 
cultures used for industrial production of recombinant proteins (Templeton et al., 2014). Cell death is 
a known critical issue as it affects the viable cell concentration thereby impacting on volumetric titre 
and ultimately on product quality hence many of the methods used to delay cell apoptosis have been 
largely considered as a highly promising and advantageous to increase product quantity and quality 
and also to reduce production costs in medical biotechnology applications (Iz et al., 2017). Due to the 
morphologically homogeneous processes by which apoptotic cell death are generally characterized, 
(Inoue & Tani 2014), anti-apoptotic cell engineering therefore remains a potential strategy to improve 




some cells like stem cells, tumor cells and memory B and T cells and this has inspired researchers as a 
Bio Design approach from nature, with this strategy for different purposes (Iz et al., 2017). However, 
the overexpression of anti-apoptotic genes, such as those in the Bcl-2 family, have been shown to 
improve cell viability and increase mAb production (Basu & Sridharan, 2017). Another promising 
strategy towards achieving improved recombinant protein production in CHO cells is the inhibition of 
the expression of caspases, which functions in apoptosis regulation (Zamaraev et al., 2017). 
 
1.5.3.2 Secretory pathway engineering in CHO cells 
The elucidation of the cell biology of the secretory machinery is of great importance, as it drives protein 
expression for biopharmaceutical industry (Lund et al., 2017). Mammalian secreted proteins and 
membrane bound receptors often contain obligate post-translational modifications including disulfide 
bonds and unique glycosylation patterns necessary for proper folding and/or biological activity, 
preventing their expression in prokaryotes (Dalton & Barton, 2014). It is therefore imperative that the 
secretory pathway is correctly regulated for the life and health of the organism (Viotti 2016).  
 
The secretory machinery includes various functional modules along the endoplasmic reticulum (ER) 
and Golgi apparatus. However, dysfunction of the secretory pathway may result in a variety of systemic 
or developmental diseases, like cancer, diabetes, Parkinson’s disease, and congenital 
neurodegenerative disorders (Wang & Kaufman 2016).  Basically, there are two main functions of the 
secretory pathway. To perform proper folding and post-translational modifications (PTMs) of proteins 
such as, glycosylation and sulfation, and to sort proteins to their final cellular or extracellular 
destination (Lund et al., 2017). Protein post-translational modifications (PTMs), such as 
phosphorylation, acetylation, methylation, and ubiquitination, have been shown to control protein 
activity, regulate protein stability, promote protein interactions and alter protein subcellular 
localization, leading to the modulation of crucial signalling pathways and affected cellular processes 
(Yang, 2018).  
 
The protein secretion pathway is controlled by some regulatory proteins responds to environmental 
changes, nutrient production as well as stress conditions. Secretory vesicles and secretory granules are 




ortega et al., 2018). Recent studies reported that the bioengineering of host cell lines may improve the 
modification or the secretion of heterologous proteins and of other therapeutics and also of functional 
proteins involved in the various post-translational steps of the secretory pathway and of exocytosis. 
Some of these pathways could be successfully engineered to solve bottlenecks and cellular limitations 
caused by recombinant protein overflow (Fourn et al., 2014) . Although efforts within bioprocess 
optimisation have led to increased product titres of recombinant proteins expressed in CHO cells, post-
transcriptional bottlenecks in the biosynthetic pathway of r-proteins remain to be solved (Hansen et 
al., 2017a). For instance, Sommeregger et al., (2016) had reported that cell lines expressing seemingly 
difficult-to-express recombinant proteins had increased levels of ER stress compared to cell lines 
expressing easy-to-express recombinant proteins.  
 
A non-linear relationship between the transcript level and cell specific productivity (qP or amount of 
protein made per cell per unit time) in CHO cells shows that there is a post-transcriptional bottleneck 
in the biosynthetic pathway of recombinant proteins  (Hansen et al., 2017). Meanwhile, previous 
studies had identified several post-translational bottlenecks in the generation of certain recombinant 
proteins such as the bottleneck in CHO cells upon the transient expression of an Fc-fusion protein 
(Johari 2015), the post-translational bottleneck of EPO transient expression at high gene doses (Ku et 
al., 2010). 
 
The overexpression of human signal receptor protein SRP14 and other components of the secretion 
pathway via proper processing and secretion resulted in the expression of the difficult-to-express 
protein to high yields (Fourn et al., 2014). This again suggests that the engineering of the secretory 
pathway may be used to improve the secretion efficiency of therapeutic proteins from CHO cells 
Indeed, overexpression of transcription factors can boost productivity and the secretory capacity of 
the cells can be improved (Pybus et al., 2014). 
 
1.5.3.3     Glycosylation engineering  
Glycosylation is the most abundant post-translational modification (Burchell et al., 2018) and the most 
complex post-translational process (Shen et al., 2018) In eukaryotes, the majority of proteins 
expressed on the cell membrane or that are secreted carry glycans (Burchell et al., 2018). Glycosylation 




(Goh & Ng, 2018). It is a critical and variable factor in the quality of several therapeutic proteins, 
particularly those with immune-system interactions such as monoclonal antibodies (mAbs) (Blondeel 
2018) and it occurs within the secretory pathways of cells, precisely in the endoplasmic reticulum (ER) 
and Golgi apparatus, where monosaccharide units such as galactose (Gal), mannose (Man), fucose 
(Fuc), N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc) and sialic acids are covalently 
attached to specific amino acids of newly synthesized proteins and lipid structures (Goh & Ng, 2018). 
Glycosylation occurs in two main forms, designated by the functional group of the amino-acids where 
the glycans are bound; the N-linked and the O-linked (Ghaderi et al., 2012). During the production 
process various parameters impact glycan structures, including cell culture conditions, protein 
structure and protein folding (Shen et al., 2018). 
 
In order to improve the pharmaceutical properties of therapeutics, the glycosylation of bio 
therapeutics is now critically defining glycosylation for each drug to maintain consistent characteristics 
which affects many general functional factors of a glycoprotein, such as stability, inhibition of 
proteolysis, solubility, aggregation, as well as other attributes (Butler & Spearman, 2014). Meanwhile, 
there are many approaches for glyco-engineering, including the introduction of new glycosylation sites 
to increase carbohydrate content or to block specific binding (Mimura et al., 2018). According to Shen 
et al., (2018), there was a reduction in glycosylation heterogeneity following changes in  culture 
environment with consistent expression and culture conditions of variants.  
 
These findings agreed with reports of Hossler (2012) on the methods to modulate glycosylation 
heterogeneity for glycoproteins in mammalian cell culture during the manufacturing process such as 
optimising pH, temperature, oxygen concentration, the media formulation and feed rate, expression 
level, and production method (batch, fed-batch, perfusion). Meanwhile glycosylation of recombinant 
proteins in non-mammalian systems are different from humans and thus have limited applications in 
the production of therapeutic glycoproteins (Loos et al., 2011).   
 
Further, renewed and increasing attention is being paid to the effect of N-glycosylation on product 
quality; such efforts are underway to develop analytical workflows to monitor glycosylation profiles 
throughout the bioprocessing production cycle (Sha et al., 2016). While strategies for generating novel 
molecules with desirable therapeutic properties are being identified, glycosylation of recombinant 




1.5.3.4     Cell Media Formulation and Feed development  
Media development is aimed at supporting cell growth, having a robust process with high viable cell 
density, high product titre and high product quality (Klein et al., 2015). Mammalian cells require a 
combination of both nutritive (for example, sugars and amino acids) and non-nutritive (for example,  
trace metals, vitamins and co-factors) components to support cell growth and protein production. One 
of the most challenging aspects of culturing recombinant CHO cells is, in fact, the optimisation of the 
diverse nutritional requirements unique to each clone. Cell culture optimisation often involves the 
development of a customized, chemically defined media along with process-specific feed supplements, 
all combined with process parameters individualized for each CHO cell clone (Baktur et al., 2016). 
Additionally, increasing demands on product quality result in higher complexity of processes and 
analytics, thereby increasing the costs for product work (Gronemeyer et al., 2014).  
 
Producing more proteins with fewer resources and in less time remains a significant challenge when 
working with mammalian cell expression systems (Lalonde & Durocher, 2017) as cells require a base 
media to support the early stages of culture followed by nutrient feeds to replace limiting nutrients 
and to extend the period of protein production, which helps to achieve high titre (Sellick et al., 2011). 
Therefore, many researchers have tried to optimise the composition of culture media to gain the most 
suitable conditions for recombinant protein production yield in CHO cells and some of the approaches 
used include the substitution and supplementation of glucose and/or glutamine, hormone, growth 
factors, lipids manipulation and nutrient engineering, amongst others (Porncharoennop, 2016). 
 
1.5.3.5     Site-specific targeting techniques 
 
Several site specific recombinases have been described and used for engineering of mammalian 
genomes (Marie, 2018). While site-specificity may not be a prerequisite for introduction of 
transgenes into a host for overexpression, there are factors that may improve integration success by 
using more specific insertion methods. The large-scale engineering of a cell’s genome requires the 
ability to precisely and efficiently integrate large amounts of heterologous DNA into genomic loci that 
support robust expression of transgenes unlike current genome-engineering (Gaidukov et al., 2018). 
Targeted integration methods are frequently applied (as reported) for the reduction of the long 




integrases or transposes for the integration of the expression cassettes (Büssow, 2015). To date, 
three main types of engineered nucleases have been developed for genome editing: zinc finger 
nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and CRISPR (clustered regularly 
interspaced short palindromic repeats)/Cas9 (Nishitani et al., 2016) but unlike ZFNs or TALENs, the 
CRISPR/Cas9 system does not require any protein engineering steps, making it much more 
straightforward to test multiple single guide RNAs for each target gene (Nakajima et al., 2017). In 
recent times, site specific gene knock-ins in cell line development have been successfully performed 
using transcription activator-like effector nucleases (TALENs) (Aida et al., 2015) or CRISPR-Cas9, RNA-
guided nucleases. However, these methods are not without setbacks as they often use the error-
prone non-homologues end joining (NHEJ) mechanism for double strand break repair, as genome 
editing still suffered from two major drawbacks as reported by Komor et al., (2017). First, that non-
homologous end joining (NHEJ) which also occurs at the site of DSBs, typically more efficiently than 
HDR, results in stochastic insertions and deletions (indels) of nucleotides at the target locus and a 
second setback which occurs due to the low probability that a known meganuclease would cleave a 
particular target locus of interest without having to incorporate either a meganuclease recognition 
site into the genomic locus of interest or perhaps engineer a meganuclease to cleave the target locus. 
 
 
1.5.3.6     Cell Cycle engineering 
Cell growth, a process that occurs during cell doubling, is defined as an increase in cell mass and size 
and this process is tightly organised involving cell division with distinct cell cycle phases that transition 
through phases regulated by several layers of checkpoint control mechanisms  (Dolatabadi et al., 
2017).  A recent review by Duggal et al., (2018) reported on the highly coordinated and regulated 
process of an ordered series of events of the mammalian cell cycle. It was reported that, though diverse 
processes, cell growth and proliferation are always linked. Although many studies have compared the 
metabolic and physiological states of different CHO cell culture phases (Pan et al., 2017), it is however 
less clear whether intrinsic cell size control plays a large role in regulating cell size in multicellular 
organisms where cell size may be constrained by tissue structure and changes in cell size are associated 
with development and morphogenesis (Jones et al., 2017).  
 
In understanding the mechanisms by which molecular determinants of cell cycle progression occurs, 




protein abundance, protein post-translational modifications and DNA synthesis as a population of cells 
moves from one cell cycle phase to the next, or when a population becomes quiescent (Carolina & 
Carolina, 2018). According to Griffith (2015), the four phases of growth for any cell in culture [lag, log, 
stationary, decline] can be targeted to increase the longevity of batch cultivation with a short lag phase 
where cells acclimatise to the environment, followed by a rapid log/exponential growth phase, where 
the cells grow to maximum density as fast as possible so that you get a longer stationary phase. Unlike 
cell growth which is defined as an increase in cell mass and size, cell cycle requires the activation of 
many stage specific signalling molecules as well as that of regulatory cell cycle proteins (Duggal et al., 
2018).  
 
For the cell to move from a phase of cellular growth to cellular energy phase where energy is being 
utilised for protein synthesis, there is the need to extend the stationary phase which is the main 
production phase, a term called Biphasic (Figure 1.8). During this extended stationary phase cells are 
able to concentrate their metabolic energy to increasing specific protein productivity and not on other 
cellular functions Griffith (2015). Some of the strategies required for the growth arrest of cells include 
chemical agents, decreasing cultivation temperature and changing media PH. These strategies have 
focused on enhancing time integral of viable cell density (IVCD) as well as specific protein productivity 
(qP). 
 
Figure 1.8     Regular and Biphasic growth curve of cells in culture. 1= Lag phase, 2=Exponential 
phase, 3=Stationary phase and 4=Decline/death phase. In regular cells, stages 1 to 4 make a 
complete cycle whereas in a biphasic culture, cells show an extended exponential phase 








1.5.3.7 Overexpression engineering 
 
The approach used in this work encompasses techniques of systems biology for cell engineering. 
Systems biology refers to an integrative discipline that attempts to describe and understand biology 
as systems of interconnected components and this approach is made possible by the explosion of data 
from genomic, transcriptomic, proteomic and metabolomic techniques developed within the last 
decade (Materi & Wishart, 2007). The emergence of Systems biology has span over the past two 
decades with the aim of examining organisms from a systematic and holistic perspective, characterized 
by large datasets and modelling (Zou & Laubichler, 2018).  
 
Hence, the data systems biology presents scientific possibilities to understand processes as a whole 
and to integrate new data and new analytical tools that are intended to solve biological problems by 
integrating parts and modules (Martins-Santana et al., 2018) and mammalian synthetic biology 
continues to developing research tools and programmable therapeutics that are based on 
sophisticated genetic circuit design (Cella et al., 2018).  With these developments, many sub-disciplines 
of systems biology have been established, such as systems pharmacology, which explores the 
mechanisms behind drugs using systems biology methods, and cancer systems biology, which applies 
computational modelling to reveal the carcinogenic pathways (Zou & Laubichler, 2018).  
 
Because the secretory pathway primarily relies on local interactions in order to make decisions on the 
fate of the secretory protein, rather than transcriptional responses (Hou et al., 2012), the need to link 
genotypes to phenotypes and other associating genes to biological path-ways as gene overexpression 
is necessary to particularly stimulate a specific activity and mimic gain‐of‐function mutations via 
systematic gene overexpression (Znaidi et al., 2018). Also, various metabolic conditions require an 
enlarged capacity in the ER-localised pathways of intermediary metabolism, and this frequently results 
in proliferation of the organelle. 
 
 Kuo et al., (2018) had reported on the recent advances in systems biology and data-driven approaches 
aiming to unravel how molecular pathways, cellular processes, and extrinsic factors (e.g. media 
supplementation) influence recombinant protein production and had summarized these approaches 
into three namely; Bioprocess and transgene expression optimisation, targeted engineering of CHO 




major site of protein synthesis, it is also a site of bulk membrane lipid biogenesis. In this study, we have 
focused on reprogramming cholesterol biosynthesis which occurs in the endoplasmic reticulum (ER) to 
target ER expansion.  
 
More studies have continued to overexpress certain genes for induced ER expansion in mammalian 
cells. For example, some studies demonstrated that overexpression of spliced XBP1 induced ER 
expansion by increasing the amount of Protein C per milligram of protein and the total amount of 
phospholipids (Sriburi et al.,  2004). Chaperones have been examined in a number of disease models 
as potential tools for lowering ER stress and preventing the activation of UPR pathways. Literature 
studies from (Zwerger et al., 2010) reported on the over-expression of three of the investigated LBR 
mutants as well as TM7SF2 and DHCR7 induced the large-scale separation of the INM from the ONM 
as well as of ER membranes, implicating an additional function of these proteins in maintaining the 
integrity of these compartments. Though they stated that assumptions are still highly speculative but 
over-expression of various LBR constructs which findings have proven to be a valuable tool to elucidate 
protein function.  
 
1.6          The Secretory Pathway 
The secretory pathway of eukaryotic cells is composed primarily of two organelles, the ER and Golgi, 
responsible for maintaining the fidelity of protein synthesis and maturation (Young et al., 2011) as well 
as provide both a specific folding environment and appropriate chaperones in the ER for the folding of 
secretory proteins and organelles for further modification of folded and assembled proteins. This 
highly complex pathway which directs the nascent polypeptides to the extracellular space, cell wall, 
plasma membrane, or organelles (Celińska & Nicaud, 2019) where the proteins ferried between 
compartments via transport vesicles bud off from one donor compartment to fuse with a downstream 
acceptor compartment, thereby mediating directional traffic of both lipid and protein (Barlowe & 
Miller, 2013) usually by an N-terminal signal sequence which directs them to the ER. This N-terminal 
signal sequence is hydrophobic in nature and binds to the signal recognition particle (SRP) (Mercier et 
al., 2017). In order to maintain homeostasis of individual organelles in the secretory pathway, the 
forward-moving or anterograde pathway is balanced by a reverse, or retrograde pathway that returns 





1.6.1       The Endoplasmic Reticulum 
The endoplasmic reticulum (ER) is the entry portal of the conventional secretory pathway where the 
newly synthesised polypeptides fold, modify, and assemble (Jiang et al., 2018).  As the site of 
synthesis for nearly one-third of the mammalian genome encoded proteins (Pobre et al., 2019) the 
ER is accordingly endowed with specialized machinery to ensure that proteins deployed to the distal 
secretory pathway are correctly folded and assembled into native oligomeric complexes (Olzmann et 
al., 2013) where they further undergo processes such as post-translational modifications, oxidative 
folding, and maturation to their functional tertiary or quaternary state (Pobre et al., 2019). As the 
protein folding factory of the secretory pathway, the ER hosts a specialized PQC (protein quality 
control) system of molecular chaperones and folding enzymes (McCaffrey & Braakman, 2016).  
 
In maintaining its role as a central coordinator for maintenance of cellular homeostasis (Rutkowski & 
Hegde, 2010), the ER engages in various cellular functions involving the biosynthesis of lipid species 
such as cholesterol, triacylglycerol, and phospholipids, the degradation of glycogen, detoxification, 
and the maintenance of Ca2+ homeostasis  (Reverendo et al., 2019). Upon entry into the ER lumen, 
newly synthesized polypeptides are folded and modified to ensure precise conformations and 
function. Impairments of this process lead to ER stress due to the accumulation of misfolded or 
unfolded proteins in the ER (Byrd & Brewer, 2012). However, abnormal accumulation of proteins in 
the ER can be a sign of cellular malfunction and stress that triggers a collection of conserved 
emergency rescue programs (Reverendo et al., 2019). 
 
Lipids are mostly synthesised in the endoplasmic reticulum (ER) and distributed to other membranes 
by non-vesicular mechanisms through mechanisms which act in conjunction with lipid metabolic 
networks for the maintenance of  the unique lipid profile of the plasma membrane and subcellular 
organelles, thus enabling rapid membrane lipid remodelling in response to signals and stresses (Quon 
et al., 2018). Therefore the ER dynamically changes its membrane structure to adapt to the changing 
cellular lipid concentrations (Almanza et al., 2019). Several studies have investigated the impact of 
ER expansion on lipid biosynthesis and cholesterol amounts as the ER contains the sterol regulatory 







1.6.2       Protein translocation across the Endoplasmic Reticulum 
 
Protein targeting to the ER has been the subject of intensive research for decades (Aviram & 
Schuldiner, 2017). Translocation of proteins into the endoplasmic reticulum (ER) is the first step in 
the biogenesis of most extracellular and many soluble organelle proteins of eukaryotic cells 
(Zimmermann et al., 2011) as proteins destined to enter the secretory pathway typically possess N-
terminal hydrophobic signal sequences, which direct them to the endoplasmic reticulum (ER) 
membrane, where they are translocated into the lumen of ER  (Nyathi et al., 2013). Protein transport 
into the ER can occur co- or post translationally (Zimmermann et al., 2011) where processes such as 
post-translational modifications (PTMs) occur on a large number of proteins de facto increasing the 
actual complexity of the proteome (Audagnotto & Dal Peraro, 2017). 
 
PTMs consist in a covalent modification of amino acids of the primary protein sequence whereby the 
function of proteins is frequently modulated by chemical modifications introduced after translation 
from RNA and post-translational modifications (PTMs) have been shown to also influence the 
interaction between proteins carrying them (Duan & Walther, 2015). Therefore, protein folding is the 
initial step for polypeptides entering the secretory pathway. Protein folding can initiate inside the 
ribosomal exit tunnel, e.g. through helix formation in the lower tunnel (Ellgaard et al., 2016).  
 
Chaperones are bio molecular complexes that help other proteins (their clients) to fold (Agozzino & 
Dill, 2018) into their native conformation, thereby preventing their aggregation. These chaperones 
as well as some folding enzymes which are expressed in the ER function to provide an environment 
for nascent polypeptide chains to reach their proper three-dimensional configuration. Many of these 
factors exist in a preformed multi-chaperone complex that may provide for coordinated catalysis of 
protein folding.  It was long thought that signal recognition particle (SRP) binds the ribosome-nascent 
chain complex only after the emergence of the nascent hydrophobic motif from the ribosome exit 
tunnel (Aviram & Schuldiner, 2017) which is thought to allow time for a ribosome-nascent chain 
complex to diffuse to the ER membrane However, recent studies suggest that, for certain substrates, 
SRP already binds to the ribosome at earlier stages during translation  (Aviram & Schuldiner, 2017) 





The co-translational pathway uses the signal recognition particle (SRP) to deliver secretory proteins 
to the ER membrane while they are still being synthesized by ribosomes and as the SRP delivers the 
nascent secretory protein together with the associated ribosome to the ER protein translocon 
(Sec61 complex) through the interaction with its cognate receptor (SR) an ER resident membrane 
protein, the ribosome nascent chain complex (RNC) engages the Sec61 complex protein synthesis 
thus enabling the nascent chain to be directly conveyed into the lumen of the ER where it can then 
fold to its final conformation (Nyathi et al., 2013). However, If translocation is much faster than 
translation elongation, translocation of all of these proteins could be accomplished in the same 
amount of time it would take to translocate a single protein co-translationally (Cranford-Smith & 





Figure 1.9 Co-translocation into the Endoplasmic Reticulum (ER). Protein targeting pathway 
involves the binding of the signal recognition particle (SRP) to the signal sequence (green) 
immediately it emerges from the ribosome nascent chain forming the Ribosome nascent 
chain – signal recognition particle (RNC–SRP) complex (1). Thereafter the newly formed 
RNC–SRP complex binds to a cognate SRP receptor (SR, consisting of α and β subunits) at 
the ER membrane (2).  Next is the transfer of RNC from SRP receptor to the Sec61 translocon 
resulting in intercalation of the signal sequence in the translocon pore and its opening (3) 
At this point, translocation of the nascent chain proceeds through the pore as SRP now 
disengages from SR (4). Finally, during translocation, the signal peptidase (SPase) and 
oligosaccharyl transferase (OST) enzyme complexes are recruited to the translocon to 
cleave the signal peptide and to add N-linked glycans to the nascent chain respectively (5). 
At this point, nascent chain is now released from the ribosome, a process known as 






1.6.3       ER Associated Degradation (ERAD) and ER Stress 
Under normal physiological conditions, upon entry into the ER lumen, newly synthesised 
polypeptides are folded and modified to ensure precise conformations and function (So, 2018). Even 
with the assistance of dedicated protein folding machinery in the ER, a large portion of proteins 
entering the ER fails to obtain proper conformation due to mutations, unavailability of chaperones, 
or changes in the amounts of interacting partners and eventually must be eliminated (Yoo et al., 
2017). Physiological conditions increase the protein folding demand, which may trigger loss of its 
regulation (Kadowaki et al, 2018) (Pereira et al., 2016) .  
 
Various stress factors, such as hypoxia, starvation, oxidative insults, changes in pH, Ca2+ depletion, 
hypoglycemia, ATP depletion, and viral infections, can disturb ER homeostasis such that all these 
aspects can interfere with the correct protein folding, results in the accumulation of misfolded or 
unfolded proteins leading to ER stress (Limonta et al., 2019). However, what defines ER stress and 
how ER stress may engender cytotoxicity, are poorly understood issues (Vitale et al., 2019). ER stress 
is defined as the accumulation of misfolded proteins in the ER although, it is unusual for anyone to 
attempt measure the load of misfolded proteins in the ER in response to stress (Howell, 2017). 
 
Indeed, the ER-associated degradation (ERAD) is the temporally and spatially coordinated 
surveillance process charged with clearance of aberrant proteins in the ER  (Olzmann et al., 2013) 
and occurs in three primary steps: (1) recognition and targeting (substrate recognition within the ER 
and targeting to the retrotranslocon), (2) retrotranslocation (substrate delivery from the ER to the 
cytosol), and (3) degradation (ubiquitin –proteasome dependent degradation) (Kleizen & Braakman, 
2004).  
 
1.6.4  Quality Control in the ER 
The best studied quality control checkpoint is the ER system, which identifies non-native features of 
proteins that have failed to fold correctly and retains them in the ER (Briant et al., 2017). Protein 
quality control (PQC) is a unique mechanism for adaptation to ER stress.  As earlier described, the ER 
contains an elegant system designed to facilitate the proper folding and trafficking of proteins, 
particularly those destined for secretory pathways  (Kropski et al., 2018), therefore cells rely on a 




synthesis to prevent protein aggregation, promote correct protein folding, and target terminally 
misfolded proteins to degradation (Peters et al., 2015). To maintain protein homeostasis, cells must 
ensure the fidelity of protein folding and maturation whereas to maintain ER homeostasis, cells have 
evolved protein quality-control systems through the action of different pathways, including the UPR, 
ERAD, and autophagy (Hwang & Qi, 2018).  
 
Basically, there are three axes that define the protein quality control of the ER; acceleration of 
adequate protein folding, activation of unfolded protein response (UPR), and protein clearance via 
ER-associated degradation (ERAD) (Yoo et al., 2017). Accumulation of unfolded or misfolded proteins 
is the trigger of ER stress, which activates the unfolded protein response (UPR) to restore the lost 
balance (Leitman et al., 2012) which in turn inhibits the proteasomal degradation of misfolded 
proteins with a coordinated action of chaperone calnexin (CNX) along with calreticulin (CRT), a 
soluble homolog of calnexin. The ER quality control system therefore senses and disposes of 
terminally misfolded proteins by ERAD, a process that is conserved in eukaryote (Byun et al., 2014) 
and the fundamental ERQC factors are the lectin chaperones calnexin (CNX) and calreticulin (CRT) 
(Volpi et al., 2017), which assist the folding of ER-synthesized glycoproteins (Lamriben et al., 2016). 
 
 In the CNX/CRT cycle, the glycan portion attached to the unfolded glycoproteins are modified so as 
to drive the alternate dissociation and re-binding of these proteins to the lectins, until their proper 
structure is reached (Figure 1.10). Another major chaperone system in the CNX/CRT complex is the 
BiP/GRP78 or Hsp70 system. After leaving the CNX/CRT binding cycle, correctly folded proteins will 
hence be targeted for trafficking to the Golgi via the ER/Golgi intermediate compartment. This 
implies that through the CNX/CRT cycle, slow- folding or misfolded glycoproteins would be 
segregated from the peripheral ER to the ERQC and then cycle back for deglucosylation, 





Figure 1.10    ER quality control (EROC) pathways.  In the ER specialised protein quality 
control (ERQC) pathways involve the synthesis, folding and maturation of proteins 
destined for secretion or insertion into the cell membrane. ER-synthesised proteins 
emerge from ER-bound ribosomes and reach their native structure, guided by ER-
resident chaperones, such as calnexin (CNX), CRT (calreticulin) and BiP (Binding 
Immunoglobulin Protein). Proteins unable to reach their native conformation, 
designated as terminally misfolded are eliminated to counter potential toxicity. (Volpi 
et al., 2017). 
 
 
1.7    The Unfolded Protein Response Pathway 
In order for the restoration of protein folding capacity with protein synthesis requirements to be 
activated, a coordinated transcriptional and translational network termed the unfolded protein 
response (UPR) is initiated (Adams et al., 2019). This response system elicits specific intracellular 
signalling pathways to protect against ER stress (So, 2018) with large-scale transcriptional alterations 
for approximately 400 genes in order to recover the secretory pathway to homeostasis (Bao, 2017). 
Other conditions that trigger a major defence system as they help cells survive any stress 
circumstances include inflammatory responses and oxidative stress caused by either physiological, 
pathological or biochemical stimuli. UPR also enhances ER-associated degradation (ERAD) processes 




The canonical core of the UPR is composed of three major transmembrane stress sensors; PERK, IRE-
1, and ATF6 (Figure 1.11)  (Doultsinos et al., 2017a) and these transmembrane proteins are major 
transducers of the UPR in mammals and mediate multiple distinct signals from the ER to the cytosol 
(So, 2018).  
 
IRE1α is a functional kinase, and RNase represents the most conserved branch of the UPR. Upon 
activation, IRE1α catalyses the unconventional splicing of X-box binding protein 1 (XBP1) removing a 
26-nucleotide intron (Hetz, 2017). Another arm of the UPR is the  ER membrane protein ATF6 
(activating transcription factor 6), a fragment of which moves to the nucleus where it functions as a 
transcription factor to activate genes that mediate protein folding (Mckimpson & Kitsis, 2017). The 
activated PERK induces a global translation attenuation by phosphorylation of the α subunit of eIF2α, 
therefore reducing folding requirements in the ER, which occurs by oligomerization and auto 
phosphorylation as well as for IRE1, unlike ATF6 which is translocated to the Golgi apparatus and 
then activated via proteolytic cleavage (Galluzzi et al., 2017). Unfolded Protein Response in the 
endoplasmic reticulum is influenced by several factors associated with lowering protein synthesis 













Figure 1.11   Schematic diagram of the UPR pathway. In the event of restoring 
protein homeostasis (proteostasis), three transmembrane proteins IRE1, PERK 
and ATF6 are activated by UPR signals. PERK phosphorylates eIF2a, leading to a 
rapid attenuation of protein synthesis as well as facilitating the non‐canonical 
translation of ATF4 mRNA. ATF4 upregulates proteins involved in protein  folding 
and secretion, ERAD, apoptosis, autophagy and lipid synthesis. The IRE1 and 
ATF6 branches of the UPR activate the transcription factors XBP1 and ATF6, 
respectively as target genes encode proteins involved in protein folding, 
endoplasmic reticulum‐associated protein degradation (ERAD) and lipid 




1.7.1       Inositol-Requiring Protein 1 (IRE1) 
Inositol-requiring enzyme 1 (IRE1) is the most highly conserved signalling node of the unfolded 
protein response (UPR) and represents a potential therapeutic target for a number of diseases 
associated with endoplasmic reticulum stress (Volkmann et al., 2011) while the activated IRE1, which 
has been reported to be associated with tumor necrosis factor (TNF) receptor-associated factor 2 
(TRAF2), unconventionally splices the mRNA of the transcription factor XBP1/HAC1, activating XBP1, 
promoting its translation and a conserved XBP1-dependent gene-expression program (Amin-Wetzel 
et al., 2017).  
 
IRE1 functions as an RNA nuclease whereby it cleaves the primary transcript of Xbox binding protein 
1 (XBP1) in order to excise a short inhibitory intron. Thereafter the newly spliced XBP1 mRNA encodes 
an active transcription factor, XBP1s (s for spliced) (Marciniak, 2019) allowing communication 
between the ER and the nucleus which results in the increased transcription of binding immunoglobin 
protein (BiP), during stress. The activated XBP1s then regulates the expression of various chaperones, 
foldases and other protective molecules (Okazaki et al., 2014). IRE1 in humans exists in the form of 
two homologues: IRE1α and IRE1β (Doultsinos et al., 2017b).  While IRE1𝛼 IRE1𝛼 is ubiquitously 
expressed, IRE1𝛽 is tissue specific (Ma et al., 2014) (Chen & Brandizzi, 2013). 
 
1.7.2       Activating Transcription Factor 6 (ATF6) 
During ER stress conditions, ATF6 is transported on vesicles toward the Golgi apparatus), where it is 
sequentially cleaved by the Site-1 and then Site-2 Proteases (S1P and S2P, respectively) (Bravo et al., 
2013). In the absence of ER stress, Binding immunoglobulin protein BiP/GRP78, a major ER chaperone 
critical for protein quality control, is associated with all three sensors PERK, IRE1 and ATF6 preventing 
their activation. ATF6 is synthesised as a type II transmembrane glycoprotein and is embedded in the 
ER membrane. In response to ER stress, ATF6 is reduced to its monomeric confirmation and 
translocates from the ER to the Golgi compartment using COP II vesicles resulting in the release of 
ATF6’s cytosolic ATF6 transcriptional activity from its cleaved cytosolic domain, which contains a 





One of the three canonical arms activated during ER stress sensors, PERK, is an eIF2α kinase whose 
phosphorylation of eIF2α leading to the preferred translation of selective mRNAs, such as the one 
encoding transcription factor ATF4. Figure 1.12 shows the functional role played by the stress 
receptors while ultimately down regulating protein synthesis in order to eliminate misfolded or 
unfolded proteins during ER stress response. 
 
1.7.3       Protein Kinase-Like Endoplasmic Reticulum Kinase (PERK) 
PERK belongs to the eukaryotic initiation factor (eIF2α) kinase family. During ER stress, PERK is 
activated in a similar manner as IRE1, whereby the activated PERK then phosphorylates Ser51 on the 
subunit of eukaryotic initiation factor 2 alpha (eIF2α) thus reducing the ER protein folding burden 
(Cao & Kaufman, 2014). This phosphorylation inhibits the reactivation of eIF2α into its GTP-bound 
form, resulting in global arrest of protein synthesis that, in turn, prevents further influx of ER client 
proteins (Ma et al., 2014) thus resulting in a decrease in PERK signalling of the translocation of new 
proteins into the ER lumen which subsequently prevents protein overload. In addition to reducing 
translation, PERK-mediated phosphorylation of eIF2𝛼 also induces preferential translation of 
activating transcription factor 4 (ATF4), a transcription activator of the integrated stress response 
which also induces a subset of ER stress genes involved in inflammation, apoptosis, and oxidative 
stress by binding to the cAMP-response element (CRE) located in their promoter or enhancer regions 
(Ma et al., 2014).  
 
While the ATF6 and IRE1 pathways regulate the transcriptional activation of various genes, including 
those responsible for increasing the translocation, protein-folding, export, degradation, and other 
functions of the ER (Lin et al., 2019), the ER may also directly activate the apoptotic pathway through 
ER stress mediated leakage of calcium into the cytoplasm which further activates death effectors, via 
the ATF4-CHOP-mediated induction of pro-apoptotic genes while supressing the synthesis of anti-
apoptotic Bcl-2 proteins (Rozpedek et al., 2016). Due to its role as a type I ER trans membrane protein 
with serine/threonine kinase activity in its C-terminal cytosolic domain, PERK can recognize the 
accumulation of misfolded proteins at its N-terminal luminal domain (Kadowaki & Nishitoh, 2013). 
 



























Figure 1.12   The Endoplasmic Reticulum stress receptors. In the absence of stress, the three 
endoplasmic reticulum (ER) stress receptors, PKR-like ER kinase (PERK), activating transcription 
factor 6 (ATF6) and inositol-requiring enzyme 1 (IRE1) are rendered inactive and remain bound 
to Binding Immunoglobulin Protein (BiP). However, due to certain cell intrinsic or extrinsic 
factors leading to ER stress, these three receptors become activated by detaching from 
BiP/GRP78, as the latter proceeds to bind misfolded proteins, caused by ER stress. To activate 
the three (released) ER stress receptors, a process of homodimerisation and 
autophosphorylation take place in PERK, and IRE1 while ATF6 become activated by protease 
cleavage in the Golgi. PERK phosphorylates eukaryotic initiation factor 2 (eIF2α) to inhibit 
general protein translation, leading to eIF2α-independent translation of ATF4, reducing protein 
synthesis in the process. IRE1 catalyses the alternative splicing of XBP1-mRNA leading to 
expression of the active XBP1 transcription factor via signalling cascades for the translocation of 
transcription factors such as; ATF4, XBP1s and ATF6f, to the nucleus where they transcriptionally 





1.8 Biosynthesis of Cholesterol in mammalian cells. 
Cholesterol is an important biological molecule because of its dual character: a friend as an essential 
component of cell membranes and a precursor for the synthesis of steroid hormones, bile acids and 
vitamin D; a foe as a predisposing factor for various diseases  (Bellezza et al., 2013). As an important 
cellular molecule involved not only in the maintenance of membrane permeability and fluidity, but 
also in the modulation of transmembrane signalling pathways, cholesterol is a key requirement for 
the synthesis of steroid hormones, bile acids and vitamin D (Silva Afonso et al., 2018). Cholesterol 
synthesis occurs in the endoplasmic reticulum (ER) where most of the cholesterol biosynthetic 
enzymes reside, suggesting the possibility of a specialized metabolon where cholesterol synthesis 
enzymes exist in an organised system in the ER membrane (Sharpe & Brown, 2013).  
 
From a biochemical perspective, cholesterol is a necessary constituent for eukaryotic cell growth 
and development and the biosynthesis of cholesterol provides crucial building blocks for cell 
membranogenesis, membrane fluid regulation, for the synthesis of sterol and non-sterol products. 
Cholesterol biosynthesis requires more than 30 chemical reactions, with acetate being its precursor 
(Alphonse & Jones, 2016).  The first two reversible reactions, lead to the condensation of two 
molecules of acetate to form acetoacetyl-CoA which is condensed with a third molecule of acetate 
forming 3-hydroxy-3methylglutaryl-CoA coenzyme A (HMG-CoA) a reaction catalysed by thiolase 
and HMG-CoA synthase. The next reaction, catalysed by the enzyme HMG-CoA reductase, a trans 
membrane protein of the ER, reduces HMG-CoA to the key point of regulation in cholesterol 
synthesis producing mevalonate (Alphonse & Jones, 2016).  
 
Following the production of mevalonate, the next phase promotes the condensation of six 
molecules of isopentenyl pyrophosphate to form squalene, which is then cyclised and converted to 
cholesterol through several steps (Berger et al., 2015). Through a series of nineteen additional 
reactions, lanosterol is converted to cholesterol. These nineteen reaction steps are catalysed by 
nine different enzymes that are localised either to the ER or to the peroxisomes. One of the 
nineteen enzymes activated during this stage is Transmembrane 7 Superfamily member 2 
(TM7SF2), discussed in this work (Figure 1.13). The terminal reaction in cholesterol biosynthesis is 
catalysed by the enzyme 7-dehydrocholesterol reductase encoded by the DHCR7 gene. Functional 
DHCR7 protein is a 55.5kDa NADPH-requiring integral membrane protein localised to the 




Literature studies have shown, that while cholesterol biosynthesis involves an energetically 
expensive multi-step process involving over 20 enzymes, the pathway leading to final cholesterol 
biosynthesis from lanosterol has been directed into two pathways, the Bloch and Kandutsch-Russell 
pathways. These pathways have common initial steps starting from acetate and then branch out 
after lanosterol and while these pathways do not have common intermediates after lanosterols. 
Both routes are not exclusive as same enzymes act in each of the pathways. NADPH-dependent 
reduction step is catalysed by the sterol reductases; Transmembrane7 Superfamily member 2 
(TM7SF2) and 7-dehydrocholesterol reductase (DHCR7), among others, which this study focuses on 
for investigative studies on their role in ER expansion (Figure 1.13). Activities of these terminal 
enzymes can affect membrane organisation and dynamics, as the addition and position of the 
double bond in desmosterol and 7-dehydrocholesterol confers very different properties to the cell 
































Figure 1.13    A schematic representation showing the link between Bloch and Kandutsch-
Russel pathways and Cholesterol biosynthesis Pathway. In a cascade mechanism, 
cholesterol is ultimately produced following a series of over 30 reaction steps (here 
briefed). After 13 enzymatic steps, the intermediate Lanosterol can enter one of two 
parallel pathways designated Bloch and Kandutsch-Russel pathways, respectively, both of 
which employ an NADPH-dependent reduction step which can be catalysed by the sterol 
reductases; Transmembrane7 Superfamily member 2 (TM7SF2) and 7-dehydrocholesterol 
reductase  (DHCR7), highlighted as shown. Lamin B Receptor is also shown. This study 
focuses on these two proteins for their investigative role in ER expansion. Adapted, with 
modifications, from (Tsai et al., 2016). 
 
1.8.1        Transmembrane 7 Superfamily member 2 
Transmembrane 7 Superfamily member 2 (TM7SF2), also known as sterol C14-reductase and 3 β-
hydroxysterol δ-reductase belongs to the ERG24 family in that, they are C-14 sterol reductases and 
catalyse the reduction of C-14 unsaturated sterol intermediates in cholesterol and sterol biosynthesis 
respectively. This 418 amino acid gene encodes 3β-hydroxysterol δ-14-reductase  which catalyses 
the reduction of the Δ14-double bond of sterol intermediates in the post-squalene segment of the 
cholesterol biosynthesis pathway (Bennati et al., 2006) using NADPH dependant reduction of 4,4-
dimethyl-5-α-cholesta8,14,24-trien-3-β-ol to 4,4-dimethyl-5-α-cholesta-8,24-dien-3-β-ol and NADP+.  
TM7SF2 
DHCR7 





TM7SF2 exacts its functional activity according to the structural organisation of its nine 
transmembrane domains (TMD) using TMpred prediction program which was reported by Roberti et 
al., (2002). As a protein coding gene, TM7SF2 presides over an anti-inflammatory loop and its absence 
correlates with an inflammatory phenotype, which are NF-kB activation and TNFα up-regulation 
(Bellezza et al., 2013).  Although located in the ER having nine transmembrane segments (TM), its 
catalytic domain comprises the C-terminal domain which is 58% identical to LBR  (Zwerger et al., 
2010) hence exposed to the cytoplasmic part of the cell (Figure 1.14). This research was conducted 
following findings by Zwerger et al., 2010 and some of the samples used by their group had been 
obtained for this work with the intention that our report will serve as a basis for further discussions 
on the impact of the genes on cellular modification.  
 
Figure 1.14 shows the site of C-terminal truncations that corresponds to LBR disease mutants as 
constructed by the Zwerger et al., 2010, some of which were further exploited in this work. As an ER 
localised protein, its role in lipid metabolism - steroid biosynthesis, as a membrane protein has been 
widely reported. Several reports suggest that modifications of the cholesterol biosynthetic pathway 
directly affect cell proliferation (Singh et al, 2013). TM7SF2 has its expression regulated by the sterol 
regulatory element binding protein (SREBP) in response to cellular cholesterol levels (Tsai et al., 
2016).  
 
For instance,  Bellezza et al., (2015), have implicated TM7SF2 in the driving of a host of protective 
responses after topical 12-O-tetradecanoylphorbol-13-acetate (TPA) challenge, centred on increased 
cholesterol and cholesterol sulphate levels when they applied 12-o-tetradecanoylphorbol-13-acetate 
(TPA) to the skin of TM7SF2(+/+) and TM7SF2(-/-) mice. TPA increased skin cholesterol levels by 
inducing de novo synthesis and up-take only in TM7SF2(+/+) mouse, confirming that the gene 
maintains cholesterol homeostasis under stress conditions. Functional redundancy suggests that 
TM7SF2 is also involved in other physiological functions (Bennati et al., 2008).  Reports have also 
shown that TM7SF2 deficiency during liver regeneration alters lipid metabolism and generates a 
stress condition, which, in turn, transiently unbalances hepatocytes cell cycle progression (Bartoli et 
al., 2016). Another study also reported on the role of the TM7SF2 gene as an anti-inflammatory agent 
aside being involved in cholesterol biosynthesis, thereby confirming the existence of cross talk 




expression following tunicamycin exposure and in the oedematogenic response in TM7SF2(+/+) was 
observed (Bellezza et al., 2013).   
 
1.8.2        7-dehydrocholesterol reductase 
The human 7-dehydrocholesterol reductase (DHCR7) protein is predicted to have a molecular 
weight of 54,489 kDa with 475 amino acids (Correa-Cerro & Porter, 2005).  It encodes δ-7-sterol 
reductase, the penultimate enzyme of mammalian sterol biosynthesis that converts 7-
dehydrocholesterol (7-DHC) to cholesterol, which catalyses the final step in cholesterol synthesis, 
by a reduction of the sterol C7 - C8 double bond, using NADPH as an electron source (Zou et al., 
2013). With a gene that spans 14,100 base pairs (bp) of genomic DNA, consisting of nine exons 
transmembrane domains (Figure 1.14), DHCR7 is ubiquitously expressed and its transmembrane 
protein localises to the ER membrane as well as the nuclear outer membrane. Cholesterol, though 
harmful in high levels, is essential to life since it is involved in membrane structure and permeability, 
synthesis of steroid hormones and proper fetal development (Peng et al., 2018), hence a lack of 
functional DHCR7 results in an accumulation of 7DHC and reduced cholesterol synthesis, resulting 
in the devastating developmental disorder Smith-Lemli-Opitz syndrome (SLOS) (Prabhu et al., 
2016).  
 
SLOS is an autosomal-recessive syndrome of multiple malformations and intellectual disability 
resulting from a genetic error in cholesterol synthesis in all cells and tissues, including brain. The 
first DHCR7 mutations were identified in 1998 by several groups and the early years of the 21st 
century resulted in more advanced molecular tests to rapidly identify DHCR7 mutations. Most 
mutations are identified through sequence analysis of coding exons and flanking intronic sequences 
(Waterham & Hennekam, 2012). When the activity of 7-dehydrocholesterol reductase is unusually 
low, there tends to be abnormally reduced levels of plasma and tissue cholesterol which in turn 
results in the accumulation of the cholesterol precursor, 7-dehydrocholesterol (cholesta5,7-dien-
3b-ol), and its isomer, 8-dehydrocholesterol (cholesta-5,8-dien-3b-ol). Because cholesterol is 
essential for the functioning of every mammalian cell and is required for normal embryonic growth, 
developmental abnormalities could result markedly via the inhibition of its synthesis or by 





1.8.3 Lamin B Receptor (LBR) is a related sterol reductase to Transmenbrane 7 Superfamily 
member 2 and 7-dehydrocholesterol reductase 
The description of Lamin B Receptor (LBR) was first published in 1988 from the Blobel laboratory 
(Worman et al., 1988). The human lamin B receptor (LBR) is a fascinating multi-span integral 
membrane protein of 615 amino acids in the inner membrane of the nuclear envelope (NE) 
(Herrmann & Zwerger, 2010) with an N-terminal lamin B and chromatin-binding domains and a C-
terminal sterol δ-14 reductase domain (Tsai et al., 2016). The relationship that exist between LBR 
and TM7SF2/DHCR7 has been widely reported (Figure 1.14). Prediction sequencing have shown, 
that LBR shares a unique relationship with Transmembrane 7 Super family member 2 (TM7SF2) and 
7-dehydrocholesterol reductase (DHCR7), with the identification of two paralogs in the genome for 
the C-terminus only of human LBR whereby TM7SF2 has 58% identical amino acids residues with 
LBR while DHCR7 has 37% identical and amino acids with LBR (Olins et al., 2010).   
 
TM7SF2 has its expression regulated by the sterol regulatory element binding protein (SREBP) in 
response to cellular cholesterol levels; whereas LBR is an inner nuclear membrane protein, and the 
LBR gene lacks an SRE consensus sequence, thus being constitutively expressed (Tsai et al., 2016).  
The nuclear envelope (NE) is highly dynamic during the cell cycle whereby it disassembles into 
membranous vesicles or tubules and disperses into the cytoplasm at the onset of prometaphase 
and reassembles around the newly replicated chromosomes at the end of mitosis (Lu et al., 2010).  
The structural organisation of the LBR shows an N-terminal nucleoplasmic region, which acts as the 
interface for interactions with many binding partners, followed by eight putative transmembrane 
regions, which have homology with cholesterol reductases such as human TM7SF2/DHCR7 
although, bioinformatics searches and TM prediction tools provide both inconsistent predictions on 
the motifs and domains as the total number of TM segments have been predicted as eight (TM 8) 
in some cases and nine (TM 9) in others (Figure 1.15) (Olins et al., 2010).  
 
Therefore predictions have shown that 208 amino acid amino-terminal part binds to B-type lamins, 
chromatin and chromatin-associated proteins, whereas 407 amino acids carboxyl-terminal part of 
has been predicted to exhibit 8 transmembrane domains that anchor the protein into the 
membrane (Herrmann & Zwerger, 2010). LBR is composed of double lipid bilayers referred to as 
the outer nuclear membrane (ONM) and the inner nuclear membrane (INM) (Figure 1.15). While 




transmembrane proteins termed INM proteins (Iwamoto et al., 2019). Genes (TM7SF2 and DHCR7) 
used in this work were obtained from Monika Zwerger. Diagram is shown to highlight the amino-
acid lengths of these genes. TM7SF2 was truncated at (1- 418) while DHCR7 at (1- 475) amino-acids. 
Zwerger et al., (2010) publication described extensively, the influence of all the truncated genes 




Figure 1.14   Structural Organisation of human Lamin B Receptor (LBR) and human sterol 
reductases Transmembrane 7 Superfamily member 2 (TM7SF2) and 7-dehydrocholesterol 
reductase (DHCR7). Inconsistent predictions have led to the generation of two transmembrane 
domains for LBR; TM 8 and TM 9 using TM prediction tools. Effects of LBR disease mutations were 
investigated by Zwerger et al., 2010 on the organization of the nuclear envelope (NE). Mutations 
were caused at the C terminal regions of TM Domains of truncated LBR with variants (in black 
boxes) of known disease-related mutations as described in PHA and Greenberg skeletal dysplasia 
patients. The Transmembrane Domain are represented with yellow-numbered boxes (1-8) and (1-
9) for LBR, and (1-9) for each of TM7SF2 and DHCR7. While the yellow colours indicate lumenal 
stretches, the dark grey colours indicate the domains exposed to nucleoplasm/cytoplasmic part 
of the cell. Highlighted numbers with grey background indicate the amino acid length (418 for 
TM7SF2 and 475 for DHCR7) while 181, 238,336, 227, 285 and 393 are the corresponding sites of 
C-terminal truncations that relate to LBR disease mutants. red numbers specify the amino acid 
that N-terminally truncated LBR variants initiate with; and green numbers identify single amino 



















Figure 1.15 Schematic diagram of the Nuclear Envelope (NE) showing link between 
Transmembrane domains and full-length Lamin B Receptor (LBR) in the inner nuclear 
membrane (INM). The Nuclear Envelope consists of the inner nuclear membrane 
(INM) and the outer nuclear membrane (ONM). While the ONM is embedded in the 
cytoplasm and continuous with the rough endoplasmic reticulum, the INM which 
consists of over 100 highly organized transmembrane proteins complexes interact 
with heterchromatin where the LBR tethers the lamina. Lamin B Receptor (LBR) is 
predicted to have two transmembrane domains (TM 8 and TM9) to the disposition 
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1.8.4       Transcriptional Regulation by SREBP of Cholesterol Biosynthesis  
 
Cholesterol biosynthesis is tightly regulated by a mechanism of negative feedback that senses 
cholesterol and oxysterols. Literature studies reveal that the SREBP (Sterol regulatory element 
binding protein) family of transcription factors are activated in response to low sterol status and 
help coordinate the cholesterol synthesis pathway (Sharpe & Brown, 2013). Therefore, nearly all 
the genes encoding cholesterol synthesis enzymes are SREBP targets. The transcription factor 
sterol regulatory element-binding protein-2 (SREBP-2) is the key regulator of genes involved in 
cholesterol synthesis such as HMG-CoA reductase (HMGCR), HMG-CoA synthase (HMGCS), and 
mevalonate kinase (MVK), as well as the LDL receptor (LDLR) which is responsible for cholesterol 
uptake (Brown et al., 2019). 
 
SREBPs are synthesised as inactive proteins and become active after forming a complex with 
SREBP cleavage activating protein (SCAP). They bind to sequences upstream of specific genes 
involved in lipid biosynthesis, called sterol response elements (SRE), and activates transcription. 
Mammalian cells produce three SREBP isoforms, called SREBP-1a, SREBP-1c, and SREBP-2 (Cheng 
et al., 2018) (Figure 1.16). As lipid biosynthesis is key to cellular activity, the ER itself is encased by 
a large membranous structure and lipids are required for formation of other secretory pathway 
components including vesicles for trafficking, the Golgi and plasma membrane, an alternative 
approach to increasing the ER capacity of the cell to up-regulating components for the UPR may 
be to expand the ER and secretory pathway itself by manipulating lipid biosynthesis.  
 
Further, other than the widely studied SREBP, numerous other transcription factors have been 
implicated in the transcriptional control of the various enzymes in cholesterol synthesis. Liver X 
Receptor (LXR) has been reported to regulate cholesterol biosynthesis by directly silencing the 
expression of two cholesterogenic enzymes (FDFT1 and CYP51A1) (Wang et al., 2008). Liver X 
Receptors (LXRs) are members of the nuclear receptor superfamily comprising several ligand-
activated transcription factors and play a crucial role in regulating the expression of genes 
involved in lipid metabolism (Fiévet & Staels, 2010). Gene transcription is modulated by LXRs, 
which heterodimerise with the retinoid X receptor and bind to LXR-response elements in the 




The work in this thesis is driven by the hypothesis that manipulation of the CHO cell ER and 
secretory capacity can be achieved by manipulation of proteins known to impact on ER expansion. 
In particular, there are reports that manipulation of the proteins; transmembrane 7 Super family 
member 2 protein (TM7SF2) and 7-dehydrocholesterol reductase  protein (DHCR7) can impact 





























































Figure 1.16   SREBP regulation of TM7SF2 and DHCR7. A transcription factor termed 
sterol regulatory element binding protein (SREBP) which binds to the sterol regulatory 
elements (SREs) and enhances transcription. However, the SREBP is held captive bound 
to the endoplasmic reticulum membrane. Activation of SREBP 1a, 1c and 2, results in an 
activation of TM7SF2 and DHCR7 which favour cholesterol production. In other words, 
the SREBPs when it is released by proteolytic cleavage travels to the nucleus, where it 









1.9.0 Rationale and Hypotheses of the Work undertaken in this Thesis 
In 2010, researchers attempted to cause fundamental influence on the endoplasmic reticulum and 
nuclear membrane expansion by manipulating Lamin B receptor (LBR), Transmembrane 7 Super 
family member 2 (TM7SF2) and 7-dehydrocholesterol reductase (DHCR7) amounts (Zwerger et al., 
2010).  Although the primary topic for research and discussion was the N-terminal domain of LBR, 
it was reported that the overexpression of intact TM7SF2 and DHCR7 as well as mutant LBR C-
terminal mutations resulted in peculiar cellular phenotype where by the large dilations were 
observed as an aftermath throughout the entire cell and especially at the nuclear periphery. When 
the distance of enlargement measured created was about 50 nm – 150 nm compared to the 30 nm 
– 50 nm observed in normal cells.  
 
These findings are indeed remarkable knowing that both the inner nuclear membrane and the outer 
nuclear membrane have a constant thickness and diameter across cells (Shibata et al., 2006). The 
notable findings also suggest an endoplasmic reticulum expansion was also impacted on some 
phenotypic characteristics. For instance, Zwerger et al., (2010) had again reported, that the 
overexpression of the wild-type forms of TM7SF2 and DHCR7 but not wild type LBR mimicked the 
phenotype observed for mutant LBR, suggesting therefore, that even fully functional proteins can 
critically affect the endoplasmic reticulum (ER) and nuclear membranes (NE) morphology. These 
findings were observed in different cell lines with different reactions/responsiveness leading to the 
dilation of the ER and NE nuclei compacted markedly and “cytoplasmic vacuoles” (CVs) as they 
developed and increased in size.  
 
Our interest in this research was to investigate further the two sterol reductases as their 
overexpression have been hypothesised to cause ER expansion. We wanted to corroborate the 
findings as published by Zwerger et al., (2010) with the overexpression of TMSF2 and DHCR7 as 
targets in CHO cells and note if the findings are same or similar to those observed when other 
mammalian cell lines were used.  From the literature studies discussed earlier (section 1.3), CHO 
cells have been widely reported to show a remarkable post translational modification qualities and 
if these would in any way influence the impact on endoplasmic reticulum size and nuclear 





While the main focus in the report by Zwerger et al., (2010) focused on the LBR, with a report that 
the two wild-type sterol reductases (Transmembrane 7 Superfamily member 2 and 7-
dehydrocholesterol reductase) also mimicked mutant LBR with the phenotype observed, suggesting 
that even fully functional proteins can critically affect the ER and NE morphology. This is interesting 
knowing that both Transmembrane 7 Superfamily member 2 and 7-dehydrocholesterol reductase 
are endoplasmic reticulum localized proteins and key enzymes of the cholesterol biosynthesis and 
their role in lipid generation has been widely reported. The Lamin B receptor protein, however, is 
known to have dual function, as it functions both as a sterol reductase and has also been implicated 
in the structural organisation of heterochromatin.  
 
Our interest therefore was to investigate if these sterol reductases, when overexpressed in stable 
expression system CHO cell line can show phenotypic characteristics which may result in 
endoplasmic reticulum expansion. Further, to investigate whether the manipulation of these 
targets can also impact on recombinant protein production, two difficult-to-express model proteins 
were also assessed in engineered CHO cell lines over-expressing wild type TM7SF2 and DHCR7 and 
their expression compared to control cell lines.  The hypothesis to be tested therefore, is that 
controlled manipulation of cholesterol biosynthesis by overexpression of Transmembrane 7 
Superfamily member 2 and 7-dehydrocholesterol reductase will result in expansion of the 
endoplasmic reticulum and also an enhancement of the efficiency of the CHO platform as a 
recombinant protein expression system by improving cell growth, yield and quality of recombinant 












1.9.1 Project Aims & Objectives 
This project set out to address the hypothesis that an alteration of key cellular components by over-
expressing target genes that play key functional role in cholesterol biosynthesis at the molecular 
level would result in a controlled systemic manipulation of cholesterol (lipid) biosynthesis and 
hence ER expansion for an improved secretion processes of the CHO platform as a recombinant 
protein expression system. Prior to the commencement of this research, studies had reported on 
the effect of overexpression of the carboxyl-terminal domain of Trans membrane 7 Super family 
member 2 (TM7SF2) and 7-dehydrocholesterol reductase (DHCR7) as described above in section 
1.9, which critically affected the membrane integrity by causing a dilation and nuclear compaction 
and that when overexpressed in U2OS cells, an identically induced phenotype was observed in both 
the truncated and the full length variants. At the onset, the aim of this thesis was to use this 
information to investigate the CHO mammalian cell secretory machinery for ER expansion by 
manipulating the expression of these cholesterol (lipid) biosynthesis genes thereby investigating 
the influence on the phenotypic traits as it affects the growth, yield and whether this resulted in an 
overall improvement of the CHO cells secretory pathway capacity for recombinant protein 
production. Therefore, the aims of this project was to: 
 
1) To generate a series of CHOS-derived cell pools and clonal cell lines 
from stable heterogeneous pools over-expressing TM7SF2 and DHCR7. 
 
2) To investigate whether overexpression of these genes individually will 
influence phenotypic characteristics such as growth and viability that 
favour CHO-S secretory machinery. 
 
3)  To investigate and determine if the manipulation of cholesterol (lipid 
biosynthesis) by altering cellular pathway processes can be used to 
enhance secretory productivity from CHO-S cells, using EPO and 









2.0       Materials and Methods 
2.1       Chemical Reagents and Preparation of Solutions 
All reagents used for the work as described in this thesis were of the highest grade and obtained 
from standard sources (such as; Sigma Aldrich, Fisher Scientific). All solutions were prepared using 
MilliQ water except where otherwise stated. Solutions were sterilised using an autoclave.  
 
2.2 Generating Competent DH5α E.coli cells and bacterial transformations  
DH5α E. coli competent cells were prepared by initially streaking cells onto Luria Bertani (LB) agar 
plates and placed in an incubator overnight at 37°C. A single colony from the plate was then picked 
and incubated overnight in 2 ml of liquid LB broth in a 15 ml falcon tube at 37°C with orbital shaking 
at 200 rpm. 0.5 ml of the starter culture was then used to inoculate 40 ml of liquid LB broth and 
incubated at 37°C with shaking at 200 rpm, until an OD600 nm of between 0.3 - 0.5 absorbance was 
obtained. The DH5α cells were then pelleted (2500 g for 5 min) and then re-suspended in 20 ml of 
50 mM CaCl2 and incubated on ice for 30 min. The cells were then pelleted again (2500 g for 5 min) 
and resuspended in 4 ml of ice-cold 50 mM CaCl2 and incubated on ice for a further 30 min. 100 µl 
aliquots of the cell suspension were then placed into sterile 1.8 ml cryovials on dry ice. Aliquots of 
the competent cells were then stored at -80°C until required. 
 
The introduction of foreign DNA into a bacterial cell was performed to generate copies of the 
required plasmid DNA. The protocol was as follows;  
 
1.       A vial (200 µl) of competent cells (DH5α) was removed from storage at -80°C and thawed 
on ice. Transformation tubes were also chilled on ice during this time.  
2.       Once thawed, 50 µl of the bacteria was added to a transformation tube along with 2.5 µl 
(5% total volume) of plasmid sample or ligation reaction mixture.  
3.     This mixture was left on ice for 10-15 min, heat shocked in a 42°C water bath for    30- 40 




4.    500 µl of Super Optimal broth with Catabolite repression (SOC) media (prepared in the 
laboratory) was immediately added, and this mixture incubated at 37°C for 1 h at 200 rpm 
agitation speed.  
5.      The sample was then transferred to a fresh 1.5 ml tube and centrifuged at 3000 rpm in a 
bench top microfuge for 3 min to pellet the bacterial cells.  
6.      The majority of the supernatant was removed and the pellet resuspended in 40 µl of SOC.  
7.      This was then spread on LB agar plates (10 g Tryptone, 5 g Yeast Extract, 10 g NaCl (Sigma, 
cat # S7653), 20 g agar select, to 1 L with MilliQ water, autoclaved before use) containing 
ampicillin or kanamycin depending on plasmid used in ligation (100 ng/ml working 
concentration) and incubated overnight at 37°C. 
 
2.2.1 Plasmid DNA recovery from E.coli cells  
DH5α E.coli cells transformed with DNA constructs were cultured in 6 ml or 250 ml liquid LB 
broth overnight with 50 µg/ml ampicillin antibiotic selection at 37°C with shaking at 200 rpm. 
DNA was extracted and recovered from transformed DH5α E.coli cells using the commercially 
available mini prep/high speed maxi prep kits from Qiagen following the protocols provided with 
each kit. 
 
2.3         DNA Restriction Enzyme digestion  
All DNA digestions were undertaken using Promega or Fermentas restriction enzymes and the 
appropriate buffers as instructed by the manufacturers. Each restriction digest enzyme was used 
with the appropriate restriction site sequence as specified in the results section (Chapter 3).  
Digests were undertaken following the protocols provided with the specified enzyme by each 
manufacturer. 
 
2.4     DNA Ligation reactions 
Ligations of DNA inserts amplified by PCR or of DNA fragments released from donor vectors by 
restriction digestion was generally achieved using a commercially available T4 DNA ligase 
(Promega) following the protocol provided with enzyme (Table 2.1). The ligation was carried out 





Insert mass (ng) =Insert length (bp)   x   Vector Mass (ng) x 5 (ratio)  













2.4.1        Alkaline Phosphatase (AP) Treatment   
This procedure precedes ligation as an intermediary step. After digestion and purification of the 
plasmid backbone and the PCR product (eluted with nuclease-free water into ~45 µl), it was 
important to ensure that there was no re-circularisation of digested plasmid backbone samples 
(Table 2.2). The purified plasmid samples were treated with alkaline phosphatase (AP) which 
dephosphorylates the phosphodiester bonds in DNA decreasing the probability of sticky ends 
(generated from restriction digests) from re-joining undesirably. This was performed to improve 
the efficiency of future ligation reactions. 








 Table 2.1    Typical example of ligation components 





Table 2.2    Typical alkaline phosphatase (AP) treatment of 
ligation components and volumes 
        Component         Volume 
Purified Plasmid  44.6 µl 
AP Buffer (10x)  5 µl 
AP  0.4 µl 
Total volume 50 µl 
 
 
2.5     Quantification of DNA and RNA Samples  
Measurements of isolated DNA and RNA sample concentrations were performed using 1 µl of the 
sample on an ND-1000 spectrophotometer (nanodrop). After initialisation with water appropriate 
solvents (as described in the following sentences) were used to zero the device; for plasmid 
samples isolated using the Qiagen miniprep kit, 1 µl of the kit’s elution buffer was used. For 
plasmid or DNA samples extracted from an electrophoresis gel using the QIAQuick gel extraction 
kit or otherwise, 1 µl of the kit’s elution buffer was used. DNA concentrations were recorded as 
the ratio of absorbance at 260 nm and 280 nm. DNA/RNA was then quantified in ng/ µl. 
 
 
2.5.1 Large Scale Preparation of Plasmid DNA (Maxiprep/Midiprep)  
For generating larger quantities of plasmid DNA, a Maxiprep/Midiprep kit was used (Qiagen). A 
larger volume of Luria Broth (LB) media was used to facilitate larger scale proliferation of the 
cells. The following protocol was performed as outlined in the operating manual;  
 
1. After successful generation of transformed colonies, a starter culture of LB and 
single colony, equivalent to a miniprep (5-10 ml universal) was made.  
2. This starter culture was then added to a further 200 ml of LB broth containing 




3.  After incubation this culture was then centrifuged at 6000 g for 15 min, 4°C, and 
the   supernatant discarded.   
4.   The resulting cell pellet was then processed using a Qiagen Plasmid Maxi kit (see 
manufacturers protocol for details), with a final DNA resuspension step carried 
out using 250-500 µl of TE buffer.  
5.  The concentration of this DNA prep was determined using a Nano Drop 1000 
spectrophotometer. This was then used in subsequent DNA manipulation 
reactions or stored at -20°C. 
 
2.5.2 Small Scale Preparation of Plasmid DNA (Miniprep)  
Commercial kits were again used for minipreps of plasmid DNA from bacterial colonies (Qiagen 
Mini kits) following protocol as outlined in the operating manual;  
1. After successful generation of transformed bacterial colonies, a single colony 
was picked and grown overnight at 37°C, 170 rpm in a 5-10 ml aliquot of LB broth 
(autoclaved before use) containing appropriate antibiotics. 
2. This culture was then processed using a Qiagen QIAprep Spin Miniprep kit (see 
manufacturer’s protocol for details), with a final DNA elution step carried out 
using 30-50 µl of TE buffer.   
3.  The concentration (ng/ µl) of this DNA prep was determined using a Nano Drop 
1000® spectrophotometer. This could then be used in subsequent DNA 
manipulation reactions or stored at -20°C. Typical yields were ~200-450 ng/ µl.  
 
This miniprep sample was then used in downstream processes; typically small scale minipreps were 
suitable and used in initial restriction digest tests to ensure cloning was successful and for sending 
a sample away for sequencing to Beckman Coulter, thereby verifying that the correct fragment 






2.6      DNA Sequencing 
Aliquots of prepared plasmid DNA constructs with genes of interest (TM7SF2 and DHCR7 in 
pcDNA3.1 Hygro vector) were sequenced using a Sanger sequencing service provided by Beckman 
Coulter Genomics in Danvers, Massachusetts. Samples (templates) were prepared at concentration 
of 100ng/10 µl in PCR tubes. Therefore samples were prepared and made up to 10 µl volume using 
nuclease free water in order to prevent EDTA in the plasmid DNA samples. Primer T7 and BGH were 
used as forward and reverse primers respectively. The technique is used to determine the precise 
order of the four nucleotide bases – adenine, guanine, cytosine and thymine that make up a strand 
of DNA.  Therefore plasmid DNA to be sequenced served as a template for DNA synthesis where T7 
forward primer starts the process of synthesis on the strand of DNA constructs to be sequenced. 
Basically, the process involved four reactions of Adenine, Guanine, Cytosine and Thymine 
deoxynucleotide triphosphates (dNTPs) and each would have a low level of one of four 
dideoxynucleotide triphosphates (ddNTPs): ddATP, ddGTP, ddCTP, or ddTTP which included four 
ddNTPs. Since, the ddNTP molecule lacks a 3' hydroxyl group, which is required to form a link with 
the next nucleotide in the chain, synthesis terminates at the incorporation of ddNTP. The cycle 
continues till cycle for nucleotides have been done. Then, an autoradiogram of the four reactions 
can be read to yield the linear DNA sequence of all four bases and this would provide information 
on the presence or absence of genes of interest, TM7SF2 and DHCR7 needed in pcDNA3.1Hygro for 
this project. 
 
2.7      Mammalian Cell Culture  
2.7.1      Cell culture maintenance  
All cell culture work was carried out in a laminar flow hood and cell culture sterile disposable plastic 
materials, manufactured by Sarstedt Incorporated, Fisher scientific, UK used unless otherwise 
indicated. When sterile glass or other materials were used, these were sterilised in an autoclave for 
45 min at 120°C. The host Chinese hamster ovary (CHO) cell line used throughout this study was 
the industrially relevant CHO-S cell line (ThermoFisher Scientific/Life Technologies). CHO cell lines 
were regularly maintained in suspension culture in flasks in chemically defined, protein free CD-
CHO media (ThermoFisher) at 37°C in a 5% CO2 atmospheric condition with shaking at 125 rpm. This 




circulated within the cell cultures thereby allowing mass transfer due to adequate mixture of 
oxygen, nutrients and heat as this discourages cells clustering which occurs due to inadequate 
circular air. By shaking at 125 rpm, following protocol, it was observed that cells were not too 
agitated which may result in collision within cells, collision with vessel walls or with impeller from 
such turbulence shear forces. Again, inadequate agitation increases viscosity within cells which 
impacts on cell efficiency. Cells were regularly passaged where spent media was aspirated off and 
cells passaged at minimal 0.2 x 106 viable cells/ml in fresh growth media. CHO-S engineered or 
variant cell lines, were routinely cultured while ensuring cells were allowed to grow and after 5-6 
passages, were suitable for experimental use. Control mechanisms used during cell culture involved 
spacing flasks in infors to prevent collisions. Also cells continue to shake in flasks during culturing 
as infors remained on and only cells being cultured under same experimental conditions were used 
for research. CHO-S cells were grown in serum-free chemically defined CD-media. All engineered 
CHO-S cells were cultured with antibiotic selection prior to experimentation following the 
generation of stable cell lines. These stable cell lines generated in CHO-S cells were cultured with 
50 µg/ml hygromycin B (Invitrogen) in order to maintain the selection for the gene of interest. Cells 
were harvested by centrifugation at 1000 rpm in a MSE bench top centrifuge. For cryopreservation 
cells were prepared in 10% DMSO (Sigma), 90% CD-CHO at a concentration of 1 x 107 viable cells/ml. 
This freezing mixture containing the cells, which had been taken from mid-exponential phase of 
growth, following the assessment for cell numbers and viability state (from a commercially available 
ViCell machine by Beckman Coulter), was then aliquoted into 1.8 ml cryopreservation tubes (Nunc, 
Roskilde, Denmark) in 1 ml aliquots, placed in a polystyrene box and stored at -20°C for 3-5 h then 
-80°C overnight or stored in a cryo 10°C freezing container (NALGENE, 5100-0001), after which they 
were transferred to liquid nitrogen storage until required.  
 
2.7.2  Recovery of cells from cryopreservation 
Cell revival was achieved by rapidly thawing one vial of frozen cells by placing the tube in a 37°C 
water bath until completely thawed. The vial contents were then added to 10 ml of appropriate 
media to wash cells by removing traces of DMSO. The solution was then centrifuged at 1000 rpm 
for 5 min and the supernatant discarded. The cell pellet was then re-suspended in 10 ml of fresh 
growth media, put in a culture flask and gassed with 5% CO2 in air before incubation for 1-2 days at 




2.7.3      Monitoring of CHO-S cell growth 
Prior to experimentation, exact cell numbers to work with, was a necessary requirement for 
research work. Cells were counted for cell concentration determination and culture viability using 
an automated ViCell instrument (Beckman Coulter). When using a haemocytometer, the 
percentage culture viability was calculated by dividing viable cells by total cells of a sample 
population. Counts were made by analysing the number of cells in four large squares followed by 
application of the equation: 
 
Culture viability (%) = Total no. of living cells x 100 




 2.8       Generation of Stable CHO-S Cell Pools and lines expressing a Target Gene of Interest 
 2.8.1      Linearisation of YFP-YM7SF2, YFP-DHCR7, GFP, pcDNA3.1HYGRO plasmids 
Prior to the generation of stable cell lines, plasmid constructs were linerarised in order to enhance 
productive integration. Fsp1 restriction digest enzyme (From New England Biolabs) was used to 
linearise the plasmids. 40 µg DNA plasmid was used in a 1: 1 ratio of DNA: Restriction Enzyme. 
Following preparation of DNA with Milli-Q water and appropriate buffer as directed by 
manufacturer, mixture was placed at 37°C over night as Fsp1 is a known slow reactive enzyme. At 
12 h post reaction, sodium acetate washes were done with 100% cold ethanol of appropriate 
volumes. This follows a series of centrifugation stages at 4°C with the careful removal of 
supernatant. With a repeat of ethanol wash, the residual fluid is collected using nuclease-free 







2.8.2     Determination of optimal selection Antibiotic concentration: THE KILL CURVE 
To generate stable cell lines, a first critical step is determining the optimal antibiotic concentration 
for selecting stable cell colonies. A “Kill curve” was therefore undertaken, which is a dose-
response experiment where the cells are subjected to increasing amounts of antibiotic in order to 
determine the minimum concentration of antibiotic needed to kill all the cells over the course of 
one week. Cells were plated in 24-well tissue culture plate of 0.5ml growth media/well one day 
prior to introducing hygromycin B antibiotic selection from Thermofisher Scientific. Cells of 
confluents between 70-80% were then seeded at 0.2x106 viable cells/ml. Therefore, for 0.5 ml 
media, cells were seeded at 0.1 x106. Next, 50 mg/ml hygromycin B was added in an increasing 
amount/volume, into duplicate wells of cells plated in complete media. There was a plate with no 
hygromycin B added to serve as control. Thereafter, hygromycin B was added into duplicate wells 
as   0, 250, 500, 750, 1000 ng/ µl. Media containing selection was replaced every 2-3days for up 
to 14 days. A decision on the optimal dose was made by considering the lowest hygromycin B 
antibiotic concentration at which all cells were dead after one week of antibiotic selection. The 
kill curve was also plotted (Figure 2.1). For the purpose of this study, 750 ng/ µl was considered 
the optimal hygromycin B concentration and was used for this study. It was observed that cells 
responded to drug at 750 ng/µl concentration with some resistance, tolerance and persistence 
over a 10 day period and this antibiotic sensitivity of cells appeared to have been retained across 
culture media with 3 independent experiments unlike the response to 500 ng/µl where cells were 
observed to be more susceptible to the effect of hygromycin B antibiotic as same pattern of 







Figure 2.1 Hygromycin B Kill Curve for stable cell line generation. Selected 
transfected cells were selected using optimal antibiotic concentration, which is 
the lowest concentration that kills cells with 14 days. Here, 750 ng/ µl was the 
optimal concentration used for this study. Error bars represent percentage among 
biological triplicates (where n = 3). 
 
 
2.8.3       Transfection protocol for stable cell line generation 
Stable CHO-S cell pools and lines overexpressing exogenous target genes of interest (YFP-TM7SF2 
and YFP-DHCR7) were generated and cultured in the laboratory for research purposes. The target 
genes were obtained from Monika Zwerger, School of Biological and Biomedical Sciences, 
University of Durham, South Road, Durham (Zwerger et al., 2010) which had been cloned with YFP 
at the N-terminal into a Clontech plasmid. The following sub-cloning strategies were carried out 
which involved releasing the target genes (YFP-TM7SF2 and YFP-DHCR7) from the donor pEYFP-






























For transfection protocol by Thermofisher, cells were initially seeded to be 70-90% confluent.  
Then a dilution into four, the amount of Lipofectamine® Reagent in Opti-MEM® media was done. 
4 µg/DNA plasmid of YFP-TM7SF2 and YFP-DHCR7 was each diluted in Opti-MEM® Media and 
allowed to mix for 5min. After the incubation of DNA with Opti-MEM® Media, the diluted DNA 
was subsequently added to the diluted Lipofectamine® 2000 Reagent in a 1:1 ratio. Again, this 
was allowed to incubate for 5-10 min before the DNA-lipid complex was introduced to cells and 
allowed to settle at 37°C for 4-6 h before, removing the transfection media and now adding more 
of cell media and allowed to incubate for 24 h. 
 
   Tube1: 300 µl optimum + 14.4 µl lipofectamine 2000 (obtained from Thermofisher 
Scientific)  
Tube2:  300 µl optimum + 4.8 µg plasmid (YFP-TM7SF2 or YFP-DHCR7 respectively) 
 
The tubes were then kept in an upright position for 5 min before mixing tubes 1 and 2 together 
by gentle pipetting. The mixture was then allowed to remain at room temperature for 20 min 
before adding 100 µl of final solution/mixture to each well while gently rock to mix. This was 
followed by incubation at 37°C for 4-6 h. Transfection media was then removed and replaced with 
fresh pre-warmed (37°C) media (600 µl/well). Cells were usually allowed to grow for a week 
before monitoring and counting. Usually, cells were moved to T25 flasks with 10 ml fresh media 
and selection antibiotics (Hygromycin stock 50 mg/ml, Invitrogen). By regular passages, successful 
stably engineered cells were subsequently cultured in 20 ml cell media at 0.2 x 106 viable cells/ml 
with regular selection antibiotics. For control cell pools, stable CHO-S expressing GFP and 
pcDNA3.1Hygro were also generated using the same procedure. 
 
2.8.4     Flow Cytometry 
Flow cytometer assay was conducted on stable cells using Becton Dickinson FACS Calibur Cell sorter, 
a multi-laser, bench top flow cytometer which has the ability to acquire parameters for a large 
number of colours. The technique utilises laser-based technology to count, sort and profile cells in 
a heterogeneous fluid mixture through the optimisation of the optical and fluidics system so as to 




scatter channel (FSC) and side scatter channel (SSC) signals. Hence, it interrogates cells with 
fluorescent markers, classifying them into groups. When stable engineered CHO-S cells expressing 
GFP were analysed along with CHO-S the aim was to investigate the expression of eGFP/YFP stable 
cells so that clonal cells can be generated from the heterogeneous population. 10 000 cells/1000 µl 
sample were gated for each sample as stable engineered cells were analysed and compared with 
GFP-expressing control at 532 nm wavelength. While 10000 cells were acquired, the gating 
strategy to identify the cells of interest leads to only 1000 cells in the final  gate, hence a 
stringent fluorescent gating cut-off was applied using CHO-S/GFP negative cells as 
autofluorescence/control with threshold number of events was set at 101 mark, below which a 
frequency is deemed negative. This would allow the Becton Dickinson software discriminate 
between positive and negative GFP expressing cells in the populations to be sorted.  
 
2.8.5     Limited Diluting Cloning to obtain Clonal Cell Lines  
In 96-well plates, cells from a culture of a viability >90% were then placed in well A1, following the 
protocol from Corning Inc™ as outlined below; 
1. Fill the reagent dispensing tray with 12 ml of the appropriate culture media, then 
using an 8-channel micropipettor add l00 µl median to all the wells in the 96-
well plate except well A1 which is left empty. 
2. Add 200 µl of the cell suspension to well A1. Then, using a single channel 
pipettor quickly transfer a 100 µl aliquot from the first well to well B1 and mix 
by gently pipetting. Using the same tip, these 1:2 dilutions were repeated down 
the entire column, discarding the original 100 from H1 so that it ends up with 
the same volume as the wells above it.  
3. With the 8-channel micropipettor add an additional l00 µl of media to each well 
in column 1 (giving a final volume of cells and media of 200 µl /well). Then using 
the same pipettor quickly transfer l00 µl from the wells in the first column (A1 
through H1) to those in the second column (A2 through H2) and mix by gently 
pipetting.  
4. Using the same tips, repeat these 1:2 dilutions across the entire plate, discarding 
l00 µl  from each of the wells in the last column (A12 through H12) so that all 




5. Bring the final volume of all the wells to 200 µl by adding 100 µl media to each 
well.  
6. Incubate plate undisturbed at 37°C in a humidified CO2 incubator.   
7. Clones should be detectable by microscopy after 4-5 days and be ready to score 
after 7 to 10 days, depending on the growth rate of the cells. Check each well 
and mark all wells that contain just a single colony. Typically the number of 
single clonal events was around 10 clones per plate.  
8. After 1-2 weeks, these clones should have spread out into larger single colonies 
visible under the microscope. These colonies can then be sub-cultured from the 
wells into larger vessels. Usually each clone is transferred into a single well in a 
12 well or 24-well plate for further growth. 
 
2.9      Transfection of transient DNA into Stable cell lines 
Transfection was carried out in several ways depending on the particular experimental strategy 
used and the scale of transfection required. However, a general procedure used to transfect cells is 
described here for transfection carried out in the 6 well experimental plate. One day prior to 
transfection (Day 1), cultures of high viability generally about 95% were seeded at 0.2 x 106 viable 
cells/ml in the appropriate volume of fresh cell media usually in 6 well experimental plate of 2 ml. 
On the day of transfection (Day 2), the cells were transfected by mixing 300 µl optimum with 14.4 
µl lipofectamine 2000 in one tube and another 300 µl optimum with 4.8 µg plasmid in another tube 
at a ratio of 1:3 for plasmid/lipofectamine2000. After preparation of solutions, tubes were placed 
upright at room temperature for 5 min after which solutions in both tubes were mixed together by 
pipetting. The final mixture was left for 20 min before adding 100 µl plasmid mix to each well and 
the plate rocked gently to mix. The plate was thereafter placed in an incubator at 37°C for 4-6 h. 









2.10     Agarose DNA Gel Electrophoresis 
Preparation of agarose gels was achieved by dissolving agarose powder in 1x TAE buffer to a final 
concentration of 1% (w/v) gel. This mixture was heated and allowed to cool to approximately 55°C 
before ethidium bromide or SYBR® Safe (0.1 µg /ml final concentration) was added to the liquid 
agarose. The mixture was poured into a prepared horizontal gel tank. Electrophoresis was 
performed with Tris/Borate/EDTA (1x TBE buffer), sufficient to cover the gel. Samples were mixed 
with 5x sample loading buffer (Promega) and 10 µl of the mixture was loaded into wells on the gel, 
with a size marker (Hyperladder™ I or V) for comparison. Before being loaded into the gel, 1xloading 
dye (Promega) was added into each sample and a Quantitative DNA (Promega) or RNA ladder (New 
England Biolab). An electrical current was applied to the gel tank at 100 V (Bio-Rad) until nucleic 
acids were appropriately separated. The gels were then visualised under ultraviolet light and 
recorded the images using a VersaDoc 3000 image system. 
 
2.10.1 Gel extraction and purification 
Agarose gels containing PCR products or DNA sequences/inserts release by restriction digest from 
plasmids were placed under UV light (minimising the time under the UV) to select the bands of 
interest and isolate them using a sterile disposable scalpel. DNA bands were visualized using a 
Transiluminator Bio view UV lamp (Biostep) in a Gel logic 100 imaging system (Kodak). Isolated 
bands from gels were transferred into new tubes and purified using a QIAquick gel extraction kit 
(Qiagen) according to the manufacturer’s protocol. After subjecting the gel to a clean-up using 
Wizard® PCR Clean-up System kit by Promega, to recover the DNA, the material was used for 
ligations or it may be kept for further use. 
 
2.11   Protein Extraction and Analysis   
2.11.1   Lysis buffer preparation  
Mammalian cells were lysed in a buffer consisting of 200 mM HEPES-NaOH pH 7.2, 100 mM NaCl, 
1% v/v TX 100 and 10 mM Na-β-glycerophopate. Before use a complete mini, EDTA free protease 
inhibitor tablet (Roche) was added to 10 ml of the lysis buffer as well as 50 mM NaF and 1 mM NaV 




2.11.2   Protein extraction from mammalian cells 
Protein from cells cultured in 6 well plates were extracted by washing the cells in 1 ml of PBS for 
each well and then the cells were incubated in 200 µl of cell lysis buffer per well on ice for 5 min. 
The wells were then scraped and the contents put into a sterile 1.5 ml eppendorf tube. An additional 
200 µl cell lysis buffer per well was used to wash each well and this was then collected and placed 
into the corresponding eppendorf tube so that a combined 400 µl of cell lysate was collected per 
6-well plate. This was then stored at -20°C until analysed. 
 
2.11.3   Bradford assay quantification of total protein concentration in cell lysates 
Protein quantification of cell lysates was determined using a Bradford assay with each lysate being 
measured in duplicate.  Total cell lysates were centrifuged for 1 min at 13000 rpm and then kept 
on ice. Following the centrifugation step, supernatant was carefully pipetted into a new eppendorf 
tube as lysate supernatant hence separated from the cell pellet (which was discarded).  5 µl of the 
lysate supernatant was then diluted in 45 µl with ddH2O and then 1 ml of Bradford reagent (BioRad) 
was added to the solution for protein estimation. The Bradford solution was then mixed and 
incubated for 10 min. The total protein was then quantified by reading the absorption of the 
solution at a wavelength of 600 nm using an eppendorf biophotometer. The concentration of 
protein in each lysate was then calculated by comparison to a standard curve generated using 
known amounts of bovine serum albumin (BSA). 
 
2.11.4   SDS-PAGE Analysis of Protein Extracts  
SDS-Polyacrylamide gels were routinely used for protein analysis. SDS page gels were prepared 
using www.changebioscience.com/calculator/sdspc.htm for dilution calculations; 30% 29:1 
polyacrylamide (BioRad), ammoniumpersulphate and tetramethlelthylenediaine (TEMED), all 
sourced from BioRad. SDS gels were prepared in Novex 1 mm gel cassettes (Invitrogen). Protein 
lysate samples for analysis were diluted in NuPAGE LDS sample buffer x4 (Invitrogen) to the volume 
appropriate for the well size used or concentration of protein required (typically 5-20 µg/well) and 
number of runs per sample (well volume (µl) x number of runs = total volume of sample). Prior to 




were assembled in a Novex mini cell tank (Invitrogen) and loaded with the prepared samples and 
electrophoresis undertaken at 125 V for 1 h and 30 min or until the dye front of the samples had 
reached the bottom of the gel. Gels were removed from the gel cassettes and both stained with 
Coomassie blue R-250 for 20-60 min and then destained until protein bands were visualised or 
prepared for transfer onto nitrocellulose for western blot analysis. 
 
2.11.5 Western Blot Analysis of Proteins 
Proteins separated by SDS-PAGE were transferred to 0.45 µm nitrocellulose blotting membrane 
(Amersham Hybond ECL) via electrophoresis using a Tris EDTA (T.E) series transfer electrophoresis 
unit (Hoefer) for 1 h at 4°C. After transfer, the blots were incubated in 20-30 ml of blocking buffer 
(5% dry milk (Marvel) in tris-buffered saline with 0.1% tween 20 (0.1% TBST) for 30 min-1h.  Blots 
were then washed in 0.1% TBST three times for 5 min per wash, then incubated overnight in a 10 
ml dilution of the appropriate primary antibodies (section 2.14.1) prepared in 3% BSA-TBS. After 
overnight incubation, the blots were washed 3 times with 0.1% TBST for 10 min and then incubated 
in the eGFP primary antibody with Anti mouse 1:5000 (from sigma) for YFP detection dilution in 
blocking buffer for 1 h. Blots were then washed again 3 times with 0.1% TBST for 10 min and 
incubated for 5 min in ECL western blotting detection reagents (Amersham), following the 
instructions provided with the reagents by the manufacturer. The blots were then exposed to high 
performance chemiluminescence film (Amersham Hyperfilm ECL), which was subsequently 
processed using a Compact X4 processor (Xograph imaging systems).  
 
2.11.5.1   Coomassie Brilliant blue staining/destaining of SDS-PAGE gels  
For staining with coomassie, the gel was carefully transferred to a staining box and rinsed with 
deionised water. Enough staining solution was poured in to the staining box to cover the gel and 
then kept rocking position for 1-2 h or overnight to stain the gel. For destaining, the gel was rinsed 
with de-ionized water after discarding the used staining solution. The gel was destained in 
destaining solution (I) for 1-2 h and then destaining solution (II) until the gel bands became clear. 





Table 2.3   Table showing composition of reagents for preparation of 
gel, washing, staining and destaining gel.  
Reagent      Composition 
Coomassie Blue Stain 0.25% (w/v) Coomassie Blue R-250  
20% (v/v) isopropanol 
 
Coomassie Blue Destain 7% (v/v) acetic acid (4x) 
 Separating Buffer for SDS-PAGE: 1 M Tris-HCl pH 8.8 (4x) 
 Stacking buffer for SDS-PAGE 1.5 M Tris- HCl pH 6.8 
(10x) running buffer for SDS-PAGE: 0.25 M Tris,  
1.9 M glycine 
1% (w/v) SDS 
(2x) Loading buffer:  25% (V/V) 4x stacking buffer 
20% (v/v) glycerol 
0.5% (w/v) Bromophenol Blue  
4% (w/v) SDS 
10% (v/v) 2-mercaptoethanol 
Blocking solution for western blot (1X) 0.1% (v/v) TBST 
5% (w/v) dry milk (Marvel)  
Washing solution for western blot:  
 












2.12         PCR Amplification of Target Genes  
 
2.12.1      RNA Extraction from Mammalian cells  
Engineered CHO-S cell total RNA lysates were analysed from 2x106cells. Each sample was firstly 
homogenized in a Lysing Matrix D tube (FastPrep® Kits) with 1 ml of Tri-regent (Sigma) using 
FastPrep® instrument for 20 sec at speed setting of 4.0. The homogenised sample was then 
centrifuged at x 12,000 g for 5 min at 4°C and the aqueous upper phase transferred into a new tube. 
An extra 5 min incubation at room temperature for 5 min was then undertaken to allow complete 
dissociation of nucleoprotein complexes. RNA was further separated from DNA by adding 300 µl of 
chloroform, vortexing for 10 sec, and incubating for 5 min at room temperature before centrifuging 
the mixture at 12,000 g for 15 min at 4°C. Following the centrifugation, the mixture was separated 
into an upper aqueous phase (colourless), an interface phase (white), and a lower phenol-
chloroform phase (red). The aqueous phase of mixture was transferred into a new 2 ml tube for 
further RNA precipitation. 500 µl of pre-cooled 100 % (v/v) ethanol (Sigma) was then added and 
incubated for at least 1 h at -20°C before centrifuging at 12000 g for 5 min at 4°C. Following the 
centrifugation, a white RNA pellet was formed in the bottom of the tube. The supernatant was 
discarded and 750 µl of pre-cooled 75 % (v/v) ethanol (Sigma) added to wash and resuspend the 
pellet. To suspend the RNA centrifuged at 12000 g for 5 min at 4°C, the supernatant was discarded 
and the pellet air-dried at room temperature for 5-10 min. The pellet was finally dissolved with 30-
50 µl of RNase free water and incubated at 50°C for 10 min or until the pellet resuspended 
completely. To remove potential genomic DNA all RNA samples were further treated with DNase 
using TURBO DNA-free™ Kit (Ambion) according to manufacturer’s instruction. All RNA samples 
were stored at -80 °C until use. The total RNA extracted from the lysate using a QIAGEN Shredder 
kit and the amount of RNA extracted determined by A260 nm measurement. Total RNA was stored 
at -80°C. 
 
2.12.2     DNase I Treatment of RNA Isolates  
The amount of RNA in each sample was quantified using a Nano Drop® ND-1000 UV/Vis 
spectrophotometry. Using the DNase I Kit (Sigma-Aldrich). RNA was treated with DNase I to remove 
any genomic DNA contamination. All the reagents were supplied with the kit unless otherwise 




treated ddH2O, 1 µl DNase (10x) reaction buffer and 1 µl of DNase enzyme. The reaction was 
incubated at room temperature for 15 min prior to addition of 1 µl of 0.2 mM EDTA stop solution. 
The mixture was then heated at 70°C for 10 min and chilled on ice for 2 min prior to use (with 
storage at -80°C). 
 
2.12.3   Assessment of total RNA quality  
A NanoDropTM 1000 spectrophotometer (Thermo Scientific) was used to directly quantify 1 µl of 
RNA sample. The purity of all RNA samples were confirmed by having the optimal ratio of 
absorbance at 260 nm/280 nm (1.9 - 2.3) and 260 nm: 230 nm (>2.2). 
 
2.12.4      Quantitative PCR Analysis (qRT-PCR) of Target mRNA Amounts 
 
qRT-PCR analysis was carried out to determine the relative amount of target mRNAs (relative to a 
house keeping mRNA) between samples was undertaken using the commercially available iScript 
TM One-Step RT-PCR kit with SYBR Green kit (BioRad) and an Eppendorf Realplex Master Cycler 
instrument. GFP primers were used for mRNA assay of samples and were designed using Primer 
Blast (available from: www.ncbi.nlm.nih.gov/tools/primer-blast). RNA samples were diluted to a 
concentration of 25 ng/µl in sterile nuclease free water (sNF). Separate master mixes (25 µl per a 
reaction) for each experimental and housekeeping gene primer pairs were prepared on ice under 











Table 2.4     Reaction mixture volumes for qRT-PCR analysis 
                                                                     
Reagent 
                                          Volume 
(µl) x1 RT reaction 
    Sodium Nitrate flotation (sNF) 8.5 
       2x SYBR Green 12.8 
   Forward Primers (10 µM) 0.75 
Reverse Primers (10 µM) 0.75 
Reverse transcriptase  0.5 
        Template RNA 2 
 
 
25 µl per reaction of the master mixes were then pipetted into a Bio Rad 96-well optical plate on 
ice. The plate was then sealed and placed in the Eppendorf Realplex Master Cycler (Thermocycler) 
and the following program used: 
● 50°C for 10 min 
● 95°C for 5 min 
● 40 cycles of  
• 95°C for 10 min 
• 55°C for 30 sec, SYBR emission reading 
● 95°C for 15 sec 
● 55°C for 15 sec 
● Melting curve: 55°C to 95°C with 0.5°C 
● 95°C for 15 sec 
 
 
The Eppendorf instrument excites the fluorescent dye used and the software calculates when the 
fluorescence reaches a critical threshold (CT). The CT value is that when the fluorescence becomes 




initial copies of template DNA (Livak and Schmittgen 2001). Calculations using the CT values of the 
sample were normalised to that of the housekeeping gene (the endogenous control GFP). This 
comparative method follows the comparative CT method equation shown below: 
              
                                                          Relative Expression = 2-∆∆C т 
 
2.12.5      Analysis of qRT-PCR Results  
The qRT-PCR data was analysed using Opticon Monitor v3.0 software. Blanks and baseline 
fluorescence (as calculated as an average over cycle range 1 – 10) were subtracted from 
fluorescent plots. The threshold setting was raised to 0.05 and the cycle C(t) value at which 
samples reached this fluorescence value was measured. A standard curve graph of log (cDNA) 
value versus C(t) value was plotted. The relative concentration of cDNA was achieved from the 
standard curve. The total amount of mRNA was normalised against GFP qPCR-value. The melting 
curve was used to assess the quality of the amplified product, where single peak at 80°C to 90°C 
reflected a pure product, whereas double peaks would reflect primers dimers and impurities. 
 
2.13   Fluorescence imaging of live cells expressing YFP-TM7SF2 or YFP-DHCR7 
For live cell imaging, mammalian cells were seeded into glass bottom petri dishes, with coverslips 
that have a collagen coating at 2.5 x 105 viable cells in 2.5 ml of media per dish. Cells were left 
overnight to adhere, then transfected with the appropriate gene of interest using the same 
transfection protocol as described for 6 well plate transfections. The plates were then incubated 










2.14    Immunofluorescence imaging of fixed CHO cells 
For immunofluorescence imaging of cells, prior to seeding cells before transfection, coverslips 
were sterilised and placed 1 per well in 24 well plates. Cells were then seeded at 6x104 viable cells 
per well and incubated for 24 h. 0.8 µg of the selected DNA plasmid was then added per well in 
triplicate wells using the 24 well plate transfection protocol (section 2.11) and incubated for 24 h. 
Cells were then prepared according to the following protocol: 
Paraformaldehyde (PFM) fixing of cells 
Cells were required to be fixed to the cover slips within each well: 
1. Siphon media from wells 
2. Wash the cells with 1 ml warm PBS (37°C) 
3. Siphon off PBS 
4. Add 1 ml 4% PFM (-20°C) 
5. Incubate the plate for 15 min on ice 
6. Siphon off PFM and air dry (about 5 min) 
7. Wash cover slips with PBS 
8. Keep plates at 4°C (for up to 1 week) 
 
2.14.1     Antibody probing of the coverslips 
Once the cells were fixed to the coverslips, the slips were probed using antibodies to visualise 
specific targets. This was achieved using the following protocol: 
1. PFM fixed cells were rehydrated with 1 ml of PBS (room temperature, RT) for 5 min 
2. PBS was then siphoned off. 
3. The coverslips were then incubated with 250 µl blocking buffer w/v sterile-filtered 3% 
BSA in PBS per well for 15 min at room temperature 
4. 25 µl droplets of 1° antibody (diluted 1:500), anti-Rabbit (sigma) in w/v sterile-filtered 
3% BSA were placed on a sheet of parafilm in a damp box and the slips applied ‘cell 
side’ down. The slides were incubated overnight at 4°C in the damp box. 
5. 4 sets of 100 µl PBS with Tween wash droplets were prepared on sheets of parafilm. 
6. Coverslips were then transferred from the damp box to the 1st wash droplet (being 




coverslips were then transferred ‘cell side’ down through the wash droplets, 
allowing 5 min per wash. 
7. Whilst the coverslips were on the 1st droplet the 2° antibody was prepared: TRITC 
antibody (sigma) was diluted 1:100 in BSA dilutions prepared in light aggregates; 
the ‘supernatant’ was then transferred to a fresh light protected tube. 
8. 25 µl droplets of 2° antibody were then aliquoted on to parafilm in a light protected 
damp box. Cover slips were transferred cells side down onto the 20 antibody 
droplets; blotting off any excess liquid from previous washes. 
9. The coverslips were then incubated in the dark for 2 h at RT. 
10. The coverslips were then washed again in 100 µl PBS with 0.1% Tween as they were 
after incubation with the 1° antibody.  
 
2.14.2   Nuclear staining of DNA 
1. 25 µl droplets of DAPI (10 mg/ml) were prepared on parafilm in a light protected  
box. 
2. Coverslips were then placed cell side down on the DAPI droplets and incubated 
for 1 min. 




2.14.3     Anti-fading and preparation of coverslips for imaging  
1. During the washing process, either after incubation of 2° antibody or post staining 
with DAPI, 900 µl of Mowiol was mixed with 100 µl of phendinediamine. 
2. 5 µl of the Mowiol/Phendinediamine mixture was then dripped onto a microscope 
slide and the cover slip applied on top of the 5 µl cell side down. 







2.14.4    Coverslip preparation for imaging 
1. The edges around coverslips were sealed with clear nail varnish and the top of the 
cover slip washed with ddH2O and a cotton bud. 
2. Cells were then imaged on a LEICA LEITZ DMRD or a LEICA DMIREZ confocal 
microscope (TCSSP2 AOBS). 
3. Wavelengths of excitation and emission of each colour visualised are shown in table 
2.5. 
 
Table 2.5   Wavelengths used for excitation and emission of 





340-380 (Blue) LP 425 (Blue) 
450-490 (Blue) LP 515 (Green) 
515-560 (Green) LP 590 (Red) 
 
 
2.15        Statistical Analysis 
All assays were repeated at least three times to ensure reproducibility and three replicates of each 
sample were performed in each test. Error bars represent standard of the mean (SEM) (which 
relates the closeness of the sample mean to the population mean) for triplicate biological samples. 
Statistical significance of differences for triplicate samples/groups was evaluated by students T-













Isolation, Cloning and Characterisation of Transmembrane 7 Superfamily member 2 (TM7SF2) 
and 7-dehydrocholesterol reductase (DHCR7) Genes and Expression 
 
3.1   Introduction   
Research on the role of Transmembrane 7 Superfamily member 2 (TM7SF2) and 7-
dehydrocholesterol reductase (DHCR7) in the ER and peri nuclear space expansion has gained 
momentum in recent years. We have explored the possibility of expanding the ER membrane and 
reprogramming of lipid biosynthesis by over-expressing TM7SF2 and DHCR7. The different 
strategies used to isolate, clone, and characterise YFP tagged TM7SF2 and DHCR7 from plasmid 
vectors in which they were provided (a eYFP-C1 plasmid vector backbone) into the commercial 
mammalian expression vectors pcDNA3.1CAT and pcDNA3.1Hygro for transient and stable 
expressions in Chinese hamster ovary (CHO) cells have been detailed in this study.  
 
This was undertaken in order to attempt to manipulate lipid biosynthesis and expansion of the 
endoplasmic reticulum for increased secretory pathway capacity and enhanced culture life (growth, 
viability and phenotypic characteristics) as described in the introduction chapter of this thesis. As 
the biosynthesis of cholesterol represents one of the fundamental cellular metabolic processes 
(Bietz et al, 2017), we have investigated the manipulation of this pathway by overexpression of 
TM7SF2 in CHO-S and the feedback effects on secretory pathway capacity and ER. 
 
The cloning and characterisation of the TM7SF2 and DHCR7 genes in CHO cells provides yet another 
example of how basic research in mammalian cells can dramatically advance the understanding of 
over-expression engineering in the secretory systems. Zwerger et al., (2010) had reported on a 
peculiar comparable phenotype induced in different mammalian cell lines observed to impact upon 
the regular organisation of the nuclear envelope and the endoplasmic reticulum (ER).  
 
Indeed, the exogenous expression of these appears to result in an expansion of the ER and thus 




and quality of bio therapeutic proteins from mammalian cells, however whether the ER can be 
expanded in such cells using this approach, and whether this results in enhanced secretory 
recombinant protein expression has not been elucidated.  
 
Because abnormal protein accumulation can be toxic to cells, it should be of no surprise that 
mammalian cells have evolved an elaborate system to monitor the status of protein folding in the 
ER and eliminate misfolded proteins when they accumulate (Romero & Summer, 2017). Proper 
regulation of protein homeostasis in a cell is critical for the health of the organism. Proteins, 
intracellular or secreted, need to be produced and maintained at the right quantity, folded into 
their three dimensional conformation with necessary post-translational modifications, targeted to 
their correct destinations to insure their optimal function, and degraded efficiently and disposed 
when needed (Yalcin & Hotamisligil, 2013).  
 
Upon detection of an unfolded protein load in the ER, an ER-nuclear signalling pathway is activated 
to protect the cell from the cytotoxic effects resulting from the accumulation of misfolded proteins 
subsequently leading to a disruption of homeostasis which in turn triggers stress responses, or 
unfolded protein responses (UPR), in these organelles (Bernales et al., 2012). The folding process is 
not completely accurate. In mammals, 30% of all newly synthesised proteins are estimated to be 
incorrectly folded. In order to improve recombinant protein production, it has been suggested that 
an optimum expression level exists for any foreign protein, which may be due to saturation of 
protein folding capacity of the ER as the maximum productivity is determined by the capacity of the 
ER to express the protein when this is saturated.  
 
However, even though in a specialised secretory cell unfolded proteins do trigger the UPR to 
increase folding capacity, this signal is not necessary for every step of ER expansion (Christis et al., 
2009). Recombinant protein production can also be improved through genetic manipulation. The 
overexpression of an individual gene in a host cell line can often achieve the effect of amplifying its 
activity, although it should be noted that the effect of gene overexpression is not always predictable 
or beneficial. A number of gene manipulation strategies have been published with the aim of 
increasing the productivity of an exogenous protein from a host cell line e.g. see (Stoyle et al., 2017).  
Many of these genes are involved in certain functions associated with the endoplasmic reticulum 




al., 2017), protein translocation and folding in the ER (ATF6)  (Gardner et al., 2013), ER stress sensor 
and cell fate executor (IRE1) (Chen & Brandizzi, 2013), critical effector of the mammalian UPR whose 
activity is regulated by IRE1 (XBP1) (Acosta-alvear et al., 2007), among others. Different situations 
that induce ER stress also lead to autophagy induction.  
 
As discussed above, the ER stress response is activated to protect cells from different alterations 
affecting this organelle. However, when the intensity or duration of ER damage cannot be restored 
by this response, ER stress can also lead to cell death (Verfaillie et al., 2010). It is possible to adapt 
the target protein and host organism to prevent ER stress; a protein that correctly folds more readily 
is less likely to cause stress to the host and the benefits of producing a host more able to withstand 
stress is obvious (Wyre, 2014). N-terminal fusions have been shown to be more effective for in vivo 
folding, as a correct initial folding of the fusion partner can impact positively on the folding of the 
recombinant protein products. 
 
This chapter describes an alternative approach to enhancing mammalian cell expression systems 
for the expression of recombinant proteins, specifically the expansion of the ER by manipulation of 
two targets of lipid biosynthesis; TM7SF2 and DHCR7 (which are both predicted to reside in the 
cytoplasm and are not believed to be in prolonged direct physical contact with chromatin (Holmer 
et al., 1998). These were to be exogenously overexpressed in order to manipulate the secretory 
pathway capacity by causing an expansion of the ER which may cause an improved quantity and 
quality in the output of recombinant materials of the cell and also may impact on growth. Such an 
approach of over-expression of target proteins can lead to cellular expansion as shown when high 
abundance of transmembrane proteins in the ER were shown to induce extensive membrane 
growth, whereas low expression did not alter ER morphology (Borgese et al., 2006). 
 
Our hypothesis therefore was that controlled manipulation of cholesterol biosynthesis by over-
expression of TM7SF2 and DHCR7 will result in an enhancement of the efficiency of the CHO 
platform as a recombinant protein expression system via expansion of the endoplasmic reticulum 
(ER) capacity of the cell. This chapter reports on the isolation, cloning, characterisation  and 
engineering of the CHO cell using these lipid biosynthesis targets where overexpression of these 




(described in chapters 4 and 5). Preliminary studies on LBR mutants of this were also undertaken 





3.2        Results 
3.2         Vector Engineering 
3.2.1 Cloning strategies for the insertion of mCherry-LBR, YFP-DHCR7 and YFP-TM7SF2 genes into 
pcDNA3.1CAT and pcDNA3.1Hygro Mammalian Expression Vectors 
Samples of mCherry-LBR, YFP-DHCR7 and YFP-TM7SF2 constructs were provided by Monika Zwerger 
(University of Durham, South Road, Durham). Information on clonings confirmed Lamin B Receptor 
plasmid was amplified and cloned into pEYFP-C1 using BspEI/EcoRI double restriction sites. The 
human DHCR7 was amplified and cloned into plasmid pEYFP-C1 using restriction digestion sites; 
BspEI/SalI while YFP-TM7SF2 plasmid construct, containing amplified coding sequence of human 
TM7SF2 had been cloned into pEYFP-C1 using BspEI/SalI or with a stop codon in pEGFP-N1 via 
BglII/SalI restriction sites. Initial cloning strategies involved removing the genes of interest (mCherry-
LBR, YFP-DHCR7 and YFP-TM7SF2) from plasmid EYFP-C1, using restriction digestion followed by the 
introduction of these inserts into pcDNA3.1CAT and pcDNA3.1Hygro vector plasmids.  
The ultimate aim of this work was to generate constructs for the expression of the target proteins 
into plasmid vectors; 3.1CAT and 3.1Hygro for transient gene expression studies and stable cell line 
generation of these targets in CHO mammalian cells, for studies on the impact of manipulating these 
lipid engineered cells on the CHO ER membrane and also on bio therapeutic recombinant protein 
expression. pcDNA3.1CAT plasmid with Chloramphenicol Acetyltransferase (CAT) at the multiple 
cloning site with a size of 660bp was to be released following the double restriction digestion of 
Nhe1/Xba1 and Nhe1/Apa1 for pcDNA3.1CAT-mcherry-LBR and pcDNA3.1CAT-YFP-DHCR7 
respectively although that wasn’t the case for pcDNA3.1CAT-YFP-TM7SF2 (Figure 3.1). All transient 
expression studies for construct plasmids of YFP-TM7SF2, YFP-DHCR7 and mCherry-LBR were carried 
out using pcDNA3.1CAT while pcDNA3.1Hygro vector was used for the stable cell line expression of 

























Figure 3.1 pcDNA3.1CAT plasmid vector containing the mCherry-LBR, YFP-DHCR7 and YFP-
TM7SF2 genes. The respective genes were cloned from pEYFP-C1 plasmid vector using 
restriction digest into plasmid vector pcDNA3.1CAT.  The restriction sites used are indicated in 
the vector maps.  
 
When pcDNA3.1CAT constructs were generated, the expectation was to undertake transient studies 
such that, the effect of over-expression of the lipid engineered genes on recombinant protein 
Insert 
















expression can be monitored over a course of time. In order to investigate the impact of 
overexpression, under stable conditions, the generation of stable cell lines was imminent. Figure 3.2, 
shows the constructed plasmid map of the lipid engineered genes in pcDNA3.1Hygro, which serve as 













Figure 3.2    Schematic displaying the principle of the sub-cloning strategy. mCherry-LBR 
(yellow), YFP-DHCR7 (red) and YFP-TM7SF2 (blue) genes were cloned from pEYFP-C1 plasmid 
vector using restriction digest into plasmid vector pcDNA3.1Hygro. The restriction sites used 
are indicated in the vector maps. Constructs were generated for stable cell generation. 
 
 
The human YFP-TM7SF2, YFP-DHCR7 and mCherry-LBR were cloned out of pEYFP-C1 using restriction 
digest of enzymes on the restriction site to release the genes of interest. The predicted TM7SF2 protein 
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proteins consist of 475 and 533 amino acids with the molecular mass of both proteins, 54 kDa and 70 
kDa respectively (Table 3.1). The expected size of YFP-TM7SF2 was cloned out using Nhe1/BamH1 
restriction sites which releases a 1.95kb fragment containing the YFP reporter gene tag. YFP-DHCR7 
was cloned out using Nhe1/Apa1 with a released fragment of 2.1kb, having the YFP reporter gene tag. 
Also, mCherry-LBR was cloned out of pEYFP-C1 plasmid using Nhe1/Xba1 (Figure 3.3).  
 
Confirmation of the YFP-TM7SF2, YFP-DHCR7 and mCherry-LBR inserts being released was done using 
gel electrophoresis. Plasmid vectors pcDNA3.1CAT and pcDNA3.1Hygro were also digested each with 
restriction digest enzymes Nhe1/Xba1, Nhe1/Apa1 and Nhe1/BamH1. A single band size of 6.2 kb was 
seen on gel electrophoresis image (Figure 3.4) for plasmid vector pcDNA3.1CAT for each of double 
digest cut while pcDNA3.1Hygro showed a single band size of about 5.6 kb for each of the three double 







































Figure 3.3.  1% Agarose Gel Electrophoresis showing restriction double digest check for two 
different minipreps (A and B) of  mCherry-LBR, YFP-DHCR7 and YFP-TM7SF2 loaded on lanes 
1-6 and 7-12 for the enzymes that will release the genes of interest. Nhe1/Xba1 for mCherry-
LBR (A) (Lane 1), Nhe1/Xba1 for YFP-DHCR7(A) (Lane 2), Nhe1/Xba1 for YFP-TM7SF2 (A)(Lane 
3), Nhe1/Apa1 for mCherry-LBR(A) (Lane 4) , Nhe1/Apa1 for YFP-TM7SF2 (A) (Lane 5), 
Nhe1/Apa1 for YFP-DHCR7 (A)(Lane 6), Nhe1/Xba1 for mCherry-LBR (B) (Lane 7), Nhe1/Xba1 
for YFP-DHCR7(B) (Lane 8), Nhe1/Xba1 for YFP-TM7SF2 (B)(Lane 9), Nhe1/Apa1 for mCherry-
LBR (B) (Lane 10) , Nhe1/Apa1 for YFP-TM7SF2 (B) (Lane 11), Nhe1/Apa1 for YFP-DHCR7 (B) 
(Lane 12) to release the gene of interest. Here, lanes 6 and 12 show YFP-DHCR7 released at 






























Figure 3.4.   Agarose gel electrophoresis analysis of restriction double digest of plasmid vector 
pEYFP-C1 to release the genes of interest. mcherry-LBR is released at the expected size of 2.3 
kb using Nhe1/Xba1, YFP-DHCR7 was released as a 2.1 kb fragment using Nhe1/Apa1 while 
YFP-TM7SF2 was released as a 1.95 kb fragment using Nhe1/BamH1 (A) Gel image shows 
restriction double digest of plasmid vector pcDNA3.1Hygro cut with Nhe1/Xba1, Nhe1/Apa1 
and Nhe1/BiamH1 for subsequent ligation procedure with inserts cut with corresponding 
restriction enzymes. (B) Gel electrophoresis image shows single band expressed at expected 
size of 6.2 kb following double digest procedure using Nhe1/Xba1, Nhe1/Apa1 and 
Nhe1/BamH1 for pcDNA3.1CAT plasmid vector. Chloramphenicol Acetyltransferase reporter 
gene (CAT) was released at 660 bp when cut with Nhe1/Xba1 and Nhe1/Apa1 only. (C)  Gel 
image shows the predicted/calculated sizes for the insert fragments cut with Nhe1/Xba1, 
Nhe1/Apa1 and Nhe1/BamH1 from pEYFP-C1 plasmid for ligation with vector of corresponding 
restriction digest enzymes as pcDNA3.1Hygro.  (D) Gel electrophoresis showing double loading 
of insert fragments of predicted sizes cut with Nhe1/Xba1, Nhe1/Apa1 and Nhe1/BamH1 from 


























































































































































3.2.2      Transformation and selection  
A ligation mixture consisting of the prepared plasmid vectors pcDNA3.1CAT and pcDNA3.1Hygro each 
with the gene fragments for YFP-TM7SF2, YFP-DHCR7 and mCherry-LBR was carried out following 
DNA purification procedure of the excised fragments from p                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
EYFP-C1 plasmid. The purified fragments of YFP-TM7SF2, YFP-DHCR7 and mCherry-LBR were 
thereafter cloned into the corresponding pcDNA3.1CAT and pcDNA3.1Hygro vectors using T4 DNA 
ligase. Ligation was performed at room temperature overnight resulting in the recombinant plasmid 
constructs pcDNA3.1CAT-YFP-TM7SF2, pcDNA3.1Hygro-YFP-TM7SF2, pcDNA3.1CAT-YFP-DHCR7, 
pcDNA3.1Hygro3.1-YFP-DHCR7, pcDNA3.1CAT-mCherry-LBR and pcDNA3.1Hygro-mCherry-LBR. 
Transformation was undertaken using chemically competent E.coli host cell strain. Putative 
transformants were selected using antibiotic selection (ampicillin). Screening of positive clones was 
based on an analytical restriction digest analysis. The plasmids with expected inserts released were 
considered as positive clones and further sequenced to confirm their identity with the experimental 
sequences compared with the human sequences available at NCBI GenBank database and that for 
YFP or mCherry. The positive plasmids were grown up and isolated using both plasmid Miniprep and 






































Figure 3.5    (A) Agarose gel electrophoresis analysis showing a representation of single bands of 
2 µg concentration of plasmid vector pcDNA3.1Hygro cut with Nhe1/Xba1 (lanes 1 and 2), 
Nhe1/Apa1 (Lanes 3 and 4) and Nhe1/Xba1 (Lanes 5 and 6) prior to bands being excised and 
subsequent DNA purification procedure using a commercially available Promega clean up kit for 
ligation with corresponding inserts with same restriction digest. (B) Gel image shows the release 
of inserts YFP-TM7SF2, YFP-DHCR7 and mCherry-LBR cut with double restriction digest enzymes 
of Nhe1/BamH1, Nhe1/Apa1 and Nhe1/Xba1 respectively. Fragments of inserts were then excised 
and cleaned-up using the commercially available Promega DNA purification kit for ligation with 
appropriate vector of same double restriction digest. For example, lane 1A ligates with lane 1B, 
























































3.3   DNA Sequence Analysis of YFP-TM7SF2, YFP-DHCR7 and mCherry-LBR Constructs 
Prior to identifying positive constructs with the required inserts, a random screening of colonies which 
had grown on Luria Bertani (LB) Agar plates with ampicillin antibiotic selection was undertaken. Several 
screenings revealed some colonies that appeared to have been cloned successfully and containing the 
genes of interest by gel electrophoresis assay (Figure 3.6).  Colonies that appeared to have the inserts 
were isolated, prepped and thereafter samples were sent off to be sequenced by Beckman Coulter 
Genomics. The sequencing was undertaken for plasmid constructs with the inserts using T7 forward 
and BGH reverse primers which flank the multiple cloning site of pcDNA3.1Hygro and pcDNA3.1CAT 
plasmid vectors. The incorporation of the sequence was also verified by gel electrophoresis with 











































Figure 3.6 (A) Analytical agarose gel electrophoresis showing the screening of constructs of 
pcDNA3.1Hygro-DHCR7. Lanes 1-4 show YFP-DHCR7 at 2.1 kb with pcDNA3.1Hygro vector at 5.6  kb 
as expected.  (B) Analytical test digest showing screening of pcDNA3.1Hygro-LBR. Lanes 5 and 6 show 
mCherry-LBR insert at 2.3 kb while vector pcDNA3.1Hygro is at 5.6 kb. (C) Gel electrophoresis showing 
analytical test digest for pcDNA3.1Hygro constructs of YFP-TM7SF2. Fragment released at 1.95 kb 
indicate constructs are positive. All positive constructs were further analysed by DNA sequencing. (D) 
1% Agarose gel electrophoresis showing constructs of pcDNA3.1Hygro with mCherry-LBR (2.3 kb), 
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3.4        Transient and Stable Expression of YFP-TM7SF2, YFP-DHCR7 and mCherry-LBR Constructs in 
CHO Mammalian Cells 
 
3.4.1     Generation of cell lines over-expressing target genes 
For biochemical and microscopy experiments aimed at investigating the subcellular localisation of YFP-
TM7SF2, YFP-DHCR7 and mCherry-LBR fusion proteins and whether their overexpression improved the 
production capacity of the secretory pathway for recombinant proteins, generation of cell lines 
expressing these proteins was a necessary process. The approach was to generate cells stably 
expressing these targets in CHO.S cells where manipulative investigations could be undertaken 
whereby all cells would be expressing the target fusion protein. This process takes months and hence, 
these proteins were also transiently expressed in CHO-S cells over different periods of time and 
analysis of the impact of transiently over-expressing these engineered cells undertaken. Confirmation 
of expression was achieved using western blot and comparing the observed protein band(s) against 
those of the calculated molecular weight of these proteins including the reporter genes YFP and 
mCherry (Table 3.2). Note that all transient transfection studies of YFP-TM7SF2 and YFP-DHCR7 were 
carried out with pcDNA3.1CAT vector while stable expressions of these sterol reductases occurred in 
pcDNA3.1Hygro vector, except where otherwise stated.                                     
                
 
 
Protein Molecular Weight  
(kDA) Tagged-Reporter Gene (KDa) Predicted Weight 
TM7SF2 46.5 27 73 
DHCR7 54 27 81 







Table 3.2: Predicted molecular weights for YFP-TM7SF2, YFP-DHCR7 




3.5         Characterisation of Stable CHO-S Cells Expressing YFP-TM7SF2 and YFP-DHCR7 
3.5.1       Generation of stable CHO-S YFP-TM7SF2 and YFP-DHCR7 expressing cells  
Following confirmation from transient expression studies that YFP-DHCR7 and YFP-TM7SF2 were 
expressed in CHO-S cells, the next step was to generate stably expressing CHO-S cells of these lipid 
metabolism modifying targets.  This approach would allow investigation of any reprogramming of the 
cell in terms of ER membrane expansion upon expressing the target YFP-TM7SF2 and YFP-DHCR7 
fusion proteins. Quantification of the impact and influence of overexpression and impact on the yield 
of recombinant protein production could therefore be more accurately assessed than in transient 
systems. Constructs of YFP-TM7SF2 and YFP-DHCR7 in pcDNA3.1Hygro were linearised using FSP1 
restriction digest enzyme for linearization of the DNA. CHO-S cells were seeded in replicates at 
different concentrations of 2x105, 5x105 and 1x106 viable cells/ml in 6 well plates and kept in an 
incubator at 37°C for 24 h. 4 µg of linearized plasmid DNA for YFP-TM7SF2 and YFP-DHCR7 were added 
equally across the 6 well plates for each stable cell pool to be generated. 24 h post-transfection, 
Hygromycin B antibiotic was added as a selection drug for stable cells. Verification of linearisation of 
the DNA was carried out using agarose gel electrophoresis (Figure 3.7). Stable cells were cultured in 
shake flasks and experiments carried out in shake flasks. Confirmation of expression of the target 
proteins in the stable pools was undertaken using western blot analysis alongside further 
characterisation studies to determine the influence of overexpressing YFP-TM7SF2 and YFP-DFHCR7 



























3.5.2     Validation Studies with Green Fluorescent Protein (GFP) as a Control 
To assess the effect of overexpressing the target proteins in the engineered stable CHO-S cells, a 
control vector stable cell line was also constructed in parallel to analyse the level of stable protein 
expression of YFP-DHCR7 and YFP-TM7SF2. GFP was used as a control for quantitative and qualitative 
characterisation. Stable CHO-S expressing GFP was generated as earlier described (3.5.1). Preliminary 
cloning was undertaken to clone GFP from plasmid vector pcDNA5FRT, using Nhe1/HindIII into 
pcDNA3.1Hygro vector for generation of stable expression in CHO-S cells.  GFP was released at 720 
bp (Figure 3.8).  Linearisation procedure was followed for the integration into CHO-S cells genome in 























































































Figure 3.7 (A) 1% Agarose gel electrophoresis analysis of linearized construct YFP-DHCR7 
in pcDNA3.1Hygro plasmid vector using Fsp1 restriction digest. (B) Agarose gel 
electrophoresis showing linearized construct of YFP-TM7SF2 in pcDNA3.1Hygro by Fsp1 
restriction digest. (C) Agarose gel image showing the comparison of both the undigested 
plasmid DNA (representative YFP-TM7SF2) with the Fsp1 digested plasmid DNA for both 
YFP-DHCR7 and YFP-TM7SF2 in pcDNA3.1Hygro vector for generation of stable CHO-S 














This study uses GFP as reporter of protein expression for YFP-tagged DHCR7 and TM7SF2 as well as 
mcherry tagged LBR proteins. 
 
The choice to establish a GFP control for an investigative role on the implication of overexpression of 
Yellow Fluorescent Protein (YFP)-tagged Transmembrane 7 Superfamily member 2 (TM7SF2) and 
(YFP)-tagged 7-dehydrocholesterol reductase (DHCR7) as well as mCherry-tagged Lamin B Receptor, 
on recombinant protein production was informed with the intention that a GFP control will serve two 
main purposes: Firstly, it would extent the perspective of this work beyond the scope of the original 
paper by Zwerger et al., (2010) where for instance a TM7SF2-specific antibody was used to detect 
the protein in U2OS cells. In CHO-S cells, a functional stably generated GFP is almost identical with 
its derivatives such as YFP at the protein level, differing only in a few amino acids and making it nearly 
impossible to differentiate between them with antibodies. GFP has become well established as a 
marker of gene expression in cell and molecular biology and is rapidly becoming one of the most 
(YFP)-tagged frequently employed molecular reporters (Campbell & Choy, 2001).  
 
Both GFP and YFP are widely used by researchers because of their brightness, fast and simple 
chromophore maturation mechanism and excellent photostability and YFP is a slightly red-shifted 
variant of GFP, a shift that is caused by a π-π stacking interaction between the chromophore and a 
neighbouring hydroxyphenyl ring from a Tyrosine side chain (Shinoda et al., 2018). We understood, 
that a GFP control will not only detect YFP in gene monitoring but also maintain a neutral effect on 
protein expression levels. This is important more so at the molecular level and the use of GFP in 
monitoring gene expression and protein localisation has been well documented (Campbell & Choy, 
2001). Although the Zwerger et al., (2010) group performed live cell imaging of U2OS cells co-
transfected with the ER-marker SP-GFP (SP refers to spacer) and mCherry-LBR, it was not reported 
that this was carried out in YFP-TM7SF2 and YFP-DHCR7 cells. Therefore the approach taken towards 
this work was to use a different fluorescent protein combination which will confer a different but 




















3.6    YFP-Reporter Expression Studies for the YFP-TM7SF2 Construct 
To investigate the transient expression of YFP-TM7SF2 both qualitatively and quantitatively, YFP and 
GFP expression were used as a positive control for validation studies. To examine YFP-TM7SF2 
expression, CHO-S cells were transiently transfected with plasmid DNA for this target following the 
transfection protocol outlined in the methods section (see section 2.9). The transfected cells were then 
harvested 24 h and 48 h post-transfection and analysed using western blot techniques (Figure 3.9). 
CHO cells were also transfected with an empty vector and a GFP expressing vector. Because the 
maximal yield of the fusion protein is highly dependent on the percentage of cells that are successfully 
transfected, exponential growth and viable cells were used for these studies with the percentage 
viability over 97%. CHO cells were then transfected using lipofectamine 2000 and Opti-MEM® media 
transfection reagent according to the protocol of the manufacturer and cells harvested at 24 and 48 h 
post-transfection. Lysates of these cells were collected and analysed. In order to enhance recombinant 


















































Figure 3.8   eGFP as a Control for Monitoring Impact of Lipid Modifying Proteins on CHO-S cells. 
eGFP was cloned from pcDNA5FRT plasmid vector using Nhe1 and HindIII restriction digest 
enzymes with expected fragment size 720 bp (A) Ligation procedure was used to clone eGFP into 
pcDNA3.1Hygro expression vector of 5600 bp size. (B) Agarose gel electrophoresis showing the 
release of eGFP from pcDNA5FRT vector. (C) After the cloning of eGFP into pcDNA3.1Hygro, it was 
linearised using Fsp1 restriction digest enzyme. Agarose gel electrophoresis was undertaken to 












on CHO cells (if any) and also their effects on secretion. Results show an increased expression of YFP-











3.7    Transient Expression of YFP-DHCR7 in CHO-S Cells 
Transient expression studies of YFP-DHCR7 was analysed on day 2 and day 3 post-transfection in CHO-
S cells. The lipid target has a predicted molecular weight of 81 kDa (Table 3.1) and transfection was 
carried out in replicates. The essence of this study was to investigate and confirm the impact of 
overexpression of this lipid target on increased secretory capacity of CHO mammalian cells and its 
influence on expansion of CHO ER membrane for improved secretory protein production. CHO-S cells 
were transiently transfected with the plasmid DNA pcDNA3.1CAT constructs of YFP-DHCR7 and an 
empty vector as a negative control. The transfected cells were then harvested on day 2 and day 3 post 
transfection and analysed using western blot techniques (Figure 3.10). Lysates were harvested on the 
appropriate days after transfection and analysed accordingly. While no expression was seen across the 
two time points for the negative control transfected CHO-S cells, cells transfected with the YFP-DHCR7 















Figure 3.9 Time course investigation studies of transient YFP-TM7SF2, GFP and empty vector 
expression in CHO-S cells at 24 and 48 h post-transfection. YFP-TM7SF2 was transiently 
transfected into CHO cells along with GFP and an empty vector and cells harvested after 24 
and 48 h. Western blot confirms expression of YFP-TM7SF2 at 73 KDa and GFP as 27 KDa, as a 
positive control while marginal increased expression was observed with increased time. 











Figure 3.10    Western blot analysis of transient YFP-DHCR7 and empty control CHO-S cells on 
day 2 and day 3 post-transfection. Cell lysates were analysed for the transient expression of 
YFP-DHCR7 at the culture times (day 2 and day 3). Increased expression was observed at 81 
KDa with increased time post-transfection. No expression was observed in CHO-S cells 
transfected with an empty plasmid at either time points as expected.  
 
3.8    Transient YFP-TM7SF2 Expression at 24 h, 48 h and 72 h post transfection 
Lipofectamine2000-mediated transfection was conducted with cells harvested on day 1, day 2 and 
day 3 post transfection to further confirm the expression of the target lipid-YFP fusion protein.  CHO-
S cells were sub-cultured at a seeding density of 2×105 cells/ml with viability >98% and transfected 
using 4 µg plasmid DNA and Lipofectamine.  To determine the transfection efficiency, cells were 
transfected with GFP for validation using the same procedure and results analysed using western blot 
(Figure 3.11A). It was observed that both GFP and YFP-TM7SF2 increased in expression with increased 
post-transfection time. The GFP band was much more intense than the YFP-TM7SF2 protein band, 
indicating that the fusion protein was expressed at lower amounts than the GFP control as might be 
expected for a membrane associated and fusion protein. 
Another transient transfection was also undertaken and transfected cells harvested on day 1, day 
2 and day 3 post transfection and cell lysates collected. Western blot analysis showed YFP-TM7SF2 
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Figure 3.11   (A) Western blot analysis of transient expression of YFP-TM7SF2 and GFP in 
CHO-S cells on day 1, day 2 and day 3 post-transfection. Lysates of cells were harvested 
on day 1, day 2 and day3 post-transfection and analysed by western blot. GFP increased 
with time post-transfection and was observed at 27 kDa. YFP-TM7SF2 also showed 
increased expression at 73 kDa as post-transfection time increased. (B) Increased 
transient expression was observed with time post-transfection in a second transient 
experiment of YFP-TM7SF2 at 73 kDa as determined using western blot. 
 
Additionally, as bands observed on western blot for transient CHO-S expression of YFP-TM7SF2 as 
well as GFP control showed varying intensities from the western blotting, the generation of 
quantitative numerical values became necessary to quantify the difference in YFP-TM7SF2 
expression over a 3 day period against a GFP control. Densitometry quantification was therefore 
used to analyse data, with an image J application software, which involved the measurement of the 
optical density of the pixels on the photographic film (Figure 3.12). The relative index showed that 
CHO-S did transiently express YFP-TM7SF2 consistently between the day 1 and day 2 post 
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to the functional role of TM7SF2 in impacting cell growth and survival. However, for a future 
experiment it would be useful to extend this culture even longer and examine transient expression  











Figure 3.12   Densitometry analysis of the western blots images shown in Figure 3.11(A). 
Analysis was undertaken using the Image J freeware. Transient studies undertaken to 
analyse CHO expression levels of YFP-TM7SF2. Transfected cells were harvested Day 1, Day 
2 and Day 3 post transfection as GFP control was analysed with YFP-TM7SF2.  Graph shows 




















Day 1                 Day 2               Day 3
Densitometry (Transient YFP-TM7SF2 Expression on 





3.9      Determining the Localisation of Exogenously Expressed YFP-TM7SF2 and YFP-DHCR7 during 
Transient Transfection of CHO Flip-In Cells 
To further characterise YFP-TM7SF2 and YFP-DHCR7 expression and investigate localisation in 
relation to any influence on ER expansion, fluorescence microscopy was carried out on transiently 
transfected CHO Flip-In cells. These CHO cells were designed for rapid generation of stable cell lines 
that express a protein of interest from a Flip-In expression vector ensuring high-level expression of 
the gene of interest. This cell line was obtained from Smales’ lab, University of Kent and only used 
for the transient studies reported here. As these lipid targets have been tagged with fluorescent 
proteins, investigation was undertaken to identify where in the CHO cells the exogenous proteins 
were localised and what influence overexpressing these proteins might have on the CHO cell.  
Fluorescent YFP for TM7SF2 and DHCR7 and mCherry-LBR (which however was not further studied) 
were investigated and DAPI staining used to show the nucleus of the cell.  
Cells were grown on coverslips and transfected after 24 h with Lipofectamine 2000 and Opti-MEM® 
media transfection reagent. Plasmid DNA (4 µg) was introduced into 2x105 cells/ml of highly viable 
CHO cells. For this study, the CHO Flip-In cells were used while a NO plasmid DNA was also 
transfected as a negative control. Upon harvest after 24 h, cells were fixed using formaldehyde 
following transfection protocol and images obtained on a DMR microscope. Cells were DAPI stained 
to identify the nucleus (Figure 3.13).  Protein production using transient transfection is an attractive 
alternative method and has been used routinely in the production of post translationally modified 
proteins including antibodies, glycoproteins, and membrane proteins as transient transfection can 
be achieved in adherent as well as suspension cells (Sastry et al, 2015).  
The essence of the investigation was to determine the extent to which transiently transfected CHO 
cells using fluorescent reporter proteins can efficiently result in greater protein expression as high 
transfection efficiency is significant in transient gene expression, hence the combination of the CHO 
Flip In and Lipofectamine transfection reagent was optimised in terms of DNA: TM7SF2, DHCR7 and 
LBR ratios to improve expression. While some signal expression of the fluorescent proteins was 
observed in the nucleus the majority was around the outside of the nuclear envelop and hence 
likely to be localised to ER as might be expected for these ER resident proteins. Some cells 




























Figure 3.13   Transient expression studies of YFP-TM7SF2, YFP-DHCR7, mCherry-LBR in 
CHO Flip-In cells. Transfected CHO Flip-In cells were counter-stained with DAPI (blue) for 
the detection of nucleus (A, C, E, G, I and K). Untransfected CHO Flip-In cells represented 
a control feedback and showed no fluorescence signal of the transmembrane proteins (B) 
while YFP detection in cells transfected with DHCR7 and TM7SF2 (D, H and L) was 
observed and appear to localize to the nuclear rim as aggregates are seen to be formed 
in the cytoplasm.  mCherry fluorescence signal was again detected in LBR (F and J) with 
signal observed to localise to the nuclear rim. Although these transmembrane proteins 
were detected in CHO Flip In cells, overall efficiency of transfection was however 
considered below 25% as percentage of cells successfully transfected was low as shown. 
Images were taken using the Leica® Fluorescent microscope 24 h post-transfection. For 
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3.10      Developing Cell Pools Expressing an Empty pcDNA3.1Hygro Vector as a Negative  
Control    
In determining if over-expression of the lipid modifying fusion targets in CHO-S cell expression 
systems influence ER expansion and/or increased secretion of recombinant protein products, a 
negative control was also necessary. The Fsp1 restriction digest enzyme was used to linearize 
pcDNA3.1Hygro for efficient transfection into CHO-S cells. These cells integrate the empty 
pcDNA3.1Hygro vector without any heterogeneous protein. Agarose gel electrophoresis was used 
to confirm the size of plasmid vector pcDNA3.1Hygro. Varying amounts of the plasmid were 
transfected into cells and all showed pcDNA3.1Hygro with 5.6 kb size. Analysis of stable expression 
of CHO-S cells with the empty pcDNA3.1Hygro vector using western blot confirmed no signal was 



































Figure 3.14   Agarose gel electrophoresis showing different loading amount of pcDNA3.1Hygro. 
2 µg amount of samples were digested with different restriction enzymes as plasmid vectors 
to be ligated with inserts. Unequal loading amounts have been done with   lanes 5 and 6 having 
the highest loading amount expressed 5600 bp. pcDNA3.1Hygro loaded on lanes 1 and 2 were 
cut using Nhe1/Xba1, lanes 3 and 4 using Nhe1/Apa1 while lanes 5 and 6 using Nhe1/BamH1. 
The implications of these was that these plasmid vectors, having being cut with corresponding 
restriction digestion enzymes would be later ligated accordingly for the generation of LBR, 
DHCR7 and TM7SF2 constructs of pcDNA3.1Hygro to the engineered in the mammalian cells 





Once the stable cell pools were generated and verified to be expressing the target YFP fusion protein, 
regular passages were undertaken to culture cells. Different concentrations of the CHO-S stably 
expressing cells of YFP-TM7SF2 and YFP-DHCR7 were harvested and analysed by western blot (Figure 











Figure 3.15   (A) Western blot confirmation of stable CHO-S cells expressing YFP-TM7SF2. 
Stable pools were harvested at different concentrations and expression levels vary 
accordingly. (B) Western blot confirmation of stable CHO-S cells expressing YFP-DHCR7. 
Expression shows the different pools of the same construct. Different passages of stable cells 
were analysed at different concentrations. YFP-DHCR7 show decreased expression as 
compared to YFP-TM7SF2 at the same cell concentration. (C) Western blot analysis of stable 
eGFP expression in pcDNA3.1Hygro vector in CHO-S cells. Stable cells of linearized eGFP 







 cells/ml in a 6-well experimental plate in duplicates. 
(D) Screening for verification shows constructs of lanes 1 and 2 as best expressing constructs 
and were carried on for further experiments. Western blot analysis of linearized 
pcDNA3.1Hygro at different concentrations to generate stable pools of pcDNA3.1Hygro 
empty vector as a negative control for monitoring CHO-S ER for expansion. Following this 
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3.11   Localisation of YFP-TM7SF2 and YFP-DHCR7 in Stable CHO-S Cells 
TM7SF2 and DHCR7 are sterol reductases located at the ER and function at distinct steps of the 
cholesterol biosynthesis pathway (Bennati et al., 2006).  Fluorescent microscopy was carried out to 
characterize these lipid biosynthesis targets in stably expressing CHO-S cells. GFP and 
pcDNA3.1Hygro were also investigated as controls. CHO-S cells were seeded on pre-coated cover 
slips to enable the suspension cells adhere to the surface of the cover slips. Cells with viability above 
98% were seeded at 0.2x106cells/mL in a 6 well plate and allowed to settle in an incubator for 24 h. 
Cells were then washed with phosphate buffered saline (PBS) and fixed with formaldehyde 
according to protocol. With the C-terminal sequence of YFP containing a localization signal, we 
monitored expression using GFP as a positive control. TM7SF2 and DHCR7 were expressed and 
localized around the nucleus, potentially at the ER as might be expected for these constructs. 
(Figure 3.16). The data confirm that TM7SF2 and DHCR7 are stably expressed in CHO-S although 
expression varied with different pools leading to the identification of two groups; named A and B. 
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Figure 3.16   Fluorescent microscopy images of CHO-S cells stably expressing YFP-TM7SF2, YFP-
DHCR7, GFP and pcDNA3.1Hygro. Following the seeding of cells on pre-coated coverslips at 37°C, 
cells were fixed with 4% paraformaldehyde. The nucleus of cells were DAPI-stained and fixed 
specimens were analysed. Expression patterns of YFP for TM7SF2 and DHCR7 were observed using 
GFP excitation wavelength between 395nm-475nm. While DAPI showed the cytoplasmic 
aggregates of the nucleus (A-F) as confirmed by the corresponding Differential Interference 
Contrast images (M-R), aggregates of TM7SF2 and DHCR7-transiently transfected cells showed 
some GFP fluorescence expressions (G-L) when compared with pcDNA3.1Hygro expressing CHO-













3.12     Generating Higher YFP-TM7SF2 and YFP-DHCR7 Expressing CHO-S Cells from Pools by 
Limited Dilution Cloning  
In order to implement TM7SF2 and DHCR7 as engineering targets, it was pertinent to first 
establish the levels of exogenous expression of these proteins in CHO-S cells. Following 
characterisation studies of the stably expressing pools described above, it was evident that pools 
of stable TM7SF2 and DHCR7 cells had improved growth but also that the amount of expression 
was low. However, statistical analysis using T-Test showed difference higher with a probability 
value (p value) of 0.05 between both sets of triplicate samples suggesting that the difference 
between the corresponding control (GFP/pcDNA3.1Hygro) and test samples (YFP-TM7SF2) was 
insignificant.  
 
Additional confocal microscopy analysis suggested that some cells had higher expression levels of 
YFP-TM7SF2 and YFP-DHCR7 than others within the pools (Figure 3.17). During the culturing of 
the engineered cells, it was observed that there was a clear disparity in the pattern of growth of 
the two kinds of pools of cells overexpressing YFP-TM7SF2 and YFP-DHCR7. Although, 
presentation appeared similar when viewed under the microscope, there remained a clear 
difference in expression levels as observed from western blot data.  The reason for this is likely to 
be due to differences in the site of integration, amount of transcript produced and subsequent 
recombinant fusion protein produced.  
 
To try isolate some of the higher expressing cells, a limited dilution cloning approach was 
undertaken. In obtaining single cell clones or monoclonal cells of YFP-TM7SF2A, YFP-TM7SF2B, 
YFP-DHCR7A and YFP-DHCR7B, we can eliminate variability of heterogeneous mixed population 
and focus on the high expressing cells. The two cultures of engineered cells YFP-TM7SF2 (A and 
B) and YFP-DHCR7 (A and B) were cultured and maintained under same experimental condition 




















Figure 3.17   Confocal microscopy of stable YFP-TM7SF2A in CHO-S. (A) Representative images 
depicting the general localisation expression of YFP-TM7SF2A in CHO.S cell pools. Not all cells 
are seen expressing the protein. (B) Images of YFP-TM7SF2B showing different signal 
expressions in cells as in (A). Scale bar: 10 µm. 
 
3.13   Growth Characterisation of CHO Cell Pools Stably Expressing YFP-TM7SF2 and YFP-DHCR7  
The alteration of key components of lipid biosynthesis could impact on cell growth and therefore it 
was necessary to examine the impact of overexpressing the lipid modifying targets on cellular 
responses which are important for cell growth, viability, and recombinant protein yields and quality. 
Therefore, the question of whether stables CHO-S cells overexpressing YFP-TM7SF2 and YFP-DHCR7 
impacts upon CHO-S growth and viability was investigated and the results are shown (Figures 3.18 
and 3.19).  Since the aim was to investigate the cell behaviour over culture, cells were seeded at a 
low concentration initially. In one study, stable cells of the empty vector control and YFP-TM7SF2 
were seeded at 0.2x106 viable cells/ml in a 20 ml shake flask in replicates and 0.2 ml of cells were 
counted over a period of 10 days. The viability of the culture was also assessed to determine whether 








over a 10-day period, YFP-TM7SF2 showed increased growth compared with the CHO-S control 
reaching a higher viable cell number. However statistical analysis showed no significant difference 
between the means of the two trials (CHO-S and YFP-TM7SF2).  In another experiment, the growth 
pattern of YFP-TM7SF2 and YFP-DHCR7 were examined with eGFP and pcDNA3.1Hygro as positive 
and negative controls. All experiments were carried out in replicates and graphs represent the mean 
















Figure 3.18   Growth profiles of CHO cells stably expressing YFP-TM7SF2 generated with 




cell/ml and cultured for 10 days. Viable 
cell counts were undertaken using 0.2 ml cells. Error bars represent the standard error of the 
mean from technical replicates (where n=3). Stable cells grow steady but decline on day 7.  (B) 
Lipid engineered TM7SF2 over-expressing CHO.S cells show a significant increase in growth as 
compared to CHO-S and does not appear to be toxic to cells. Quantification of three 
independent experiments using t-test with p-value (<0.05), when comparing CHO-S control 


































































Figure 3.19   Stable CHO-S expressing TM7SF2 cells were cultured at the same time as 
stable pools expressing GFP and pcDNA3.1Hgro as controls. Cells were seeded at 0.2x10
6 
viable cell/ml in a 20 ml shake flask and cultured for a 10-day period. Cell counts were 
undertaken using 0.2 ml cells with 0.8 ml to a 1 ml sample volume. Error bars represent 
the standard error of the mean from technical replicates (where n=3). No statistical 
significance at p˂0.05 when comparing YFP-TM7SF2 to the controls GFP and 
pcDNA3.1Hygro. 
 
Two pools of YFP-TM7SF2 and YFP-DHCR7 stably expressing CHO-S cells were generated with each 
showing different culture viability and viable cell counts. Each pool was labelled as YFPTM7SF2A, 
YFP-TM7SF2B, YFP-DHCR7A and YFP-DHCR7B. During cell culture, cell pools of YFP-TM7SF2B 
attained a higher viable cell number as compared with YFP-TM7SF2A. Meanwhile, YFP-DHCR7A 
pools obtained a higher maximum viable cell number when compared to YFP-DHCR7B pools. To 
study their growth pattern further, 10-day growth profiles of YFP-TM7SF2A, YFP-TM7SF2B, YFP-
DHCR7A and YFP-DHCR7B in replicate, with GFP and pcDNA3.1Hygro stable CHO-S cells, were 
setup.  Cells were seeded at 0.2x106 cells/ml and counts taken on day 0. Results show data 
generated on days 0, 3, 4, 5, 6, 7 and 10 (Figure 3.20A). TM7SF2B pools showed more rapid growth 
when compared to TM7SF2A as longevity span day 3 to day 6 suggesting an extended survival in 
culture when compared to theTM7SF2A pools. By day 7, both the controls and the lipid 






























essential nutrients. Pools of DHCR7A showed a similar growth pattern when compared to DHCR7B 
cell pool although, DHCR7A pools showed a higher viable cell number from day 0 until day 5 where 
DHCR7B pools were observed to have increased viable cell numbers. However the growth rate of 
TM7SF2 pools and DHCR7 pools do not show statistical significance at p˂0.05 when compared to 
controls GFP and pcDNA3.1Hygro. 
 
Figure 3.20B shows a growth profile of the average growth cell data from three independent 
experiments.  Stable pcDNA3.1Hygro expressing CHO-S showed a lower maximum viable cell 
number when compared with the GFP control and pools of TM7SF2 and DHCR7. It is 
interesting to note, that pools of YFP-TM7SF2 and YFP-DHCR7 CHO-S cells do not negatively 
impact on cell growth and viability but appear to positively impact as viability and growth 
pattern increased in the lipid engineered CHO-S cells. 
 




































































Figure 3.20   Graphs showing growth of stably expressing TM7SF2A, TM7SF2B, DHCR7A and 
DHCR7B CHO-S pools. (A) Comparison of TM7SF2A and B pools indicate there was a higher 
maximum viable cell number for TM7SF2B over TM7SF2A. DHCR7A shows a similar growth 
pattern to DHCR7B pools although a higher viable cell number was observed on day 7 for the 
B pool. Viable cell counts on day 0, 3, 4, 5, 6, 7 and 10 are shown. Error bar represents standard 
error of biological triplicates of samples, where n = 3. (B) Effect of overexpressing TM7SF2 
and DHCR7 in CHO-S cells. Graph shows typical growth pattern of engineered DHCR7 and 





3.14   Flow Cytometry Analysis of CHO-S Cells Stably Expressing YFP-TM7SF2  
To further elucidate and characterise the engineered cell pools, we analysed pools of YFP-TM7SF2 
by flow cytometry. The experimental technique was carried out as it has the ability to detect 
functional and identify correctly folded YFP whereby it measures forward scattering. The 
heterogeneity in the populations and the expression of the fluorescence of single cells of stable 
CHO.S cells expressing YFP-TM7SF2A and YFP-TM7SF2B were analysed and compared the CHO.S 
growing cells from culture samples. While each pool population behaves in a heterogeneous way 
with potentially dead cells not generally excluded from the analysis, the amount of folded and 
functional YFP present in the cells may be detected at the excitation of 514 nm and emission peak 
at 527 nm using flow cytometer. Cells were washed once in phosphate buffered saline and 10,000 
events were counted for each sample. Data generated show a shift to the right on the histogram 
for YFP-TM7SF2A and YFP-TM7SF2B due to the yellow fluorescence intensity being emitted by each 
cell per each count. Following analysis from this data, clones from each pools were generated and 


























































































Figure 3.21 Histogram comparing of yellow fluorescence intensity emitted by representatives 
of heterogeneous populations of YFP-TM7SF2 pools (A and B) as compared with the CHOS 
host. Stable YFP-TM7SF2 cells pools show a shift to the right as YFP is emitted in the cell 
population. The histogram is plotted by counts of each event independently which represents 
the signal intensity which was detected using fluorescein isothiocyanate (FITC) forward-
scatter, side-scatter, and each wavelength of fluorescence emission. Analysis of the data was 
gated at the 10
1 
mark where positive events are observed. Data suggests the gated region 


























3.15     Conclusions and Summary Statements from this Chapter 
 
This chapter focused on the cloning and characterisation of TM7SF2 and DHCR7 overexpressed in 
CHO.S cells and therefore reports on the manipulation strategies used to improve the capacity of 
CHO lipid biosynthesis machinery by altering key components. Our preliminary synthetic biology 
approaches involved identifying the subcellular localisation of YFP-TM7SF2 and YFP-DHCR7 as target 
models and analysed interpretations of possible implications. Elnasri et al., (2018) had reported on a 
detailed peculiar connection between the DHCR7 gene and TM7SF2 gene despite its association with 
20 other different genes. It was reported that transiently and stably overexpressed TM7SF2 and 
DHCR7 in particular have led to expansion of the ER in CHO cells (Zwerger et al., 2010). Using the 
principle of sub-clonal genetic engineering, we showed how TM7SF2 and DHCR7 lipid targets were 
cloned into expression vectors for transient and stable investigation studies for overexpression. 
 
With the introduction of an affinity YFP-tag for reporter of expression studies, Zwerger et al., (2010) 
in their report had expressed a wild-type and C-terminally truncated TM7SF2 and DHCR7 and N-
terminally truncated LBR where they observed a compaction of the nucleus with development of 
NAVs in U2OS cells and this was the case with untagged TM7SF2 wild-type and TM7SF2 indicating 
impact was independent of the fluorescent tag. A direction taken in this work, was to analyse how 
CHO-S cells may be influenced for improved protein production. Hence, the sequences for these 
tagged genes were released from EYFP-C1 plasmid vector expressed in U2OS cells using restriction 
digest enzymes following a sub-cloning approach and using the same restriction enzymes to cut and 
ligate into the expression vector pcDNA3.1CAT and pcDNA3.1Hygro.  
 
Confirmation of fragment and vector sizes was carried out using agarose gel electrophoresis. YFP-
DHCR7 was released from plasmid vector EYFP-C1 using Nhe1/Apa1, releasing the fragment at a 
predicted size of 2.1 kb from the 4.7 kb vector after which sub-cloning of this was done into the 
pcDNA3.1CAT and pcDNA3.1Hygro vectors (Figures 3.1 and 3.2).  The sub-cloning of LBR, another 
target protein which was released as a 2.3 kb sequence from EYFP-C1 and thereafter cloned into 
pcDNA3.1CAT and pcDNA3.1Hygro plasmid vectors using the same restriction enzymes. Research on 
the LBR protein was discontinued and focus was on YFP-TM7SF2 and YFP-DHCR7 only as targets to 




Expression of the constructs was initially assessed using transient expression. Advances in 
transient mammalian expression systems enable high yields ( >100 mg/liter) that now allow for 
effective recombinant antibody production at a reasonable cost (Vazquez-lombardi et al., 2017).  
 
In one approach, we transiently transfected pcDNA3.1CAT constructs of YFP-TM7SF2 and YFP-
DHCR7 where we monitored the localisation of the protein. Fluorescent microscopy was used to 
detect the presence of YFP-TM7SF2 and YFP-DHCR7 in the CHO.S cells (Figure 3.16). While the 
transfection efficiently was less than 30%, YFP signal was observed and confirmed the expression 
of the target proteins. Western blot analysis was also used to confirm expression of the target 
proteins. Different time points post-transfection were harvested and analysed using this 
approach. Results showed there was an increase in the expression of the proteins with increased 
post-transfection time. The calculated sizes were used to confirm expression. GFP was also 
transiently transfected as a control and observed as a 27 kDa band while YFP-TM7SF2 and YFP-
DHCR7 were observed as 73 kDa and 81 kDa bands respectively. Although it was interesting to 
test product gene expression by transient approach system, a more desirable involves the 
generation of stable cell lines over-expressing these targets. 
 
Quantitative evaluation was done to determine whether there was a significant level of protein 
expression in engineered cells when compared to controls. Densitometry results provided further 
evidence that CHO-S cells showed increased expression of YFP-TM7SF2 from day 1 to   day 3 and 
although the expression observed on western blot given the exposure time analysed, the 
densitometry assay showed a gradual and consistent expression level as confirmed with the GFP 
control. On day 3, CHO-S cells were transiently expressing YFP-TM7SF2 protein nearly as much as 
they expressed GFP which suggests that the lipid machinery of the CHO platform was capable of 
proper protein folding and the proven ability of CHO cells to produce complex recombinant 
proteins and to perform human like post-translational modifications underlines the advantages 
connected with these host cells (Thoring et al., 2017) .  
 
We have confirmed the stable CHO.S expression of the target proteins using hygromycin B 
selection, and also of eGFP and pcDNA3.1Hygro as controls. The strategies carried out to generate 
these stable cell lines have been detailed in this chapter. Stable cells were selected with 




transgenic protein expression (Kaufman et al., 2008).  Biochemical and cytolocalisation studies 
suggested that the lipid targets are associated with the ER. However, not all CHO.S cells expressed 
these proteins and there was a variety of expression amounts observed across cells.  Variance in 
their expression levels was confirmed by fluorescent microscopy analysis where pools of stable 
CHO.S cells expressing YFP-TM7SF2 and YFP-DHCR7 showed different growth patterns in the 
growth profile analysis carried out. It was therefore decided to investigate the higher expressing 
YFP-TM7SF2 and YFP-DHCR7 stable CHO.S by limited cloning dilution. 
 
The studies here show that over-expressing YFP-TM7SF2 or YFP-DHCR7 stably in CHO.S over a 10-
day cell growth period does not have toxicity to the CHO-S cells. Growth profiles were carried out 
with GFP and empty pcDNA3.1Hygro vector expressing CHO.S as controls. The different pools of 
stably expressing YFP-TM7SF2 and YFP-DHCR7 did not impede growth of CHO.S while empty 
pcDNA3.1Hygro expressing CHO.S cells showed a reduced growth pattern compared to the CHOS 
host alone. The over-expression of the two target proteins did appear to confer a growth advantage 
on the CHO-S cells. Therefore, the next focus was to consider the influence of this over-expression 
and impact on growth on production capacity of recombinant proteins. The next chapters therefore 
describe investigating whether these engineered cells can deliver enhanced expression of 






                     Chapter 4      
    
Molecular Characterisation and Functional Consequences of the Transient and Stable Expressions of 
Transmembrane7 Superfamily member 2 (TM7SF2) on the Recombinant Protein Expression from 
CHO-S Cells 
 
4.1    Introduction 
This chapter describes the impact of the investigations on the engineered CHO-S cells developed and 
described in Chapter 3 of this thesis to determine if the overexpression of YFP-TM7SF2 enhances the 
ability of CHOS cells to produce target bio therapeutic recombinant proteins. As described in the 
introduction chapter of this thesis, recent years have witnessed the emergence of new engineered, 
non-nature bio therapeutic proteins, such as fusion proteins (e.g. Etanercept). These so called next-
generation biologics can be significantly more difficult to express (DTE) compared to natural protein 
formats as generally host cells cannot correctly fold and process the recombinant polypeptide (Johari 
et al., 2015).   
 
A number of gene manipulation strategies have been published with the aim of increasing the 
productivity of such DTE exogenous protein from a host cell line (Chalmers, 2016). For example, a 
previous work published on a novel CHO cell line which was developed by researchers contained two 
stably overexpressed genes thought to be capable of improving the efficiency of protein folding (Cain 
et al. 2013). In order to investigate the impact of overexpression of lipid target YFP-TM7SF2 on 
engineered mammalian CHO-S cells and their recombinant protein secretory capacity, CHO-S cells 
expressing YFP-TM7SF2 were transfected to transiently or stably express target recombinant proteins 
for investigation. Stable CHO-S expressing GFP and empty vector pcDNA3.1Hygro cell pools were also 
generated and used as controls to validate the impact of YFP tagged TM7SF2 expression levels on CHO-
S cell phenotypes and behaviour.  
 
Phenotypic studies included evaluation of engineered cells cellular secretory capacity to secrete 
recombinant protein products, investigated by transiently transfecting Erythropoietin (EPO) and 
etanercept, two major bio therapeutic recombinant proteins used in the clinic and manufactured 
using CHO cells by the biotechnology industry. Protein expression was characterised using gel 




also analysed by characterisation of growth profiles and fluorescence microscopy analysis. mRNA 
transcript analysis was also attempted to investigate the correlation between the stable CHO-S 
expressing YFP-TM7SF2 protein and mRNA expression levels. The results and implications of these 
findings are discussed in this chapter. 
 
It is noted that the work in this chapter uses in particular transient gene expression (TGE) systems to 
investigate the impact of overexpression of TM7SF2 on transient expression of recombinant bio 
therapeutic proteins. Transient expression is an attractive alternative for rapid production of 
research-grade protein during the early stages of drug development due to the substantial time and 
resources associated with stable cell line generation (Johari et al., 2015).  As the preliminary 
characterisation of stable CHO-S over expressing YFP-TM7SF2 engineered cells using microscopy 
showed a wide variation in expression levels of YFP-TM7SF2 in CHO-S cell pools (Figure 3.14), limited 
dilution single cell cloning was undertaken to generate more clonal cell lines from the population of 
YFP-TM7SF2 stable CHO-S expression cells. Qualitative and semi-quantitative analysis was 
undertaken on these, including western blot, fluorescence imaging, growth characterization and 
immune staining localisation to investigate any impact on cell behaviour and the CHO-S ER in 
particular.  
 
As described above, investigations into the molecular implications of over-expression of engineered 
cells on Erythropoietin (EPO) production levels has been detailed here. In addition, the chapter also 
investigates the fusion protein etanercept. This is protein that fuses the ligand binding domain of a 
receptor to neutralize or destroy the targeted protein or cells with an antibody Fc heavy chain 
constant region (see introduction chapter for more detail). Examples of targeted protein drugs are 
the antibody drug (Infliximab) and decoy receptor drug (etanercept) that sequester the tumor 
necrosis factor alpha (TNFα). Tumor necrosis factor alpha has been implicated in the pathogenesis of 
many human diseases such as graft-versus-host disease (GVHD), Crohn’s disease, and several 
autoimmune diseases (Chiang et al., 2014).  
 
The overall aim of this chapter was therefore to determine if there is/are any significant impact(s) on 
increased recombinant protein production in TM7SF2 engineered CHO-S cells with reference to 
control cell pools or lines and determine what influence this engineering exerts on CHO-S cell growth, 




4.2         Results 
 
  4.2.1       Consequences of YFP-TM7SF2 over expression on growth characteristics of CHO-S cells 
TM7SF2, like most of the enzymes involved in the cholesterol biosynthesis pathway, localises to 
ER membranes, and its expression is regulated by the sterol regulatory element binding protein 
(SREBP) in response to cellular cholesterol levels (Nikolakaki et al., 2017). In fact, the master 
regulator of the TM7SF2 is SREBP (Bennati et al., 2006). Further, reports have previously shown 
that expression of YFP tagged versions of TM7SF2 results in expansion of the ER membrane 
although the mechanism by which this occurs is unknown. We hypothesised therefore, that 
overexpression of TM7SF2 in CHO-S cells would influence the CHO-S ER membrane expansion and 
overall influence increase in secretory capacity of the cell and impact on cell growth 
characteristics.  
 
A summary of the work, discussed below, shows that two stably expressing pools of YFP-TM7SF2 
show different recombinant protein yield patterns and productivity levels. However, the 
significance of the expression is relative to controls. It has previously been reported that the 
overexpression of fully functional TM7SF2 can critically affect the ER and nuclear envelope 
morphology (Zwerger et al., 2010).  Stable Pools of YFP-TM7SF2 (A and B), GFP expressing and 
empty pcDNA3.1Hygro in CHO-S cells were cultured in the presence of hygromycin B. The 
hygromycin-resistant CHO-S stable cells were cultured with several passages prior to experimental 
use.  
 
The initial studies were to understand any impact of overexpression of YFP-TM7SF2 on cell growth 
and to confirm that the protein was indeed being expressed. To better understand the impact of 
overexpression of TM7SF2 on CHO-S, a 10-day growth profile study was carried out on YFP-
TM7SF2 pools as well as the control (GFP expressing and empty vector containing) cell lines.  Cells 
were sub-cultured to a starting concentration of 0.2x106 viable cells/ml and cell number counted 
on day 0.  This is as a result of the inaccuracy in numbers when cells were confluent and 
overgrown, hence the low starting concentration. The experiment was carried out in triplicate and 
average data analysed. The resulting growth data is shown in Figure 4.1. There was a very similar 




growth characteristics to the negative control and GFP expressing cells (Figure 4.1A). This pattern 
of growth was observed in repetitive cultures and therefore both pools had similarities in cell 
growth pattern as shown. Of the pools, TM7SF2B reached a higher maximum viable cell number 
by day 6 when compared to TM7SF2A, although TM7SF2A had a higher viable cell number on day 
4. All cell pools showed a similar death pattern upon diminished nutrients. Thus, expression of the 
YFP-TM7SF2 protein does not appear to have a major negative impact on CHO-S cell growth. 
 
The growth dynamics of the TM7SF2 pools suggest a similarity in the phenotypic and metabolic 
characteristics and therefore tend to behave in a typical way. However, the presence of the 
overexpressing lipid target appears associated with increased growth and reduced apoptosis as 
confirmed by comparison to the control. It was observed that TM7SF2 overexpressing cells grew 
faster and had prolonged viability compared to the control and by day 4 in culture, TM7SF2 pools 
was nearly double the amount of cells  compared to the pcDNA3.1Hygro-expressing cells.  
 
To further validate the data on increased growth of TM7SF2 engineered cells with reference to 
the control, and relate this to YFP-TM7SF2 expression, investigations into the expression and 
localisation of TM7SF2 was done.  By confocal imaging, confirmation of expression levels of stable 
YFP-TM7SF2 in CHO-S cells was carried out, with GFP as a control. Cells were seeded at 5x105 
viable cells/ml on a pre-coated poly D-lysine cover slips with viability generally above 97%. After 
24 h, cells were then washed with PBS and fixed using 4% PFA in PBS for 15 min (Figure 4.1B).  
 
The data confirms expression of the target YFP-TM7SF2 in the cell pools but that there was 
differential expression between cells. This was also true for the GFP control. It is not possible from 
these data to confirm that expression of the TM7SF2 is localised to the ER. In essence, the 
rationale for overexpressing TM7SF2 as a target of driving ER expansion will not be achievable if 
certain phenotypic characteristics which are beneficial, are not first considered. Factors such as 
resistance to apoptosis, cell growth, quality and yield of recombinant protein products and also 


























4.2.2     Clones of CHO-S cells expressing different amounts of YFP-TM7SF2 differ in phenotypic 
characteristics 
The specific attributes of large-scale mammalian cell cultures (for example, high level of spatial 
heterogeneity) demand a modelling framework that captures both the biology and the 
hydrodynamics of the system and also their interactions (Farzan & Ierapetritou, 2018).  
Mammalian cell culture systems are intrinsically heterogeneous at all scales from the genetic to 
bioreactor level (Davies et al., 2013). Having identified variation in expression levels of YFP-
TM7SF2 engineered CHO-S cells, there was a need to distinguish the high-expressing clones from 
the pool which consists predominantly of low expressers as determined by fluorescence 
microscopy (see Figure 4.1B). Clonal variation for recombinant CHO cell lines does not originate 
only from functional heterogeneity in the host cell line, as genetic heterogeneity is also introduced 
during the generation of recombinant cell lines (Hansen et al., 2017).  
Figure 4.1   Analysis of stable YFP-TM7SF2 pools and a control GFP pool overexpression in CHO-S 
cells. (A) A 10-day growth profile of the two pools of YFP-TM7SF2 with GFP and pcDNA3.1Hygro 




cells/ml in a 20 ml media 
volume of a 125 ml shake flask in triplicates. TM7SF2B reached a higher maximum viable cell 
number than TM7SF2A on day 2 and day 6, although TM7SF2A had a higher viable cell number on 
day 4. Overexpressing TM7SF2 for both pools do not appear to inhibit CHO-S growth. Error bars 
represent standard error between three biological samples where n = 3. (B) Microscopy imaging 
comparing CHO-S expressing GFP and pools of YFP-TM7SF2. Pools of different passage numbers 
were randomly selected and analysed. YFP-TM7SF2A and B show sparsely-expressed YFP when 
compared to stable GFP-expressing CHO-S. YFP-TM7SF2B appears to have more cells expressing 
the target and this may relate to the growth pattern as shown in (A).  Original images were 
collected with a 100x objective. Scale bar: 10µm. 
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The cell cycle is a complex regulatory network that influences not only growth and division, but 
also other relevant cellular events (for example; death and productivity)  (García Münzer et al., 
2015) hence, it is an important aspect of biological systems that impacts either directly or 
indirectly on the ordered series of events relating to cellular growth, death and productivity. 
Therefore there is the need for a better understanding and knowledge of the cell cycle timing, 
transitions and associated production profiles which can aid the development (modelling, control 
and optimisation) of industrially-relevant systems (Karra et al., 2010).   In this case, differences in 
expression may be due to the site of integration into the genome (more or less active 
transcriptionally), mRNA amounts/turnover or stability, limitations in different cells abilities to 
synthesise the material and impact on cell fitness. 
 
The approach used to isolate higher YFP-TM7SF2 expressers from the low, was the limited dilution 
cloning method. The methods utilised for this purpose are described in section 2.8.5. The 
presence of a single cell in wells, or potential clones, in each well of a 96-well plate was identified 
by using a microscope to examine cells of individual wells. Clones derived from potential single 
colonies were transferred to a 24 well plate once they had started to grow into colonies and the 
media amount doubled and cells grown at 37°C for a further week. After a week, the growing 
colonies from a single clone were further transferred to a 12 well plate and later into a 6-well 
plate. 
 
In the development of the monoclonal cell lines of engineered YFP-TM7SF2 in CHO-S cells, clones 
were cultured over a period of time in the shake flask and the relative expression amounts 
identified in individual clones by western analysis. A Bradford assay was carried out to calculate 
the amount of protein required for equal loading on SDS-PAGE analysis. eGFP primary  antibody, 
known to bind YFP, was used to probe for YFP-TM7SF2 expression while anti-mouse IgG whole 
molecule, peroxidase produced in rabbit from SIGMA was prepared at 1:5000 and used for 
secondary antibody and detection. A total of 11 clones of CHO-S overexpressing YFP-TM7SF2 from 
TM7SF2B pool which showed the higher expression of both pools were investigated (see Figure 
4.2A). The size of the band observed was consistent with that for YFP-tagged TM7SF2 and was not 





Of the clones investigated, six clones (C3, C4, C7, C8, C1O and C11) of the total of eleven clones 
were considered to belonging to higher expressers/producers of YFP-TM7SF2 generated from 
TM7SF2B clones (numbered C1-C11). Upon confirmation of YFP-TM7SF2 expression and the 
relative amounts by western blotting, growth profiling was also analysed for the clones to identify 
the relative growth characteristics in relation to YFP-TM7SF2 expression (Figure 4.2B). To confirm 
that expression of the different amounts of YFP-TM7SF2 as determined by western blotting in 
Figure 4.2A did not negatively impact on CHO-S cell growth, batch-culture growth curves were 
setup and followed. The resulting data from days 3 to 7 are shown in Figure 4.2B. On day 6, clones 
4, 10 and 11 achieved the highest viable cell number when compared to the pcDNA3.1Hygro 
negative control engineered cells. This pattern is in agreement with the blot representation as 
shown in Figure 4.2A. On day 6, all 6 clones were either at, or close to the maximum viable cell 
number but this dramatically reduced on day 7, presumably due to nutrient deprivation. This was 
observed in control too.  
 
Capturing the dynamic behaviour of the system sometimes requires considering multiple phases 
for cellular growth and death, during which cells react differently to environmental stimuli, Xing 
et al. 2010. Since it is a known fact that variability exists in steady state protein expression levels 
among the variants, we hypothesised that there might be feedback implications in the viability 
rates hence the need to assess clonal cells’ viability over time-course. The viability profile of clones 
further validates the stability of TM7SF2 engineered clones of CHO-S cells. This positive impact in 
a batch culture of a 10-day period eliminates the query of whether there may be an impedance 
in growth of stable clones (see Figure 4.2C).  
 
The representative plot shows the average of triplicate samples for each clone as we monitored 
the viability of culture over the time course. One would expect, that individual clones would show 
a particular pattern of growth as a result of variance from distinct phenotypic characteristics. With 
a starting viability of about 97%, clones showed an overall rather impressive cell density and 
culture viability when compared to the control. The viability of the engineered clones remained 
high and above 80% until day 8. From this characterisation of YFP-TM7SF2 expression and cell 
growth, the remainder of the study focused on the 6 of the 11 clones that appeared to exhibit the 





Thus, a key difference between the clones and the control was their response to growth. While 
pcDNA3.1Hygro showed a fast and steady decline in viability from day 0 to day 7, TM7SF2 clones 
grew slower but with robust viability as growth was maintained to almost a constant state during 
the exponential phase between day 3 and day 6. At this stage the comparison of clones with the 






















































































































Figure 4.2   CHO-S   YFP-TM7S2 expressing engineered clones exhibit variation in YFP-TM7SF2 
expression and growth profiles and in Culture viability (A) Western blot analysis probed for YFP 
showing 11 individual clones generated from both pools of YFP-TM7SF2A and TM7SF2B. 20 ug 
of total protein from prepared samples was loaded onto SDS-PAGE. Clones show a varied YFP 
signal of YFP-TM7SF2 protein molecular weight of 73 kDa. Clones 3, 4, 7, 8, 10 and 11 were 
identified as higher expressers when compared to the other clones and pools. (B) Growth 
profiles of 6 of the 11 clones generated for YFP-TM7SF2. Clones were sub-cultured and seeded 
at 0.2x10
6
 viable cells/ml and grown for 10 days. A cross-section of 5 days is shown here. At 
day 3, all 6 clones show increased growth when compared to negative control pcDNA3.1Hygro. 
There was variation between clones in terms of the maximum viable cell number obtained 
with clone11 achieving the highest. Error bars represent standard error of replicate biological 
samples where n = 3. (C) CHO-S expressing TM7SF2 were cultured for a 7-day period for six 
high expresser clones (Clone 3, Clone 4, Clone 7, Clone 8, Clone 10 and Clone 11) as well as 
pcDNA3.1Hygro control. Clones were seeded at 0.2x10
6
 viable cells/ml and in replicates. Cell 
viability was observed to be above 80% as all clones showed cells of post exponential phase by 





















4.2.3        Investigation of the cell morphology and localisation of YFP-TM7SF2 fluorescent protein 
in CHO-S cells stably expressing the protein 
 
To try and assess if the YFP-TM7SF2 protein was localised to the ER, and hence could potentially 
have a positive impact on the expansion of the ER membrane and influence the secretory pathway 
capacity, it was important to investigate the cellular localisation of the expressed protein. It has 
been reported that the human sterol reductase, TM7SF2 is located at the endoplasmic reticulum 
(ER) and functions at distinct steps of the cholesterol biosynthesis pathway (Nikolakaki et al., 2017). 
Confocal microscopy was carried out to investigate the localisation of YFP-TM7SF2 which had been 
reported to be present, along with some other secretory pathway proteins, in the ER (Bellezza et 
al., 2015). 
 
Stably-generated YFP-TM7SF2 clones in CHO-S were therefore analysed for localisation studies 
where the presence of YFP would indicate the subcellular localisation of YFP-TM7SF2. The results 
(Figure 4.3) revealed the six different clones showed different expression signals in CHO-S nucleus, 
potentially ER and cytoplasm. YFP was detected at an emission signal of 527 nm when its excitation 
peak was 514 nm. Comparison of subcellular localisation showed YFP being expressed at the outer 
region of the nuclear envelope where the outer nuclear membrane compartmentation of ER is 
localised (Figure 4.3). While YFP signal was observed across all clonal cells, the level of signal and 
presentation of nucleus observed somewhat differed across the clones.  
 
Microscopic evidence confirmed that each clone showed peculiarity both in expression levels and 
also in cellular morphology. Panel A, for instance, which assessed clone 3 showed cells to be 
presented in a layer-like formation with smaller cells attaching to bigger cells while the signal level 
appear reduced when compared to other clones. Clone 4 cells showed a rather different condensed 
presentation as clones appear in groups, YFP signal is observed to be fully expressed as overlay of 
DAPI and YFP images of panel B cells showed YFP expression covered in the intercellular bridges in 
a synchronistic form. The same differential cellular morphology was observed in clones of panel C 
to F. Variation in presentation pattern may be related to different growth dynamics. For example, 
YFP-TM7SF2 Clone7 cells appear in a cluster-like presentation and cell nucleus appearing relatively 




cells show similarity in cell morphology to YFP-TM7SF2 Clone 10 cells but expression signals differ 
between both clones.   
 
The YFP-TM7SF2 clone 4 (Figure 4.3B) showed a pattern that would be consistent with ER 
localisation. In the production of an expansive ER membrane frame network system in CHO-S cells, 
the cellular levels of this biological target is key in driving the alteration of normal cellular processes 
of lipid biosynthesis with YFP signalling confirming the presence of TM7SF2 over expression 
reported to be functional in the outer nuclear membrane channel of the cells. Meanwhile, from the 
data presented (Figure 4.3), there are no evidences to confirm the site of YFP signal expression from 










































DAPI YFP OVERLAY 
Figure 4.3   Confocal microscopy of clones generated for CHO-S overexpressing YFP-TM7SF2. 
Stable cells overexpressing YFP-TM7SF2 were seeded at 0.2 x 10
6
 viable cells/ml and fixed using 
4% PFA. Upon washes with Tween, nucleus was DAPI-stained and YFP signal detected using 
confocal imaging. Images represent cellular presentation of ER-localised TM7SF2 where 
expansion has been predicted for improved capacity secretory pathway. Each clone showed 
peculiar cellular morphology as YFP signal is observed to be relative to individual clones. (A) 
Clone 3 presents in a layered cellular formation with smaller cells clumping to bigger cells and 
presents in a conformation similar to clone 10. YFP signal varies across clones although all 
clones showed significant YFP expression level. (B) Clone 4 cells (which presents in a condensed 
cellular conformation appear to have larger cell size. (C) Clone 7 cells however showed 
conformation similar to clone 11 with a higher YFP signal. Images are shown relative to 5 µm 
size bar. Expression levels appear to vary with each clone and some clones show similarity in 
presentation such as clones 3 and 10. 
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4.2.4    Further Profiling of ER targeted YFP-TM7SF2 by microscopy to confirm subcellular 
localisation in engineered CHO-S cells 
 
The ER network membrane is the site for much of lipid biosynthesis, hence is an important site for 
controlling expansion and control of secretory pathway capacity. Correct protein folding and 
modifications of most secretory and membrane proteins depends on the availability of molecular 
chaperones and enzymes located in the ER such as protein disulfide isomerase (PDI), calnexin 
(CANX), calreticulin (CALR), glucose-regulated protein (GRP78/BiP) and glucose-regulated protein 
(GRP94) (Bode et al. 2012).   
 
Further investigation into whether engineering of CHO-S cells to express YFP-TM7SF2 results in 
localisation to the ER and if any influence on the appearance of the CH0-S ER was carried out by 
examining the isolated clones for immunolocalisation studies whereby the localisation of YFP-
TM7SF2 with calnexin, a molecular chaperone which helps nascent proteins during folding and 
assembly and remains retained in the ER, was investigated. The ER was therefore marked using 
calnexin, as a reporter of compartmentation where YFP-TM7SF2 co-localises and to further analyse 
phenotypic characteristics for ER expansion. In order to define the ER, anti-calnexin antibody was 
used to visualise the ER and compared to the YFP signal from the YFP-TM7SF2 of clones to probe 
the connection between YFP-tagged TM7SF2 and the ER resident secretory protein calnexin.  
 
In order to do this, engineered and control CHO-S cells of culture viability over 96% were seeded at 
0.2x106 viable cells/ml on a poly D-Lysine coated cover slip placed in 24-well plates. 24 h later, cells 
were washed briefly in PBS before being fixed in 4% PFM for 15 min at 37°C. Following several 
washes, BSA blocked cells were incubated with anti-calnexin antibody, prepared in BSA/PBS and 
slides were incubated overnight at 37°C in a dark humidified chamber. For the immunofluorescence 
in-situ hybridisation 50 µl drops of 1:100 TRITC-mouse was introduced onto slides in a light 
sensitive, darkened area. After 2 h reaction time, antibody was washed using Tween-PBS while cell 
nucleus were DAPI stained for 1 min before washing off with PBS. DAPI (4′6-diamidino-2-
phenylindole) is a blue-fluorescent DNA stain that exhibits ~20-fold enhancement of fluorescence 
upon binding to the A-T region of dsDNA. It is commonly used as a nuclear counterstain for the  




thereby forming non-fluorescent intercalative complexes with double-stranded nucleic acids. DAPI 
staining was used to confirm and identify the presence of the nucleus of CHO-S cells.  
 
When YFP-TM7SF2 expression was compared to calnexin localisation, the aim was to investigate 
whether the two were co-localised. The presence of DAPI confirmed the position of the nucleus 
allowing the monitoring of highlighted YFP of TM7SF2 protein in the ER membrane compartment. 
The co-localisation observed for YFP-TMSF2 and calnexin further confirmed that TM7SF2 is targeted 
to the ER secretory pathway and accumulation of this transmembrane protein may impact on ER 
secretory capacity. The confocal microscopy also confirmed that TM7SF2 clones had variation in 
expression levels as clusters of cells express YFP. Clones 3 for instance appear to produce more 
TM7SF2 proteins than clone 5. Clones 6 and 7 appear to have similar expression levels while 
presentation of clone 8 is somewhat different than as expected (Figure 4.4).  
 
This is in agreement with the previously reported localisation studies that the TM7SF2 gene resides 
in the ER (Roberti et al., 2002). Thus, the YFP tag does not appear to effect localisation.  Results 
generated from microscopy show four images of representative clones at different excitation 
wavelengths for respective parameters. DAPI, Calnexin, YFP and the merge of all three. All images 
are shown at the same magnification. Calnexin was observed to spread around the nucleus into the 
























Figure 4.4   Immunofluorescence microscopy analysis to investigate ER localisation of 
YFP-TM7SF2 in different engineered CHO-S clones by co-localisation with the ER 
resident protein calnexin. Fixed CHO-S cells section were stained with primary anti-
calnexin and a secondary anti-rabbit TRIT-C and DAPI to monitor and determine any 
cellular compartmentation of stably overexpressing YFP-TM7SF2 in ER membrane. 
Clones show the expression signals for calnexin and YFP of YFP-tagged TM7SF2. Clones 
show different expression levels of YFP through the GFP channel. Here, an examination 
of the clones was done without the GFP and pcDNA3.1Hygro expressing control cell 
lines, which would have been beneficial for comparative analysis to determine 
whether there was an influence or changes in the ER membrane structure on over-
expression of YFP-TM7SF2. Co-expression of calnexin and YFP-TM7SF2 indicate the 
targeting of TM7SF2 to the ER. Original images were collected with a 100 x objective. 






















































































4.2.5       The impact of YFP-TM7SF2 overexpression in CHO-S cells on Transient EPO expression 
 
Since the ultimate objective of this study was to improve the recombinant protein productivity of CHO-
S cells, investigations into whether secretory productivity was impacted from the YFP-TM7SF2 
genetically modified CHO-S cells were undertaken. Genetic modification of host cells can be a promising 
strategy to eliminate or reduce the bottlenecks in recombinant protein expression (Zhao et al., 2012), 
although few such systems have yet been used industrially for the large manufacturing of recombinant 
bio therapeutic proteins. Although protein secretion in mammalian cells is a complicated process, the 
genetic engineering strategies based on the overexpression of individual components of the secretory 
pathways might not always improve product secretion (Rahimpour et al., 2016). By altering TM7SF2 
expression, we hypothesise that cholesterol biosynthesis may be altered, leading to ER expansion as 
previous reported and thus increase secretory capacity and secreted recombinant protein products 
yield.   
 
However, EPO is considered difficult to express and is a highly glycosylated protein. Many studies have 
been conducted to try and increase the production of recombinant human EPO (Trummer et al., 2006) 
which is widely used for clinical purposes in the treatment of anaemia that results from chronic renal 
failure (Walsh 2014). In the studies here, we investigated the impact generated on transient 
recombinant EPO secretion in the engineered YFP-TM7SF2 expressing CHO-S cells compared to GFP 
expressing and pcDNA3.1Hygro control cells. Both extracellular and intracellular relative amounts of this 
protein were determined using western blotting. Two pools of stable CHO-S overexpressing YFP-TM7SF2 
(A and B) were transfected with 4 µg EPO plasmid DNA as well as the control cell lines and cell 
supernatants processed and analysed using western blot to determine EPO secretion levels. In additional 
studies, clones of YFP-TM7SF2 engineered CHO-S cells were transfected with EPO and recombinant 











4.2.5.1   Effect of YFP-TM7SF2 expression in CHO-S cells on recombinant transient EPO expression 
To determine if expression of YFP-TM7SF2 had any impact (positive or negative) on EPO secretion, we 
conducted a transient transfection of recombinant EPO on both pools of TM7SF2 and the control cell 
line (GFP). In this study, EPO plasmid DNA was transfected using lipofectamine 2000 and Opti-MEM® a 
day after stable cells were seeded at 0.2x106 viable cells/ml in a 6-well plate containing 2 ml of cell 
media. Transfection was undertaken on the same cell pools and lines at different passage numbers. For 
instance, in Figure 4.5A, transfections were carried out in replicate with TM7SF2 pools A and B and GFP 
stables of CHO-S cells after passage numbers 5 and 9 whilst for pcDNA3.1Hygro this was of passage 
number 9. On day 2 after transfection, cells were collected and supernatants analysed. Equal volume of 
samples were loaded onto SDS-PAGE gels.  
 
The recombinant EPO contained a His-Tag and an anti-his-tag antibody was used to detect EPO 
expression at approximately 37 kDa. Generally, as described below, when analysed by western blotting 
there was an increase in the amount of transient EPO detected in both the YFP-TM7SF2 engineered 
CHO-S pools when compared to the GFP and pcDNA3.1Hygro control cells (see figure 4.5A). In order to 
further investigate the impact of over-expression of YFP-TM7SF2 on EPO expression, a further study was 
done where transfections of TM7SF2 pools A and B with controls were carried out in replicates and 200 
µl cell media collected on day 1, day 2 and day 3 post transfection and the samples analysed for EPO 
expression. 
 
To analyse the samples from this experiment, 15 µl of prepared supernatant  was loaded onto SDS-PAGE 
gels, protein samples transferred onto a nitrocellulose membrane for 1 h and then western blotting, 
using a conjugated anti-EPO (anti-his tag HRP) antibody, undertaken. The antibody was diluted to 1/1000 
before use and the western protocol followed as described in section 2.12. By day 1, no EPO expression 
was detected in the control cell samples (pcDNA3.1Hygro, GFP) and very weak bands at the size 
expected observed from the YFP-TM7SF2A and YFP-TM7SF2B cell pools (Figure 4.5B). By day 2 post 
transfection, EPO was detected in control samples and the YFP-TM7SF2 although there was little 
difference in observed expression levels, unlike that in Figure 4.5A. By day 3, the YFP-TM7SF2B pool 
(that previously was shown to have higher YFP-TM7SF2 expression than pool B) did have increased EPO 
expression compared to controls although the YFP-TM7SF2A pool did not show an increase compared 






















To further investigate whether there was a positive impact of overexpression of YFP-TM7SF2 pools on 
CHO-S secretory capacity, EPO band intensities from the western result (Figure 4.5 A and B) were 
analysed using quantitative numerical values using densitometry to quantify the difference in EPO 
production where comparison was done with GFP and pcDNA3.1Hygro expressing control cells 
analysed on day 2 post transfection. Upon calculation of a percentage and fold-change increase 
relative to the control samples at each time-point, there was a considerable increase in the YFP-
TM7SF2 B pool EPO expression than the A pool as shown (Figure 4.6A). A similar pattern was observed 
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Day 1 Day 2 Day 3 
Day 2 
Figure 4.5    Western blot analysis reveals increased EPO expression in CHO-S YFP-TM7SF2B pools 
compared to control cells. Transient EPO transfection was carried out to investigate the secretion 
amount of EPO in CHO-S overexpressing YFP-TM7SF2 pools A and B along with GFP control. 4 µg 
EPO plasmid DNA was transfected into cells of different passage times. Experiments were 




cells/ml to a 2 ml total cell media per well. (A) Representative blot shows increased EPO 
expression on day 2 in YFP-TM7SF2A and B expressing CHO-S cell pools when compared to GFP 
control. Analysis of the different passage time points of construct showed similar expression 
signals. (B) Blot shows experimental study of transient EPO transfection in CHO-S constructs of 
YFP-TM7SF2A and YFP-TM7SF2B as well as GFP and pcDNA3.1Hygro controls. 200 µl cell media 
was collected per well of replicate samples for all constructs and analysed. EPO was detected by 
using a conjugated anti-His tag HRP antibody at about 37 kDa. An increased expression signal was 
observed for TM7SF2B unlike A, on day 3. It is not clear why controls showed more expression 
than TM7SF2A and B on day 2. Samples were loaded respectively as follows; Lanes 1, 5, 9 = 






in another study where post transfection time was extended over a 3 day period. YFP-TM7SF2B pool 
again showed to have expressed increased EPO levels unlike pool A (Figure 4.6B) by day 3 although 
was almost same till on day 2. It appears therefore that the B pool of YFP-TM7SF2 was expressing EPO 
















































Figure 4.6    Densitometry analysis of the western blots images shown in Figure 4.5. 
Analysis was undertaken using the Image J freeware. The density of each band was 
determined and then normalised to the GFP and pcDNA31Hygro controls for quantitative 
analysis of expression levels of pools of lipid engineered CHO-S. (A) TM7SF2A pool cells 
expressed EPO on day 2 post transfection at a decreased level than TM7SF2B pools, while 
both pools showed higher EPO secretion levels (B) Quantification of EPO expressed at 
day 1, day 2 and day 3 post transfection. Again YFP-TM7SF2B showed increased quantity 


























4.2.5.2   YFP-TM7SF2 engineered CHO-S Pool B cells deliver higher transient EPO productivity over 
a batch culture than control cells  
CHO-S cells overexpressing YFP-TMSF2 pools A and B were grown in batch culture in 6-well plates 
where cells were seeded at 0.2 x 106 viable cells/ml in triplicates. Viable cell counts were undertaken 
throughout culture (Section 2.7.3). The YFP-TM7SF2B pool showed increased EPO expression level 
on day 3 (lane 2) compared to the control cells, unlike YFP-TM7SF2A pools which did not appear to 
have increased EPO expression over that observed in the control samples. When analysed along with 
the controls, GFP (lane 4) and pcDNA3.1Hygro (lane 5), YFP-TM7SF2B pools showed much higher 
expression levels of EPO in supernatants compared to the controls whereas the YFP-TM7SF2A pool 
did not appear to show any increased EPO secretion. This experiment was carried out along with YFP-
DHCR7 engineered CHO-S cell pools (Chapter 5), as shown on lanes 3 and 8 for all time points and 
this is discussed in detail in chapter 5. When comparing expression on day 3 with day 8, both YFP-
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Figure 4.7     Western blot analysis of transient secretory EPO expression on day 3, day 5 and day 
8 post-transfection in YFP-TM7SF2, YFP-DHCR7, GFP and empty vector control expressing CHO-S 
pools. EPO was detected using anti-his HRP antibody and represented blots were analysed at 
same exposure time of 2 min. 20 µl supernatant samples were analysed for EPO expression in 
YFP-TM7SF2 pool A (lanes 1 and 6) and pool B (lanes 2 and 7), YFP-DHCR7 pool A (lanes 3 and 8), 
GFP expressing (lanes 4 and 9) and pcDNA3.1Hygro empty vector control (lanes 5 and 10) CHO-S 




The western blots of Figure 4.7 were quantified using densitometry where further evidence 
showed that YFP-TM7SF2 B pool did produce more EPO than YFP-TM7SF2 A pool from day 3 post 
transfection to day 8 post transfection with an increase of over 1.00-fold on the average. This 
confirmation agrees with findings reported in section 4.2.5.1 where the YFP-TM7SF2 pools had 
been transiently transfected with EPO, in another study, along with GFP and pcDNA3.1Hygro 
expressing CHO-S cells. While the submissions are interesting to know, it would be ideal to extend 
the culture, longer than day 3 and examine EPO productivity beyond as product quality tend to 







                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        


























































Figure 4.8 Densitometry analysis of the western blots presented in Figure 4.7 
Supernatants were loaded equally per each sample presented. Quantitative analysis of 
transient EPO expression confirms YFP-TM7SF2 B pool doubled in expression levels over 
the controls and YFP-TM7SF2 A pool on day 3 and day 5.  By day 8, where there might 
have been a decline due to nutrient deprivation, although YFP-TM7SF2 B pool    showed 
a drastic decline, EPO expression was near twice as much of YFP-TM7SF2A and 
pcDNA3.1Hygro controls. Densitometry confirms, there was a positive impact of over-
expression of YFP-TM7SF2 B pool on CHO-S ER secretory system. Numbers 1 to 5 (A and 
B) represent YFP-TM7SF2A, YFP-TM7SF2B, YFP-DHCR7A, GFP and pcDNA3.1Hygro on 
day 3. Numbers 6 to 10 (A) represent YFP-TM7SF2A, YFP-TM7SF2B, YFP-DHCR7A, GFP 
and pcDNA3.1Hygro on day 5 while numbers 6 to 10 (B) YFP-TM7SF2A, YFP-TM7SF2B, 
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4.2.5.3 Effect of YFP-TM7SF2 expression in a range of CHO-S engineered clones on transient EPO 
secretion 
The studies described earlier in this chapter established that six of the eleven generated clones of 
CHO-S overexpressing YFP-TM7SF2 showed increased YFP signal when compared to pools and these 
are being identified as the high expressers of YFP-TM7SF2 (section 4.2.2). To further investigate the 
impact of the impact of expression of YFP-TM7SF2 on secreted recombinant protein production, 
transient EPO transfection was carried out on all eleven clones. Cells were seeded at 0.2x106 viable 
cells/ml and EPO DNA transfected using NovaCHOice™ transfection reagent and booster as 
previously described (section 4.2.5.1).  Western analysis was used to detect EPO expression in all 
eleven clones (Figure 4.7), although no GFP and pcDNA3.1Hygro controls are presented in Figure 4.7. 
As earlier reported, we observed that six of the eleven generated clones showed increased EPO 
expression of which the 6 clones identified as high producers had increased EPO expression 
compared to controls. Clones 3, 4, 7, 8, 10 and 11 appear to have increased expression of YFP-TM7SF2 
in CHO-S. EPO was produced more in all 6 clones and also clone 2, which was not observed as a higher 
YFP-TM7SF2 producer. This experiment focused on investigating whether EPO secretion levels in 
each clone had any relationship with amount of lysates expressed as shown in Figure 4.2A. 
 
Note that this study was carried out without a loading control, which accounts for the validation of 
the outcome of findings on western blot due to common errors in loading. Hence when this study 
was undertaken, a useful direction would have been to load a control, for the interpretation of 
western blots as to whether there was a change in abundance of YFP-TM7SF2 clonal cell lines being 
expressed per well. Meanwhile, it is important that the protein levels of loading controls remain 
constant (relative to the total protein content) under the test conditions (Johnson 2018). In other 
words, in future, it would be good to express a protein loading control such as Beta-actin with the 
cells presented on western blots. Beta-actin is a common loading protein and is usually present in 
cells at high concentrations. Others include Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 





















4.2.6    The impact of lipid engineered TM7SF2 over-expressing CHO-S cells on recombinant and 
transient etanercept expression. 
To further investigate whether engineering of the CHO-S host with YFP-TM7SF2 had a general impact 
on the transient secretory capacity of the cell to generate recombinant proteins, and to compare with 
the transient EPO expression studies that showed increased secretion in the lipid engineered cells 
when compared with controls, a second bio therapeutic molecule was transient expressed. In this case 
the molecule was etanercept, an important target drug molecule manufactured by the 
biopharmaceutical industry. Etanercept, although originally developed for rheumatoid arthritis and 
Crohn’s disease, has also demonstrated beneficial activity in other inflammatory diseases (Genovese 
et al., 2005). Transient expression studies were therefore undertaken to investigate the effect of 








































































Figure 4.9       Western blot analysis of EPO expressed in CHO-S clones engineered to express 
YFP-TM7SF2. Upon isolating 11 clones overexpressing YFP-TM7SF2, 6 were selected as high 
producers. EPO was expressed in all 11 clones and supernatants assayed using conjugated anti-
histag antibody. Interestingly, all 6 earlier selected clones as high YFP-TM7SF2 expressers 
showed enhanced EPO secretion compared to other clones (Clone 3, Clone 4, Clone 7, Clone 8, 
Clone 10 and Clone 11) whilst Clone 2 also exhibited enhanced EPO expression compared to 




transfecting an etanercept plasmid into stably expressing YFP-TM7SF2 cells and analysing the amount 
of secreted product in the supernatant collected at different times across a batch culture. 
 
 
4.2.6.1 Effect of YFP-TM7SF2 expression in CHO-S cells on recombinant transient 
etanercept expression  
 
To determine the effect of YFP-TM7SF2 expression on recombinant etanercept secretion, transient 
transfection studies were carried out as described in section 4.2.5.1 in triplicates in 6 well-plates 
and 200 µl of cell culture media collected on day 1, day 2 and day 3 post-transfection. Supernatant 
was collected, centrifuged and appropriate SDS-PAGE Laemmli sample loading buffer of 4x was 
used to prepare samples. Equal volume loading of samples at 15 µl were loaded onto the SDS-PAGE 
gel for electrophoresis after which protein samples were transferred onto a nitrocellulose 
membrane probed for the presence of etanercept using anti-heavy chain antibody overnight and a 
secondary anti-rabbit IgG peroxidase antibody for detection.  
 
For each harvest, the secreted amounts of etanercept from the YFP-TM7SF2 pool A and YFP-
TM7SF2 Pool B CHO-S engineered cells were investigated alongside the GFP and pcDNA3.1Hygro 
control cell pools. After western blot analysis it was observed that on day 1 post-transfection, there 
was weak expression from all pools although the YFP-TM7SF2 pools were less than (Pool A), or 
approximately the same as (Pool B), the GFP control (Figure 4.10A).  However, by day 2 post-
transfection etanercept amounts were elevated in the YFP-TM7SF2 pool B compared to the control 
pools whilst the pool A cells had similar amounts to the empty vector control (Figure 4.10A). 
 
When day 3 expression was investigated, it was observed that all constructs expressed etanercept 
at different expression levels, with pool B and the GFP control showing similar amounts and the 
pool A and empty vector control having less, but similar amounts. The YFP-TM7SF2 pool B cells 
showed a general trend of increased etanercept expression compared to the other pools from day 
1 to day 3 post-transfection (Figure 4.10 A). 
 
Again, we investigated clones of TM7SF2 Pool B with pcDNA3.1Hygro as a control. For this 




of 0.2x106 cells/ml in 2 ml media per well. A transient transfection experiment was set up as 
described in section 4.2.5.1.  On day 2 post-transfection, supernatant was collected and prepared 
using SDS-PAGE Laemmli sample buffer. Samples were equally loaded on the SDS-PAGE gel for 
electrophoresis and thereafter prepared for blotting. Anti-heavy chain antibody was used as 
primary antibody which was allowed to react to a secondary anti-rabbit IgG peroxidase after day 1 
(section 2.4.3) and proteins were later assayed using western blotting. Findings from data showed 
that clones showed different expression levels of etanercept with clone 2, clone 3, clone 8 and 



















































































































































































Figure 4.10    Western blot analysis of the ability of YFP-TM7SF2 engineered CHO-S cell 
pools in (A) and clones in (B) to express and secrete the recombinant bio therapeutic 
protein etanercept compared to a GFP engineered and empty vector engineered CHO-S 
pool. (A) YFP-TM7SF2 Pool B generally shows increased expression from day 1 to day 3 
post-transfection compared to other pools. (B) Eleven generated YFP-TM7SF2 engineered 
CHO-S clones were assayed for their ability to secrete etanercept and compared to the 
amounts from an empty vector pcDNA3.1Hygro CHO-S control. Different expression 









Following western blot analysis, there was the need to quantify the amount of etanercept being 
expressed by the engineered cells relative to control cells. Densitometry was used to determine the 
level of expression of etanercept in YFP-TM7SF2 pools on day 1, day 2 and day 3. Data showed that 
on day 1, there was a fairly similar level of expression between control cells and lipid engineered 
cells. However by day 2, there had been a drastic increase in the secretion amount allowing YFP-
TM7SF2 B pool to express Densitometry confirms the data  from western blot as there was a gradual 
increase across all cell lines on day 3 and even at that, YFP-TM7SF2  B pool maintained an enhanced 



































Densitometry (etanercept) on day 1, day 2 and  day 3 
Figure 4.11   Densitometry analysis of the western blot shown in Figure 4.10. Levels of 
etanercept expressed in lipid engineered cells and control cells.   Pools of TM7SF2 were 
transfected with etanercept and harvested on day 1, day 2 and day 3  post transfection. 
Experiment undertaken with GFP and pcDNA3.1Hygro control cells. Densitometry data 
suggest an increase in etanercept expression on day 1 in YFP-TM7SF2 B pool and 














4.2.7        Effect of Expression of YFP-TM7SF2, EPO and etanercept transient transfection on CHO-S 
cell growth and viability during batch culture 
An important aspect to this study was to determine the effect, if any, of YFP-TM7SF2 and transient 
EPO and etanercept expression on CHO-S growth over a batch-culture time course (section 4.2.2). It 
was hypothesized that expression of YFP-TM7SF2 would improve cell growth and product yield 
resulting in an overall enhancement in cell productivity.  On days 0, 3, 5 and 8 post transfection, 
samples were taken to assess viable cell numbers and culture viability for both EPO and etanercept 
transfected cells. Data obtained (Figures 4.12 and 4.13) show that generally, the viable cell numbers 
increased steadily during the time of experimental study and culture viability of pools transfected with 
EPO and etanercept had a similar pattern of growth as both YFP-TM7SF2 CHO-S expressing pools had 
a similar culture viability compared to controls. This thus confirms that the expression of the YFP-
TM7SF2 did not negatively impact viable cell division and culture viability when expressing a 


















Figure 4.12     Characterisation of batch cell index versus culture viability of CHO-S 
engineered pools transiently transfected with EPO over 8 days of culture. Cell counts were 
done during the time course of study as cell numbers remarkably changed. By day 3, cells 
had doubled in cell size as TM7SF2 pools maintained a higher growth pattern than 
negative control. Counts were taken on days 0, 3, 5 and 8 post transfection. Assay for 
viability of stable TM7SF2 pools with controls showed a similar pattern in growth from 
day 0 to day 8 of culture. On day 8, YFP-TM7SF2 engineered cell pools showed higher 
viability over negative control. With p value ˂ 0.05 determined by students T-Test when 
comparing YFP-TM7SF2pools to the controls GFP and pcDNA3.1Hygro, there was no 
statistical significance at p˂0.05. Error bars represent standard error of the mean of 




































































































































GFP                   pcDNA3.1Hygro           YFP-TM7SF2A          YFP-TM7SF2B
Etanercept(A) 
Figure 4.13 Characterisation of batch cell index versus culture viability of CHO-S engineered pools 
transiently transfected with etanercept over 8 days of culture. (A) Cell counts were done during the 
time course. By day 3, cells had doubled in cell size as TM7SF2 pools maintained a higher growth 
pattern than negative control a similar observation seen when EPO was transiently expressed. Counts 
were taken on days 0, 3, 5 and 8 post transfection. Error bars represent standard error of the mean 
for three biological samples (n =3). (B) A similar viability pattern was observed for both pools of lipid 
engineered cells and the controls. Cells maintained a steady decline in growth 8 days post 
transfection. TM7SF2 pools maintained a higher yield than negative control (pcDNA3.1Hygro. No 
significant inference at p˂0.05 as determined by students’ T-Test when comparing YFP-TM7SF2 pools 









4.2.8   Investigation of YFP-TM7SF2 mRNA and protein amounts in engineered CHO-S cells 
In order to determine if protein expression levels of CHO-S engineered to express YFP-TM7SF2 
correlated with mRNA yield, engineered clones and pools cell pellets were harvested and RNA 
isolated from the cells in the exponential growth phase. Cells were lysed according to QIAprepR 
Miniprep protocol. Following purification, the RNA extract was transferred into a sterile micro 
centrifuge tube and stored at -80°C. In order to determine if mRNA transcript of YFP-TM7SF2 was 
present, pre-designed primers for GFP in the laboratory were used that would also be appropriate 
for detecting YFP. Analysis was performed in a 96-well reaction plate. For confirmation of the GFP 
primers, a PCR analysis was carried out using a GFP template which is a plasmid vector GFP and the 
presence of an amplicon of the expected size verified by running an agarose gel along with a no 




















Figure 4.14    Agarose gel electrophoresis analysis showing PCR amplification product for 
GFP, DNA positive control template quality check. A band of the expected amplicon size 
of 100 bp was observed at the expected size for the positive control (Lane 1) and no band 
with the negative control (no DNA, Lane 2). Separate master mixes (25 µl prepare 
sample) were prepared for each master mix and housekeeping gene primer pairs were 
prepared on ice under sterile conditions. In lane 1, the GFP positive control master mix  
had sterile nuclease-free water (8.5 µl), SYGR Green intercalating dye (12.5 µl), GFP 
Forward primer 10 µm (0.75 µl), GFP Reverse primer 10 µm (0.75 µl), Reverse 
transcriptase (0.5 µl) and GFP (2 µl), as template. For the master mix of 25 µl prepared 










Following confirmation that the GFP primers gave a band of the expected size with a positive 
template, extracted RNA samples from the YFP-TM7SF2 cells to be analysed by qRT-PCR were first 
DNAse treated and then the PCR reaction undertaken In order to verify that mRNA transcript was 
present and a band of the expected size was generated, the reaction products from the PCR 
reaction for the clones and pools were analysed along with samples from known amounts of a 




















100bp C1 C4 C3 C2 C7 C6 C5 
C11  C10 C9 C8 
Standards Samples 
S1 S2 S3 
Figure 4.15   Agarose gel electrophoresis analysis of RT-PCR analysis for presence of YFP 
transcript in mRNA samples generated from YFP-TM7SF2 expressing CHO-S cell pools and 
samples. Lanes 1, 2 and 3 represent bands from a positive GFP containing plasmid with 
differing known copy numbers whilst lanes 5 to 13 contain samples from different pools 
and clones Bands of the expected size were observed, however these were also observed 
in the absence of the reverse transcriptase enzyme suggesting the bands originate from 
genomic DNA. Whilst this does not allow any conclusions about mRNA amounts to be made, 
it confirms the presence of the YFP gene sequence integrated into the genome. Standards 
were generated from standard curve (101 to 106) onto qPCR reaction plate as sample set 




The transcript analysis data in figure 4.15 and that from a PCR without any reverse transcriptase 
(no RT, data not shown including the PCR data from the non-engineered cells) showed bands of the 
expected size. The fact these were observed in the no RT reaction shows DNA template must be 
present to allow amplification without mRNA being reverse transcribed into cDNA. Whilst this was 
disappointing and did not allow any conclusions around the amount of mRNA in different clones 
and pools to be evaluated, it did confirm that YFP was present in the genome and successful 






















4.3       Conclusions and Summary Statements from this Chapter 
 
The overall aim of this study was to gain an understanding of the impact of engineering CHO cells on 
recombinant protein production and investigations in this chapter have been summarised broadly 
into two. The consequence of TM7SF2 and DHCR7 over-expression on CHO cells’ growth and 
productivity and the investigations into the localisation of TM7SF2 and DHCR7 as ER resident proteins 
with confirmation studies using calnexin. By limited dilution cloning approach, a total of eleven clones 
from TM7SF2 pool B and six clones of total eleven identified as top producers/expressers of TM7SF2 
by western blot techniques hence focus for the rest of the study was on these six.   
 
Generally, the ability of CHO cells to reach high cell densities in suspension conditions, in chemically-
defined media free of serum, is a key principle that underpins the process of recombinant protein 
production from mammalian cells growing in culture (Whitfield 2014). When these targets were 
engineered in CHO cells, the propensity was for cells to reach a maximum level in growing culture. 
There is a need for a clear understanding of the effect of cell culture parameters obtainable from 
engineered cells with its influence on recombinant protein production. By qualitative analysis, our data 
shows that proliferation rate of experimental cultures was higher when analysed with GFP and 
pcDNA3.1Hygro expressing control cells with increase in rate of growth and turnout of EPO and 
etanercept secretion level. The effectiveness of EPO and etanercept delivery from TM7SF2 and DHCR7 
have shown that EPO and etanercept production increased transiently with increased exposure time. 
 
Further investigations showed the heterogeneity of clones with variations in expression capacity, an 
observation reported also by Pedrazzini et al., (2003), that the high abundance of transmembrane 
proteins in the ER can induce extensive membrane growth, whereas low expression does not alter ER 
morphology. With the identification of cells, we carried out localization studies where we identified 
distinct expression levels of each clone. When we carried out western blotting, the observation 
confirmed the increased TM7SF2 pool B expression over TM7SF2 pool A and interestingly related with 
the growth profiles analysed for the parent pool and resulting generated clones. When we expressed 
EPO in the clones, the expression level varied significantly and was not unconnected to their TM7SF2 




controls and the B pool of TM7SF2 remained the more producer/expresser of EPO and etanercept 
when both pools were analysed. This findings was consistent across different experiments and further 
investigations should be done to optimise the approach.  
 
An investigation into the impact of transient EPO and etanercept expression on CHO-S cells’ viable cell 
numbers and viability showed there might have been a positive influence by engineering the cellular 
circuit of CHO-S secretory system by over-expressing YFP-tagged TM7SF2 and YFP-tagged DHCR7 sterol 
reductases of the cholesterol biosynthesis pathway. When EPO and etanercept were expressed over a 
time course, both pools of YFP-TM7SF2 showed increased EPO expression (Figure 4.6) and as post 
transfection time increased, it was observed that EPO expression level increased.  
 
It is important to note that the B pool of YFP-TM7SF2 maintained a higher level of expression which 
suggests that these cells have a higher cell division so as to maintain complete coverage of cholesterol 
biosynthesis. Considering the importance and the efficient regulation of cholesterol metabolism and 
transport, it is likely that these finely tuned mechanisms will become altered during the high velocity 
of cell division and membrane synthesis needed for carcinogenesis (Cruz et al., 2013). As expression 
levels of EPO and etanercept appeared to have increased in lipid-engineered CHO-S as presented on 
western blots, there was a need for a further analysis as to how much of these recombinant proteins 
were expressed with reference to GFP and pcDNA3.1Hygro control CHO-S cells, hence densitometry 
analysis was undertaken for Protein (EPO and etanercept) quantification as measured by band 
intensity using Image J. Note that all constructs of proteins were quantified by Bradford assay to allow 
for equal loading on SDS PAGE gel. 
 
Densitometry data generated for Western blots are commonly used to compare protein abundance 
between samples (Butler et al., 2019) by measuring intensities of specific bands, corresponding to the 
proteins of interest using commercially available software. For example, when EPO bands presented 
on western blots (Figure 4.9) were analysed using densitometry, the relative amounts of each protein 
ratio was quantified with lipid-engineered cells compared to controls. It was confirmed that B pool of 
YFP-TM7SF2 over-expressing cells produced more transient EPO over a time course before a decline 
(day 3 to day 8) than the A pool, suggesting there was a positive impact of overexpressing YFP-
TM7SF2B on CHO-S secretory system. However, the increase in EPO and etanercept observed on 




p˂0.05. Some other assays could also be used to quantify EPO and Etanercept, which could require the 
use of traditional methods such as the measurement of Ultraviolet (UV) absorbance at 280 nm, 
Bicinchoninic acid (BCA) and Bradford assays, as well as alternative methods like Lowry, Biuret or novel 
assays developed by commercial suppliers whereas individual protein quantitation methods include 
enzyme-linked immunosorbent assay (ELISA) assay, western blot analysis, and more recently, mass 
spectrometry, among others (Johnson 2018).   
 
To probe the localisation of TM7SF2, Calnexin, an ER chaperone protein served as an ER marker for 
verification studies of YFP-TM7SF2 as both calnexin and TM7SF2 co-localise to the ER. Morphological 
presentation showed YFP-signal of TM7SF2-engineered cells in the inner nuclear membrane along with 
calnexin. Although the size of ER was not monitored as at the time of this report, the identification of 
calnexin in the ER, where TM7SF2 is reported in the literature to be localised further supports the 
involvement of the transmembrane protein in ER secretory processing.  
 
However some other methods have addressed the ER monitoring by using the ER tracker dye (for 
example, the bodipy green or bodipy red ER which binds to potassium channels in the ER by targeting 
glibenclamide) where the ER is stained for easy detection and size analysis. We compared our results 
with previous findings on TM7SF2 overexpression studies in other cell lines and our findings may not 
be peculiar to CHO-S as studies done on TM7SF2 using other cell lines also confirmed that the presence 
of wild type TM7SF2 might also alter membrane properties, e.g. membrane fluidity or permeability. 
(Herrmann et al., 2009). Attempts to correlate mRNA with protein levels was not successful. Overall, 
our study shows promising data that overexpressing TM7SF2 can positively impact on secreted 













Molecular Characterisation and Functional Consequence(s) of Expression of YFP-tagged 7-
dehydrocholesterol reductase (DHCR7) in CHO-S Cells 
 
5.1      Introduction and Objectives 
 
As described earlier in this thesis, over half the bio therapeutic protein products on the market are 
made in mammalian cells (Walsh, 2014). Although mammalian cell culture is generally more 
complicated and expensive than microbial cultivation, the former is often preferred for the production 
of bio therapeutics because mammalian cells are capable of performing human-like post-translation 
modifications of proteins, especially glycosylation (Walsh & Jefferis, 2006). Indeed, mammalian cells 
are currently the main hosts for commercial production of many therapeutic proteins, particularly 
monoclonal antibodies and antibody like molecules (Lee et al., 2009). The majority of these products 
are made in CHO cells, where the ER plays a major role in the folding and assembly of these products 
and hence the focus in this chapter was on CHO-S cells and the ER secretory system when expressing 
YFP-DHCR7.  
 
In this chapter, stable over-expression of YFP-DHCR7 was undertaken and the impact investigated on 
CHO-S cell recombinant protein secretory yields. Such engineering of CHO cells for increased 
survival/growth/viability, have been attempted to try and increase the capacity of mammalian cells 
and by far, the greatest demand for recombinant mammalian proteins is for therapeutic development 
and applications (Bandaranayake & Almo, 2014). To try and reprogramme the CHO-S cell ER for 
improved secretion of protein yields, we manipulated YFP-DHCR7, a terminal enzyme in the 
Kandutsch-Russell pathway of cholesterol synthesis reported to occur in the ER. When the lipid 
engineered CHO-S cells overexpressing YFP-DHCR7 were generated, two pools were isolated. 
Subsequently, by using a limited dilution cloning approach, we identified a number of relatively high 





In order to assess the level of recombinant protein production from YFP-DHCR7 engineered CHO-S cells 
in relation to controls, model protein-based bio therapeutics were used for the basis of establishing 
the impact on the CHO-S cell secretory machinery, and in turn, any impact on cell growth and viability 
investigated. To elucidate the impact on secretory productivity, two model biomolecules were 
investigated, Erythropoietin (EPO) and etanercept, which were transiently transfected into CHO-S cells, 
as discussed in Chapter 4, and the yields from YFP-DHCR7 engineered cells compared with control cells 
(stable CHO-S expressing GFP and an empty pcDNA3.1Hygro vector engineered CHO-S control cell 
pool) using western blotting techniques. In addition, cell growth, cell morphology and localisation of 
YFP-DHCR7 were studied. DHCR7 localisation was assessed by fluorescent microscopy studies and co-







5.2   Results 
 
5.2.1   The Effect of YFP-DHCR7 Expression on CHO-S Cells’ ER Secretory System 
 
DHCR7 is a human sterol reductase, located at the ER and functions at distinct steps of the cholesterol 
biosynthesis pathway (Bennati et al., 2006) (Porter, 2008). It has been reported that both DHCR7 and 
TM7SF2 (discussed in Chapter 4) are two structurally related sterol reductases and that a comparable 
phenotype in susceptible cells lines is observed when a forced expression of DHCR7 or TM7SF2 is 
placed on the cell (Herrmann & Zwerger 2010).  Due to the reported similarity in phenotypic expression 
of DHCR7 and TM7SF2, we further investigated the effects of over-expression of YFP-DHCR7 on the 
CHO-S host cell and ER expansion and secretory system. By analysing YFP-DHCR7, the possibility of 
enhancing recombinant protein production in CHO-S cells by stable over-expression was explored.  
 
The impact of YFP-DHCR7 expression on CHO-S cells was compared with that observed when GFP was 
expressed and to cells engineered to express an empty vector pcDNA3.1Hygro control, both stably 
expressed in CHO-S.  The empty vector control means that all cells under assessment have been 
through the same selection process and have the same metabolic load other than the GFP control and 
YFP-DHCR7 having the additional load of an additional exogenous protein (the GFP where YFP-of 
DHCR7 is to account for this). Several investigation strategies confirm there was a positive impact of 
YFP-DHCR7 overexpression on the accumulation of recombinant protein expression levels as detailed 
below. Stable hygromycin-selected CHO-S expressing YFP-DHCR7 cells were generated and cultured 
and subsequently two distinct pools were isolated with different proliferation rates and secretory 
productivity levels. We further characterised these two distinct pools both qualitatively and 
quantitatively. A 10-day growth profile analysis was initially carried out to examine the cell 
proliferation rate of CHO-S cells over-expressing YFP-DHCR7 in comparison to the empty vector and 
GFP expressing CHO-S controls.  
 
For the growth curve studies, cells were seeded at 0.2x106 viable cells/ml in 125 ml shaker flasks in 
triplicate and cells counted from Day 0 and then every day to determine the total cell number, viable 
cell number and culture viability. The resulting data is presented as the average of the replicate 
cultures (Figure 5.1A). The two YFP-DHCR7 expressing pools, designated YFP-DHCR7A and YFP-




showed an initial faster growth rate than the pcDNA3.1Hygro control and on days 2 and 4 had 
approximately twice the number of viable cells compared to the empty vector control although only a 
small difference was observed compared to the GFP control cell numbers than the pcDNA3.1Hygro 
control on day 8 of culture.  
 
To confirm expression of the YFP-DHCR7 molecule in the cell pools isolated, qualitative analysis by 
fluorescent microscopy to detect YFP expression as a reporter for DHCR7 was also undertaken (Figure 
5.1B). YFP-DHCR7 lipid engineered stable cells from a culture viability of approximately 96% were 
seeded on D-lysine pre-coated cover slips in 24-well plates at 5x105 viable  cells/ml with 600 µl cell 
media at 37°C. Cells were washed 24 h later using PBS and subsequently fixed with 4% PFM. Following 
a BSA block and several TBST washes (section 2.3.4), images of fixed cells were taken using Leica® 
Fluorescent microscope (Figure 5.1B). These data showed YFP expression in both engineered cell pools 
and a variety of expression levels between cells as would be expected in a cell pool. However, these 
data only confirm expression of YFP, not of YFP-DHCR7 as the YFP could be cleaved from the fusion 
molecule and hence western blot analysis was also undertaken as described in the next section. 
 
 
5.2.2      Screening of YFP-DHCR7 Engineered CHO-S Cells Shows they Exhibit Different 
Amounts of YFP-DHCR7 Expression  
  
During the generation of stable CHO-S over-expressing YFP-DHCR7 pools, two pools were isolated. 
Because mammalian host cells have been reported to vary considerably in their intrinsic ability to 
manufacture a given recombinant protein independent of transgene copy numbers (Char Aniya et al., 
2009), we investigated clonal populations of the heterogeneous YFP-DHCR7 pool A, generated using a 
limited dilution cloning approach. This allowed the isolation of seven clones which were further 
characterised. Clones were generally cultured in a 125 ml shaker flask in 20 ml cell culture volume and 
regularly sub-cultured in the presence of hygromycin selection and investigated using western analysis. 
Western analysis would also confirm that the full, intact YFP-DHCR7 molecule was expressed or if any 

















      
For western blotting analysis, YFP-DHCR7A and YFP-DHCR7B engineered CHO-S cells were harvested at 
1x106 viable cells/ml and lysed using freshly prepared lysis buffer. A Bradford assay was subsequently 
used to calculate a 20 µg protein amount to allow for equal loading on SDS-PAGE gels. To probe for YFP, 
anti-eGFP primary antibody was used with a secondary anti-mouse IgG whole molecule, peroxidase 
labelled antibody for detection. When CHO-S YFP-DHCR7A and YFP-DHCR7B pools were analysed along 
with the GFP and pcDNA3.1Hygro controls, a band of the expected size for the YFP-DHCR7 molecule was 
observed in both pools (at 81 kDa, see Figure 5.2). Further, the YFP-DHCR7A pool appeared to have 
increased signal, and hence expression, when compared to the YFP-DHCR7B pool, in agreement with 
the fluorescent microscopy studies reported in Figure 5.1B. A band corresponding to GFP at 27 kDa was 
observed in the GFP control pools and as expected there were no bands detected in the pcDNA3.1Hygro 
samples.  
 
Of the seven generated clones from pool A, labelled clones 1 to 7, three were identified as high 
expressers of DHCR7; Clones 4, 6 and 7 (Figure 5.2B) and further evaluated. However, a recurrent 
observation was that the expression tendency of DHCR7 was generally poor when compared to TM7SF2. 
Initially, it was thought that this might be due to improper stable cell line generation of these constructs. 
However, attempts to re-generate the stable cells expressing YFP-DHCR7 still showed low signal 
YFP-DHCR7A YFP-DHCR7A 
Figure 5.1    Characterisation of CHO-S stably expressing YFP-DHCR7A and YFP-DHCR7B pools. 
(A) A 10-day growth profile viable cell numbers of YFP-DHCR7A and YFP-DHCR7B pools 
alongside the GFP expressing and empty vector CHO-S controls. Error bars represent 
standard error between three biological cultures (n = 3). (B) Fluorescence microscopy studies 
showing expression of YFP in the CHO-S pools engineered to express YFP-DHCR7. Both 
DHCR7A and DHCR7B pools show stable YFP signal detected, although different expression 
levels are apparent in individual cells. Representative images show YFP-DHCR7A pool 



































strength. Interestingly, these YFP-DHCR7 constructs continued to show increased maximum viable cell 
concentrations .Thus it is likely that cells expressing higher amounts of the YFP-DHCR7 do not survive 
the selection process.  
 
Attempts were made to improve YFP signal in case the presumably membrane associated YFP-DHCR7 
was not being fully lysed or released from the membrane, by subjecting the cells to sonication, which 
involves using sound energy to cause agitation of the particles in samples in sonication water bath, and 
shearing of the lysate material using a needle shear to break open the cell wall. Neither of these resulted 
in a stronger signal being observed. The appearance of non-producing populations of cells, can lead to 
an overall decrease in production. Cellular burden represents a significant problem in the scaling of 
fermentation processes from proof-of-concept to long-term cultures, as the load of heterologous gene 
expression and depletion of the cell intracellular resources cause unpredictable cellular physiological 
changes that can lead to decreased growth and lower production yields (Bena et al., 2018). Nevertheless, 
stably expressing YFP-DHCR7 cells were isolated and hence further evaluation in the variations of key 
phenotypic traits, including investigating their proliferation rate, peak viable cell diameter, cell size and 
cell biomass content and morphology, were investigated. Note that all constructs of proteins were 










































































Figure 5.2    Western blot analysis of YFP-DHCR7 expression in CHO-S clones. (A) Pools of YFP-DHCR7 
(A and B) alongside the GFP and pcDNA3.1Hygro controls were analysed for expression. 20 µ g 
amount of protein was loaded for each sample on an SDS-PAGE. YFP signal for YFP-DHCR7 was 
observed at 81 kDa while GFP positive control is observed at 27 kDa. The blot represents a 5 min 
exposure time. (B) Analysis of YFP-DHCR7 expression in the parent pool A and B and clones isolated 
from these that show a varying YFP-DHCR7 band/signal. Clones 4, 6 and 7) were considered as 
higher expressers when compared to the other clones and further examined. Represented blot 




5.3.0     The impact of engineering YFP-DHCR7 expression in CHO-S cells on transient secretory EPO 
expression 
 
One of the main goals of this study was to improve recombinant secretory protein productivity of CHO-
S cells. Since protein productivity is directly proportional to viable biomass, viability and culture 
longevity of the producer cells (Kumar et al., 2007), we hypothesised that the impact of expressing 
YFP-DHCR7 on the CHO-S secretory system would result in an expansion of ER membrane network, 
which would in turn result in increased amounts of secretory recombinant protein production. This 
was investigated using recombinant Erythropoietin (EPO), a therapeutic protein manufactured in CHO 
cells and efficient mammalian erythropoietin (EPO)-expression systems are required for therapeutic 
applications (Kim et al., 2004). As previously described in Chapter 4, EPO is a commonly used model 
protein in development of CHO-based bioprocesses (Surabattula et al., 2011) and metabolic 
engineering of CHO cells for improved protein production (Kim et al., 2011). As discussed in Chapter 4 
for the engineering of CHO-S cells with YFP-TM7SF2, where the impact of engineering CHO-S with YFP-
DHCR7 on transient recombinant EPO secretion was compared to the GFP and pcDNA3.1Hygro control 
cells. Extracellular amounts of EPO were therefore determined using western blotting. The two pools 
of stable CHO-S expressing YFP-DHCR7 (A and B) were transfected with 4 µg EPO as were the controls 
and cell culture supernatants processed and analysed using western blot to determine EPO secretion 
levels. Clones of the YFP-DHCR7 engineered CHO-S cells were also transfected with EPO and EPO 
expression determined by western blot.  
 
 
5.3.1     Clones of YFP- DHCR7 engineered CHO-S cells express different transient EPO amounts 
 
To characterise the ability of YFP-DHCR7 engineered CHO-S to produce EPO, samples were collected 
from the cell culture supernatant day 2 post-transfection and prepared for SDS-PAGE and western 
analysis with 4X laemmli sample buffer. 20 µl volume of samples were then loaded equally across the 
SDS-PAGE gel for electrophoresis. Following nitrocellulose membrane transfer, recombinant EPO was 
probed using conjugated anti-his tag HRP antibody (the EPO was tagged at the C-terminal with a his-
tag) for western analysis with the EPO band being detected at approximately 37 kDa (Figure 5.3). 
Clones 4, 6 and 7 were observed to express higher amounts of recombinant EPO than the two pools 




shown to be higher expressers of YFP-DHCR7 in CHO-S. Clone 3 did not show an elevated EPO signal 
from supernatant samples compared to the GFP control, suggesting there may be other limitations in 
the clone on secretory productivity.  
The fact that not all YFP-DHFR7 clones exhibited the same phenotype with respect to EPO expression 
is perhaps not surprising. Cultivation of recombinant cells is performed in different ways, depending 
on the goal of the experiment (Ley et al., 2015). Previous reports have suggested that clonally-derived 
cell lines can display erratic and uncontrollable behaviour in culture such as variation in specific growth 
rate (Barnes et al., 2006) and differences in productivity characteristics (Heller-Harrison et al., 2009). 
This is because there are other factors that determine the ability of a cell to make recombinant protein 
than ER and secretory capacity (for example.; transcriptional and translational limitations) and hence 
whilst in clone 4, clone 6 and clone 7 secretory capacity improvements may account for increased 








































































 Figure 5.3    Western blot analysis of the ability of pools and clones of CHO-S expressing YFP-
DHCR7 to secrete EPO. Cells were seeded at 0.2x10
6
 viable cells/ml in 2 ml of cell media of a 
6-well plate. Transient EPO transfection was carried out with 4 µg EPO plasmid DNA using 
NovaCHOice™ transfection reagent and booster. Equal amounts of prepared supernatant with 
laemilli sample buffer were run on SDS-PAGE gel two days after transfection. Analysis of both 
pools and clones showed elevated EPO levels in clone 4, clone 6 and clone 7 when compared 





Additionally, EPO band intensities from the western result were converted into quantitative numerical 
values using densitometry in order to quantify the difference in EPO production between CHO-S 
expressing controls and engineered CHO-S expressing DHCR7 pools including their generated clones. 
Using Image J software, analysis was done to determine the optical density of the relative levels of 
bands on pixels of the photographic film (Figure 5.4). The densitometry data suggested that there had 
been an increase in EPO expression in pool A over pool B and that clonal cells overexpressing DHCR7 
appeared to be expressing more amount of EPO than pcDNA3.1Hygro as clones 4, 6 and 7 did show 
















































Figure 5.4    Densitometry analysis of EPO expression levels on western blot image in 
Figure 5.3. Relative levels of the two pools of DHCR7 were determined alongside clonal 
cells generated from pool B as well as GFP/pcDNA3.1Hygro expressing control cells, 




5.3.2 Comparison of the transient secretory EPO productivity ability between YFP-DHCR7 
and YFP-TM7SF2 engineered CHO-S cell Pools 
 
Almost all of the enzymes required for cholesterol synthesis reside in the ER. DHCR7 and TM7SF2 are 
human sterol intermediates and function at distinct steps in the cholesterol biosynthesis pathway. 
However when these two related sterol reductases were over-expressed, they were reported to have 
induced identical phenotype, including membrane dilation and nuclear compaction when expressed 
both as truncated and full length variants in U2OS cells (Hermann & Zwerger, 2010). The influence of 
expression of the YFP tagged version of these proteins in engineered CHO-S in terms of ability to 
influence secreted EPO amounts was directly compared. Transient transfection of EPO was carried out 
on stable CHO-S cells expressing YFP-DHCR7 (A pool) and two pools of YFP-TM7SF2 alongside the GFP 
and pcDNA3.1Hygro controls.  
 
The YFP-TM7SF2 pool B cells gave the highest amounts of EPO as determined by western blot (see 
Figure 5.5) whilst the pool A samples were marginally higher visually than the controls (Figure 4.6). The 
YFP-DHCR7 samples were generally similar to the controls, although by day 8 of culture, these were 
higher than the controls (Figure 5.5). The YFP-TM7SF2 pools therefore appear to give a greater increase 
in transient EPO expression than the YFP-DHCR7 pool, possibly due to the fact that YFP-TM7SF2 
expression, as determined by YFP amounts, is higher than YFP-DHCR7 expression in the pools (Figure 
4.7). A greater increase is observed in the YFP-DHCR7 clones than the pools (see Figure 5.3) and hence 
these clones may have been more appropriate to investigate than the pools for such a comparison.  
 
In assessing the level of recombinant protein expression, it is crucial to undertake a comparative study 
between YFP-TM7SF2 clonal cells and YFP-DHCR7 clonal cells on their influence on protein production 
for a significant correlation on their respective capacities. While expression data has shown by western 
blots and densitometry, confirm the levels of EPO expressed in pools and clones to CHO-S expressing 
GFP and pcDNA3.1Hygro controls (Figure 5.5), we did not directly compare the respective clones with 
controls for investigation on their functional expression levels. It will be of great benefit to investigate 
the responsiveness of these clones for transient EPO and etanercept production. Since these clonal 
cells reveal high proliferation rates under appropriate culture conditions, it is conceivable therefore, 




(Willmann et al., 2013). Hence, a western blot analysis comparing clones of CHO-S over-expressing 
















5.3.3       Transient EPO expression from different clones of CHO-S expressing YFP-DHCR7 
 
In addition to analysing EPO expression in YFP-DHCR7 pools, the highest expressing YFP-DHCR7 clones 
were investigated by using a western blot to look at the relative transient secreted EPO amounts from 
these (Figure 5.6). This experiment was carried out on four of the six identified high expressers of 
DHCR7 (A) pool and cells harvested day 2 post EPO transfection. Western analysis was used to detect 
EPO expression in all four clones. It was observed that all clones showed elevated EPO levels when 
compared to the empty vector pcDNA3.1Hygro control cell pool (Figure 5.6). While EPO was observed 
at the expected size of 37 kDa, the amount of expression observed among the four clones varied. There 
was generally a relationship between the amount of YFP-DHCR7 expression detected in the clones by 
western blot (Figure 5.2 and Figure 5.3) and the amount of EPO secretion observed, suggesting that 
the expression of YFP-DHCR7 was influencing secreted EPO amounts. The presented western blot 
image is without a loading control. Loading controls are used to confirm that protein loading is the 
same across the gel (as errors are common during loading) and these controls are usually proteins that 
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Figure 5.5     Western blot analysis of transient secretory EPO expression on day 3, day 5 and day 
8 post-transfection in YFP-TM7SF2, YFP-DHCR7, GFP and empty vector control expressing CHO-
S pools. EPO was detected using anti-his HRP antibody and represented blots were analysed at 
same exposure time of 2 min. 20 µl supernatant samples were analysed for EPO expression in 
YFP-TM7SF2 pool A (lanes 1 and 6) and pool B (lanes 2 and 7), YFP-DHCR7 pool A (lanes 3 and 8), 
GFP expressing (lanes 4 and 9) and pcDNA3.1Hygro empty vector control (lanes 5 and 10) CHO-




exhibit high-level, constitutive expression in the cell and should be of different molecular weight to the 
protein of interest so as to be able to distinguish between bands. Usually, housekeeping genes are 
often chosen for use this purpose. A loading control would serve as a confirmation to the observed 
findings that DHCR7 clones expressed more EPO amounts than pcDNA3.1Hygro. In the future, this 
should be undertaken. Examples of loading controls include Alpha tubulin, Beta tubulin, 


















Following data from western blot, there seemed to be a relationship between these band intensities 
and culture productivity. The densitometry analysis confirmed the results of the initial study with 
relative levels of clones reaching about 0.5 fold of pcDNA3.1Hygro, suggesting that the clones 
continued to express EPO transiently on day 2 post transfection (Figure 5.7). While the clones continue 
to show increased EPO expression levels over control cells, it is important to note, that this observation 
was for 2 days post EPO transfection and it is not certain, whether this is applicable for a longer period. 
When EPO was transiently expressed on day 8 (Figure 4.8) however, findings were observed to be 
reproducible suggesting a positive impact may be observed on the long run during culture 




































Figure 5.6   Western blot analysis of secreted EPO from CHO-S clones expressing YFP-
DHCR7 and the empty vector control (pcDNA3.1Hygro). Four clones identified as high 
producers of CHO-S expressing YFP-DHCR7 were analysed with pcDNA3.1Hygro. His 
tagged EPO was detected at 37 kDa in supernatant using conjugated anti-his HRP tag 






















5.4.0   The impact of YFP-DHCR7 expression in CHO-S cells on transient etanercept expression 
 
The previous studies in this chapter have shown that YFP-DHCR7 expression appears to impact on 
secreted EPO expression. In order to determine if this was an EPO specific impact, or a more widely 
applicable impact, the transient secretory expression of a second bio therapeutic protein was 
analysed in these and the control cells. For this purpose etanercept, which remains a very successful 
therapeutic protein in terms of commercial success with annual sale of 9.3 billion US dollars (Willrich 
et al., 2015) was transiently transfected into the different CHO-S engineered cells. We investigated 
the influence of both pools and clones of YFP-DHCR7 expression on etanercept. The approach 
involved transfecting etanercept in stable cells and analysing the extracellular culture supernatant at 
different times of a batch culture time-course for anti-TNF expression signal. As stated in chapter 4, 
etanercept, has been demonstrated to have beneficial activity in a number of inflammatory diseases 























Clone 3           Clone 4         Clone 6          Clone 7         pcDNA3.1Hygro
Densitometry (EPO) in YFP-DHCR7 Clones
Figure 5.7    Densitometry analysis of the western blots images shown in Figure 5.6. The 
density of each band was determined and then normalised to pcDNA31Hygro control 
for quantitative analysis of EPO expression levels of YFP-DHCR7 clones. YFP-DHCR7 Pool 
A cells expressed EPO at about 0.5 fold above pcDNA3.1Hygro expressing CHO-S cells 





5.4.1      Clones of YFP-DHCR7 engineered CHO-S cells express different amounts of etanercept 
under transient conditions 
 
To examine the impact of YFP-DHCR7 expression on etanercept secretion, we carried out transient 
transfection in replicates in 6 well plates, where three clones (clone 4, clone 6 and clone 7) which 
were considered higher expressers of YFP-DHCR7 were investigated. These clones were previously 
shown to give enhanced EPO secretion compared to control cells. Upon transfection, 200 µl cell 
media was collected 2 days post transfection. After western transfer, probing of etanercept was 
achieved using a heavy chain 1° antibody overnight and a re-probe with 2° anti-rabbit IgG peroxidase 
antibody. While between the clones there was different etanercept secretion (Figure 5.8), YFP-
DHCR7 Clones 3 and 7 showed higher etanercept amounts in their culture supernatant than other 
clones. Although western blot image (Figure 5.8) was shown with the intention to compare the 
relationship of high-expresser clones using etanercept, there are no GFP and pcDNA3.1Hygro 
























Figure 5.8     Western blot analysis of etanercept expressed in CHO-S clones expressing YFP-
DHCR7.  Five clones of CHO-S expressing DHCR7 were analysed for transient etanercept 
expression detected at 150 kDa in supernatant using anti-heavy chain 1° antibody with anti-







5.5.0    Investigating the cellular localisation of YFP-DHCR7 in stably engineered CHO-S cells by 
comparison to an ER resident protein, calnexin 
 
DHCR7 is endogenously located in the ER membrane. The ER is an important site of protein synthesis 
and post-translational modification and for proteins to be transported from the ER to other sites 
within the cell and even out of the cell, biologically active proteins follow a well-defined route known 
as the secretory pathway (Bouchekhima et al., 2009). The forward route, starts with the ER, followed 
by the Golgi complex and the trans-Golgi network, before proteins reach the plasma membrane (PM) 
which surrounds the cell, and subsequently the extra cellular space (Anelli & Sitia, 2007).  
  
Here it was investigated whether expression of YFP-DHCR7 in CHO-S still targeted DHCR7 to the ER. 
The hypothesis of this work is that the quality control mechanism of DHCR7 in the lipid biosynthesis 
pathway enhances the ER secretion production capacity by providing a greater ER capacity, thus 
balancing inward and outward flux of recombinant protein load, hence preventing accumulation of 
toxic misfolded proteins. Thus, the ER subcellular localisation of YFP-DHCR7 in the cell was 
investigated by determining its localisation status relative to the ER resident protein calnexin of the 
calnexin/calreticulin machinery, which monitors the folding status by interaction with sugar residues 
in folding intermediates (Ellgaard & Helenius, 2003).  
 
Immunocytolocalisation studies were therefore carried out to investigate the localisation of YFP-
DHCR7 as DHCR7 has been reported to be localised in the ER. Stable YFP-DHCR7 clones were analysed 
for localisation studies. The presence of YFP can be used to highlight the subcellular localisation of 
YFP-DHCR7 as the intact YFP-DHCR7 molecule was shown to be present by western blot analysis. 
Microscopy was performed on five CHO-S clones of YFP-DHCR7 which were identified as high 
expressers relative to other clones as previously described. Detection was carried out using confocal 
imaging. Images obtained from immunoblotting are presented in three panels in figure 4.4 for each 
clone at different excitation wavelengths for respective colours; Calnexin, YFP, and an overlay image 
of the two colours to determine if there is co-localisation.  
 
All images are shown at the same magnification as indicated by the 10 µm bar in each figure (Figure 
5.9). Both the anti-calnexin antibody and YFP show cellular morphology of clones while the most 




Some of the clones analysed showed peculiarity of expression, for instance YFP-DHCR7 clone 6 cell 
nucleus appear clustered together whereas DHCR7 clone 7 show defined sparsely dispersed nucleus. 
There was considerable over-lap of the YFP and calnexin staining suggesting some of the YFP-DHCR7 
was co-localised to the ER whilst other was cytoplasmic. This agrees with previous work (Zwerger et 
al., 2010) although the YFP-DHCR7 does not have a ER localisation signal at the N-terminal and 
suggests that the molecule interacts with ER membrane in some manner. Images presented here 
(Figure 5.9) show the morphology of YFP-DHCR7 clones only when counterstained with calnexin and 
DAPI for compartmentation studies for the localisation of the ER and do not show the presentation 
of the nuclear envelope of CHO-S expressing GFP and pcDNA3.1Hygro as controls which would be 
necessary for analytical discussion. This would be considered in the future. Another approach to an 
investigative study is to analyse CHO-S cells morphology with live cell imaging which would allow for 



















Figure 5.9   Immunocytolocalisation of YFP-DHCR7 clones to monitor ER by co-localisation of 





TRIT.C and chromatin, counterstained with DAPI to monitor the potential cellular 
compartmentation of stably over-expressing YFP-DHCR7. Clones appear to show signals in 
nuclear membrane where the ER is located. Expansion has been predicted to occur in the ER 
when YFP-DHCR7 was over-expressed in U2OS cells (Zwerger et al., 2010). Images are expressed 
at 10 µm. Expression levels of YFP-DHCR7 vary in agreement with western blot analysis between 
clones. Images presented were generated from two different studies (A and B). Study “A” does 
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5.6.0      Comparison of the Growth and Culture Viability of YFP-DHCR7 Clones of CHO-S with 
Controls during Batch Culture 
 
While acknowledging the variation of YFP-DHCR7 expression amounts observed for clones, it was 
important to examine the relationship between their culture viability and proliferation rate with YFP-
DHCR7 expression levels in the engineered CHO-S compared to the controls. Indeed, there is the 
potential to increase the productivity of cells by controlling cell growth (Du et al., 2015). The selected 
clones were analysed throughout a 10-day batch culture with reference to controls (Figure 5.10). 
Both culture viability and viable/total cell numbers were monitored over the batch-culture time 
course. Cells were seeded at 0.2x106 viable cells/ml while 0.2 ml was taken for cell counts at each 
time these were assessed over the 10-day period.  
 
The cell counts across the culture period of days 3 to 7, which fall within the exponential growth and 
decline phase, are shown in Figure 5.10. Although the time course for the study was a 10-day period, 
analyses discussed and shown here are the period between day 3 and day 7. It was observed that 
unlike CHO-S cells overexpressing YFP-TM7SF2, YFP-DHCR7 overexpressing cells exhibit great 
variation in specific proliferation rate and showed peak viable cell density usually within days 3 and 
7, suggesting that cells may be extensively undergoing an exponential growth phase due to an initial 
stimulating effect on specific cell growth rate rather than to the higher availability of those nutrients 
at any other time of the culture. The peculiar growth pattern had been persistent and therefore, it 
became interesting to have a closer look at this period of culture in CHO-S over-expressing YFP-
DHCR7 growth was necessary. 
 
All clones had a peak viable cell concentration on day 6 of culture and had similar profiles with the 
pcDNA3.1Hygro control obtaining the lowest maximum viable cell number (Figure 5.10A). As cells 
expressing YFP-DHCR7 do not appear to be impacted in terms of  toxicity to cells, it appears likely 
that the levels in the clones isolated is tolerated by the CHO-S cell and hence any impact of this 
amount of expression on the secretory capacity of the cell and ER membrane for increased 
recombinant protein production could be assessed. In order to determine whether the stable cells 
expressing YFP-DHCR7 functionally influences the stability and viability of CHO-S, the percentage 






All clones expressing YFP-DHCR7 showed sustained viability from day 3 to day 6 compared to the 
empty vector control and all except clone 1 (the lowest expressing YFP-DHCR7 clone) maintained 
higher culture viability than the GFP control cell pool (Figure 5.10B). Collectively the data in figure 
5.10 shows that expression of the YFP-DHCR7 molecule in the CHO-S cells at the amounts isolated 
does not detrimentally impact upon the growth and culture viability and may have a positive impact 

















































































5.6.1        Comparison of the Impact of Transient and Stable Expression of YFP-DHCR7 in CHO-S 
Cells on Growth Profiles during Batch Culture 
Many studies use transient expression of target proteins in mammalian cells to assess the impact 
of their expression on cell phenotypes. In this study stable expression of YFP-DHCR7 and any 
impact on regulating growth and secretion processes in CHO-S was investigated. However, this 
was also compared to transient expression of YFP-DHCR7 in terms of the influence on phenotypic 
diversity and proliferation rate. For all assays, the maximum viable cell concentration obtained 
was on day 3 of culture. Interestingly, on day 2 the transient transfected samples of YFP-DHCR7A 
had a higher viable cell number and seemed to have thrived more than it did by day 3 (Figure 
5.11). Cell concentration was more-or-less the same for most of the pools investigated for both 
the transient and stable pools. One of the causes of instability of recombinant protein production 
from CHO cells is the loss of the gene of interest from the recombinant host cells’ genome, 
particularly for the CHO expression system (Kim et al., 2011) and hence it is possible that gene 
expression is lost over time in stable cells. However, this occurs over multiple passages and 
prolonged culture and hence would not explain any difference on day 2 between the transient 
and stably expressing cells investigated here. The data again confirms that the expression of YFP-

























5.6.2      Assessing the impact of EPO transient transfection on YFP-DHCR7 engineered CHO-S culture 
viability 
 
The YFP-DHCR7 cells could respond differently to transfection and the load of EPO on them than the 
controls with respect to growth and viability, hence the viability was monitored across the batch culture. 
When the viability was assessed on CHO-S growth over a time course (section 5.4.4.2), the aim was to 
evaluate the influence on CHO-S growth as we hypothesised that by controlled expression of lipid 
biosynthesis ER membrane, cell growth and viability can be influenced for improved productivity. It was 
observed the DHCR7 pool A cells maintained a similar culture viability to the GFP control and both were 
higher than the pcDNA3.1Hygro control (Figure 5.12). Thus, there was no negative impact, nor a positive 
impact, of the expression of YFP-DHCR7  
Figure 5.11 Growth profile of transient (designated by T day 2 and T day 3) and stable 
(designated by S day 2 and S day 3) YFP-DHCR7 expressing CHO-S cells during batch culture. 
Cells were seeded at 0.2x106 viable cells/ml in replicates and viable cells counted on day 2 
and day 3 post transfection for stably expressing cells or after transfection with the 
appropriate construct for the transiently expressing cells. Error bars represent standard 
error of the mean for replicate biological samples (n = 3).  
T day 2 
S day 2 
T day 3 




















































Figure 5.12     Percentage culture viability during transient EPO expression in YFP-DHCR7 
pool A and the GFP and empty vector control. Analysis of cell viability at different days 
(day 3, day 5 and day 8) of an 8-day batch culture experiment, show DHCR7A pool to be 
steadily proliferating as compared with pcDNA3.1Hygro as a negative channel. Error bars 




5.7 Conclusions and Summary Statements from this Chapter 
    
The main findings are discussed in the main discussion chapter (Chapter 6) but a brief discussion of 
the implications of the findings of the work in this chapter is presented. The results presented in this 
chapter describe the approaches taken to investigate improving CHO-S cells’ secretory productivity 
by engineering YFP-DHCR7 expression. As approximately 30% of newly synthesised proteins have 
been reported to not fold properly and are thereby degraded (Goeckeler and Brodsky, 2010), there 
remains potential to improve secretory productivity by manipulation of the ER capacity to meet the 
increase in demand for protein synthesis, as a concomitant increase in the number of proteins will 
be degraded based on quality control (Teodoro 2012).  
 
Here, an attempt to influence more recombinant protein production in the CHO-S secretory systems 
by overexpressing DHCR7, a key target protein in sterol biosynthesis, was undertaken. Our interest 
was to investigate an adaptive response approach that affords the cells secretory system the capacity 
to maximise its role effectively without activating the ER stress signal pathway which almost always 
ends in apoptosis. When stable CHO-S cells over-expressing YFP-tagged DHCR7 were generated, 
strategies carried out to characterise the engineered CHO-S cells resulted in the generation of two 
pools, named A and B, which showed distinct growth patterns. Although high protein yields are 
desirable, resultant proteins are less valuable if they are aggregated, misfolded, degraded or 
improperly glycosylated (Liu et al., 2015). Pool A appeared to express YFP-DHCR7 more than pool B 
when probed by western blotting. 
 
Initial clonings undertaken in the research produced constructs that were engineered into expansive 
CHO-S transcriptome, for the generation of stable cell lines for gene expression analysis. 
Consequently, our data showed that over- expression of DHCR7 did not alter CHO-S cell’s molecular 
dynamics as cellular differentiation and growth were not impeded neither was CHO-S cells’ viability 
negativity impacted.  From our stability analysis, we have shown that over a time course DHCR7 
engineered cells were not toxic to cells and were not apoptotic as decay rates were consistently low 
when compared to controls. The heterogeneity of cells which was responsible for CHO-S cells’ range 





With the generation of clones by limited dilution cloning methods, the focus was on investigating 
how over-expression of these may impact on cell productivity. According to Ley et al., (2015), 
production bottleneck is often reported to be independent of the heterologous target protein, 
indicating a general limitation of the secretory protein processing capacity, while in some cases 
secretory bottlenecks are linked to the synthesis of a specific post-translational protein modification. 
Previous reports have suggested that, when cells are not growing nor dividing they can concentrate 
cellular energy on protein synthesis (Anisimova et al., 2018). While high abundance of 
transmembrane proteins in the ER can induce extensive membrane growth, low expression does not 
alter ER morphology (Herrmann & Zwerger, 2010). Consequently, the aim of this study was to 
investigate the influence of reprogramming lipid synthesis on CHO-S cells’ recombinant protein 
productivity.  
 
Using western blot techniques, YFP-DHCR7 protein was confirmed to be stably expressed in CHO-S In 
order to obtain quantitative data for EPO and etanercept from western blots, we carried out 
densitometry. Densitometry is the quantitative measurement of optical density in light-sensitive 
materials, such as photographic films and as a first choice, it is considered the gold standard (Gallo-
Oller et al., 2018). When EPO was transiently transfected and assayed in clones (3, 4, 6 and 7) of YFP-
DHCR7 engineered cells in relation to pcDNA3.1Hygro control cell line, it was observed that the clonal 
cells proliferated by up to 0.5 fold over pcDNA3.1Hygro expressing cells when over an 8-day 
experimental period (Figure 5.7). This suggests that there perhaps was an improvement in the 
secretory vesicle system of the engineered cells allowing for some modulations of the cellular circuits 
which in turn results in a better maintained lipid homeostasis. Armstrong et al., (2017) had reported, 
on how cell engineering techniques such as genetic modification, metabolic labelling, and exogenous 
delivery have been used to change the surface expression and cargo of extracellular vesicles as the 
secretion of proteins from eukaryotic cells requires the coordinated function of multiple organelles 
and cellular machineries (Hua & Graham, 2013).                                                                                       
Despite the quantifiable difference observed when protein bands were quantified using 
densitometry, it was observed that statistically, the correlation was not significant at a probability 
less than 0.05 (p˂0.05),  in the levels of EPO observed in YFP-DHCR7 engineered CHO-S in relation to 
control. Several other assays which are applicable for the quantification of EPO and etanercept but 
not used in this study include the measurement of Ultraviolet (UV) absorbance at 280 nm, 





For confirmation studies of the localisation of YFP-DHCR7 to the ER, the calnexin an ER resident 
protein was probed for co-localisation of calnexin and DHCR7 to the ER. This may present a promising 
approach in identifying the role of DHCR7 which catalysis the final step in sterol biosynthesis. Our 
data showed that both DHCR7 and calnexin co-localise and therefore informs the subcellular 
localisation of DHCR7.Many of the analysis have allowed the identification of the implications of over-
expression DHCR7 in CHO-S cells while analysing the biochemical implications of what might be 
occurring to cell at molecular level with reference to cell’s phenotypic and biochemical function.  
 
DHCR7 is a transmembrane protein involved in cholesterol biosynthesis. Regulation of DHCR7 at the 
transcriptional level by the sterol regulatory element-binding protein-2 (SREBP-2) transcription factor 
is widely reported (Prabhu et al., 2014). By manipulating cellular processes of cholesterol 
biosynthesis, there might be a feedback on SREBP-2 which functions in a cascade mechanism to 
preferentially activate DHCR7 and some other sterol reductases. In examining the possible 
implications of causing an expansion of CHO-S ER membrane capacity by overexpression of YFP-
DHCR7 and the feedback effect on cell proliferation and product yield, expression of EPO and 
etanercept by transient transfection of lipid engineered cells with control channels showed variations 
in expression levels of these bio molecules with expression levels higher when compared to 
pcDNA3.1Hygro.  
 
Knowing that there is an accumulating evidence which suggests that cancer cells show alterations in 
different aspects of lipid metabolism. The potential dependence of cancer cells on the deregulated 
lipid metabolism also suggests that enzymes and regulating factors involved in this process are 
promising targets for cancer treatment (Cha & Lee, 2017). The molecular implications of these are 
the changes proffered on cellular processes such as cell growth, proliferation, differentiation, and 
survival by changes to lipid bioprocesses. However some questions are yet unanswered. If 
deregulated lopid biosynthesis is known to trigger alterations that may cause cancer cells to 
proliferate, would the overexpression of DHCR7 be impacting on lipids levels and cholesterol 
amounts? Could the reprogramming of cholesterol biosynthesis alter the chemical conformation of 
lipids at molecular level, thereby affecting their functional roles?  We have not looked into this yet. 








Here, an overall discussion of the results from studies described in the previous result chapters are 
detailed. 
 
6.1  TM7S72 and DHCR7 are potential lipid biosynthesis targets for ER expansion in CHO-S cells  
Over the last years, the biopharmaceutical industry has significantly turned its biologics production 
towards mammalian cell expression systems as recent advances in omics technologies have allowed 
for new possibilities which will improve these expression platforms, including developing new 
strategies, in particular for Chinese Hamster Ovary (CHO) cells (Lalonde & Durocher, 2017).  
Therefore, recent advances in systems biology and data-driven approaches aim to unravel how 
molecular pathways, cellular processes and extrinsic factors influence recombinant protein 
production (Kuo et al., 2018).  
 
Although O’Callaghan & James (2008) had reported that improvement of productivity in mammalian 
cell production systems have been achieved despite a dearth of specific knowledge of how 
engineered cells successfully function in vitro, the metabolic burden imposed by heterologous 
protein production in mammalian cells is still not well characterized and thus may offer opportunities 
for further improvement of protein productivity (Ley et al., 2015). In the production and synthesis of 
proteins, the endoplasmic reticulum (ER) remains the central organelle where proteins traffic 
through the secretory pathway. As protein secretion is not only essential for cellular function but also 
provides the driving force for cell growth via delivery of newly synthesized lipid and protein that 
permit cell expansion (Barlowe & Miller, 2013), it is therefore critical to determine how the 
engineering of the CHO lipid biosynthesis machinery may improve productivity.  
 
The work presented in this project has exploited the functional roles of Transmembrane 7 
Superfamily member 2 (TM7SF2) and 7-dehydrocholesterol reductase (DHCR7) sterol reductases of 
the cholesterol biosynthesis pathway by over-expression of their capacities for recombinant protein 




drawn from the publication by   Zwerger et al., 2010 who had reported on a novel, as yet undescribed 
cellular phenotype observed in the endoplasmic reticulum (ER) lumen and the perinuclear space 
(PNS) with large dilations throughout the entire cell and specifically at the nuclear periphery when 
TM7SF2 and DHCR7 were over-expressed. Samples used in this work were obtained from their group 
as our findings sought to corroborate their work. 
 
Literature studies have reported on the crucial role of TM7SF2 and DHCR7 in cholesterol biosynthesis. 
Bellezza et al., (2013) reported that TM7SF2 functions in cellular response to stressful conditions. 
While Bellezza et al., (2015) demonstrated that the loss of Tm7sf2 alters the expression of proteins 
involved in epidermal differentiation by reducing the levels of cholesterol sulfate and accelerating 
skin papilloma formation, Herrmann & Zwerger (2010), had reported that the very same step in 
cholesterol synthesis that is catalysed by LBR can also be catalysed by a closely related sterol 
reductase, TM7SF2. For instance,  Bennati et al., (2008) reported, that TM7SF2 knockout mice (which 
should not have active 3ß-hydroxysterol ∆14-reductase) continued to show a 3ß-hydroxysterol ∆14-
reductase activity required for cholesterol biosynthesis in the presence of Lamin B receptor (LBR), 
which although resides in the nuclear membranes, may be contributing to cholesterol biosynthesis 
in Tm7sf2(-/-) mice. Another study investigated the long-term effects of altered TM6SF2, a variant of 
TM7SF2 levels in cholesterol metabolism (Fan et al., 2016).  
 
While, several functional proteins involved in the various posttranslational steps of the secretory 
pathway and of exocytosis have been studied where some of these pathways were successfully 
engineered to remove bottlenecks and cellular limitations caused by recombinant protein overflow 
(Mariati et al., 2010), we have identified  TM7SF2 and DHCR7 sterol reductases as potential 
engineering targets of the CHO secretory machinery and have exploited these sterol reductases while 








6.2 Stable Overexpression of TM7SF2 and DHCR7 in CHO-S shows beneficial phenotypes over 
control CHO-S cells 
The propensity as to whether or not over-expression of resident proteins can influence productivity 
have been a major focus in the recent years. In some cases, protein secretion have been significantly 
increased such as by manipulation of BiP chaperones  (Payne et al., 2008), Xbp1, a transcription factor 
that regulates secretory cell differentiation, ER maintenance and expansion, to decrease ER stress 
and increase protein processing and secretion (Mohan & Lee, 2010) . Stable cell lines over-expressing 
TM7SF2 and DHCR7 were therefore generated for the characterization of stably over-expressing 
hygromycin-resistant CHO-S cells. To investigate whether the genetically engineered cells could 
impact beneficial phenotypic properties on CHO-S for improved productivity, two different controls 
to monitor expression levels of lipid engineered cells. With no insert cloned, the empty vector was 
stably inserted as a negative control. Qualitative analysis of growth profiles showed that as culture 
viability was on the increase when compared with stably generated controls expressing GFP and 
pcDNA3.1Hygro vectors (Figure 3.18), the rate of growth of CHO-S cells over-expressing DHCR7 and 
TM7SF2 was significantly higher than control CHO-S expressing GFP and pcDNA3.1Hygro cells (Figure 
3.20).  
 
When CHO-S cells were analysed with stable TM7SF2 over- expression, there was a higher secretory 
EPO amount as analysed by western blot (Figure 4.7) (Figure 5.5). This initial indication was a pointer 
to the fact that the presence of over-expressing TM7SF2 protein was impacting upon the secretory 
processes of CHO-S but there was no detailed indication as to whether the ER size was influenced. 
Meanwhile, two pools of cells were generated for both TM7SF2 and DHCR7. Although these parental 
pools (A and B) showed higher growth rate and robust viability compared to the CHO-S host, there 
remained a peculiarity in their growth pattern. For instance, TM7SF2 Pool B maintained an increased 
and robust growth rate over TM7SF2 Pool A and there was consistency in their proliferation. For 
DHCR7 parental pools, DHCR7 Pool A showed a consistently better growth rate than DHCR7 Pool B. 
Other techniques such as western blotting, fluorescence microscopy were also used for the 
characterisation of cells which confirmed variance in expression signals of distinct pools.  
 
The growth rate analysis was carried out to monitor expression levels in cells and data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
obtained from fluorescence microscopy suggested that not all cells were actively over-expressing 




averaged data about the population, by which important information about a small but potentially 
relevant subpopulation is possibly lost in the background (Gross et al., 2015)For example, stable cell 
lines that constitutively expressed SERT grew very slowly and only about 25% of the cells actually 
expressed the transporter, which precluded large scale culture (Andréll & Tate, 2013). This resulted 
in an approach to isolate some of the high expressers as against the low expressers by using a limiting 
dilution cloning approach. The focus of the study remained on the high expressers of lipid-engineered 
CHO-S cells following selective measures by diluting cloning. For relative impact of engineered CHO-
S over-expressing DHCR7 and TM7SF2 on the secretory capacity of ER to be investigated, it was 
imperative to identify the possibly high producing cells for further studies.  
 
6.3 Stable Integration and Overexpression of GFP and pcDNA3.1Hygro as control for 
investigation into TM7SF2 and DHCR7 engineered cells. 
Two DNA integration systems were cloned and stably generated in CHO cells to enable the 
monitoring and quantification analysis of expression levels in TM7SF2 AND DHCR7 engineered cell 
lines. The choice to use GFP as a control was to ensure that the process of generating stably 
expressing cell lines and the presence of a protein load was in the control CHO-S pools and could be 
related to the observations when the YFP-tagged proteins were overexpressed (Figure 3.8). GFP is a 
quantitative reporter of gene expression (Soboleski et al., 2005) and has been shown to have no toxic 
effects on cells Chalfie et al., 2008) as it is devoid of cellular function. Also, as a widely used reporter, 
GFP is not known to show any high-affinity with other proteins hence would not influence the 
phenotypic characteristics of cells. pcDNA3.1Hygro expression vector with empty backbone stably 
transfected in cells generated blank pools upon analysis by western blotting and was used in this 









6.4         TM7SF2 and DHCR7 show characteristic clonal variation in stable CHO-S cells 
 
Having observed beneficial phenotypes attributed to both TM7SF2 and DHCR7 overexpression in 
CHO-S cells, it was confirmed that there was a high degree of heterogeneity within cultures, leading 
to the identification of different parental pools for both TM7SF2 and DHCR7, referred to as A and B 
(Figure 3.16). Phenotypic heterogeneity is observed not only between CHO host cell lines but also 
within the cell population of CHO host lines. In fact, CHO cells are known for being able to adapt to 
changes in process conditions, which has been exploited in the industry to generate clonally derived 
cell lines with enhanced manufacturing capabilities (Frye et al., 2016). Some of the factors when 
considering stable cell lines include those that showed tendencies for high growth rate, slow death 
rate and also high specific cell productivity (Qp).  
 
Further, more investigations into the presence of heterogeneity in cells were observed during growth 
profiling of cells where cells showed variation in growth rate. When microscopic analysis was done, 
cells were observed to show different levels of YFP expression suggesting the variations in the 
expression level of cells of the population (Figure 3.17). The desire to investigate clones with a high 
specific productivity rate was necessary as the heterogeneity of CHO cells confers individual clones 
with different copy numbers, integration sites resulting in varying specific productivities. By 
comparing clones for their highest growth and productivity rate, the best clones were isolated. 
 
Clone-specific variations at the functional genetic level have been extensively described. In one study, 
high and low producer CHO-mAb sub-clones were observed to differ mainly in their DNA fragment 
sizes where high numbers of differentially expressed genes were identified (Ghorbaniaghdam et al., 
2014). In another study, clonal variations in response to culture condition variation was reported 
(Datta et al., 2013). Peculiarity of clonal cells is relative to their specific productivity, strong variations 
in cell density, nutrient uptake and metabolic generation patterns. Clones generated from TM7SF2 
Pool B following limiting dilution cloning methods were analysed by western blotting techniques for 
investigating expression levels of the various CHO-S clonal cells.  
 
In addressing the heterogeneity in clonal behaviour, a crucial factor is due to the genetic instability 
that occurs during integration of copy number variant and vector-integration transformants during 




ultimate propensity was for these clonal cells to reach higher growth densities and have longer 
viability in culture while still maintaining cellular homeostasis.  Phenotypes of such, are actively being 
sought for bioprocessing engineering in order to increase batch productivity and yield, (Dorai et al. 
2010). 
 
6.5   Localisation of the YFP-tagged TM7SF2 and DHCR7 proteins 
All constructs used in this study were designed as detailed in the Zwerger et al., (2010) published 
paper. The YFP fusion proteins they express, following the N- to C-terminal order of the expressed 
entities had been cloned into the constructs. Target genes were subsequently cloned into different 
expression vectors which were expressed in CHO-S cells for this study. When a YFP fusion protein of 
TM7SF2/DHCR7 is expressed in mammalian cells, it is efficiently targeted to the ER membrane. 
Leader sequences are very important for guiding protein along the secretory pathway. However 
there was no ER leader sequence cloned into these constructs as published. Their approach was to 
characterize the structural consequences on both the nuclear and the cytoplasmic side of the NAV of 
U2OS cells overexpressing YFP-TM7SF2 and YFP-DHCR7, where they monitored the distance between 
the INM and ONM segregates.  
 
We took a different approach as the focus was the functional implications an expansive CHO-S ER 
membrane secretory capacity might have on recombinant protein production. We monitored the ER 
by staining calnexin for localization studies (Figure 4.4) (Figure 5.9) where expression levels were 
monitored. In order to effectively monitor changes leading to ER expansion by the over-expression 
of TM7SF2 and DHCR7 for productivity however, the need to monitor ER by other approaches, such 
as using ER tracker dye may be necessary as we did not design new ER leader sequences compatible 
with the new cassette system which was important (as discussed in section 4.3).  
 
Several studies however, have shown that sequence variation among signal sequences can affect the 
efficiency of protein targeting, translocation, and signal sequence cleavage (Randhawa et al., 2004). 
With reference to the paper published by Zwerger et al., (2010), they had reported that the N-
terminal domains of both TM7SF2 and DHCR7, which they compared to LBR, did not interfere with 
the C-terminal domain and upon over-expression, induced prominent nuclear compaction and 




investigated using confocal microscopy approach where we monitored YFP signals (Figure 3.17), it is 
observed that cells showed nuclear compaction but whether expression was in the peri nuclear space 
was not confirmed.  
 
6.6 Transient expression of YFP-TM7SF2 and YFP-DHCR7 in CHO-S cells   
Transient recombinant protein production is a promising alternative to stable systems, particularly 
for emergency situations in which rapid production of novel therapeutics is needed (Sukenik et al., 
2018) An initial investigation to confirm the presence of TM7SF2 and DHCR7 where YFP reporter gene 
tagged to the N terminal of TM7SF2 and DHCR7 was monitored using fluorescence microscopy 
techniques (Figure 3.13). A brief study was also undertaken on mCherry-tagged LBR although this 
was later dropped to allow focus on TM7SF2 and DHCR7. Findings from the transient transfection 
studies showed some cells expressed the YFP signal for TM7SF2 and DHCR7 while mCherry was also 
expressed in LBR as red. The viability of CHO-S cells, which had been confirmed to be above 95%, 
prior to the experimental study, however declined following transfection procedure, with only about 
50% of cells successfully transfected.  
 
As it is a promising alternative to stable transgenic systems, particularly for emergency situations in 
which rapid production of novel therapeutics is needed (Sukenik et al., 2018)transient expression of 
five YFP-LBR mutants in human U2OS cells showed that they localize to the nuclear rim and also 
formed aggregates in the cytoplasm, similar to those seen in cells expressing YFP-LBR wild-type and 
they do not alter nuclear morphology Zwerger et al., (2010). When transient over-expression studies 
of these protein were carried out along with wild-type untransfected CHO cells (without TM7SF2 and 
DHCR7 DNA plasmids), wild-type untransfected CHO-S cells did not show any expression signals, 
whereas TM7SF2 and DHCR7 showed increased expression levels over the time course suggestive of 
the continued translation activities between day 2 and day 3 as expression on day 3 also doubled 
expression on day 2 post transfection  as confirmed by western blotting (Figure 3.9).  DHCR7 was also 
studied on day 2 and day 3 post transfection and similar expression level was observed (Figure 3.10) 






6.7      Effect of TM7SF2 and DHCR7 overexpression on recombinant protein productivity 
The essence of this research was to investigate the relationship between engineered overexpressing 
TM7SF2 and DHCR7 and specific recombinant protein productivity.  Literature has it well 
documented, that the production of proteins in appropriate quantity and quality is an essential 
requirement of the present time as there now appears to be a progressive increase in the application 
of mammalian cells for proteins production as seen in a review by Hayat Khan, (2013). Mammalian 
cells are currently the main hosts for commercial production of therapeutic proteins, including 
monoclonal antibodies (mAbs) (Lee et al., 2009) after it was first used to produce active antibodies 
in 1987.  
 
Quite a number of strategies have been used to engineer mammalian cells for improved quantity and 
quality of therapeutics such as chaperone engineering (Jossē et al., 2012), unfolded protein response 
(UPR)-based engineering (Chien et al., 2014) and secretion engineering (Peng et al., 2010). There has 
been significant progress in developing and engineering new cell lines, introducing novel genetic 
mechanisms in expression, gene silencing, and gene targeting have been achieved through optimal 
expression system for productivity, bioactivity, purpose, and physicochemical characteristics of the 
interest protein while taking into consideration the cost, convenience and safety of the system itself 
Hayat Khan,( 2013).  
 
The productivity of EPO and etanercept following the over-expression of genes have been 
investigated before using other targets (e.g. not DHCR7 or TM7SF2), albeit with mixed results (Pybus 
et al., 2014) reported no effects of XBP1s over-expression on EPO productivity in stable cell lines but 
significantly enhanced transient production in EPO-saturated CHO cells. Pybus et al., (2014) showed 
that the effects of xbp1s overexpression were more pronounced on CHO cells expressing ‘difficult-
to-express’ recombinant proteins with limiting folding and assembly reactions, than cells expressing 
an ‘easy-to-express’ recombinant proteins.  
 
Bioprocess engineering often focuses on growth/proliferation strategies to improve productivity 
(Kumar & Starly, 2015). Alternatively, yields can be improved by targeting specific pathways, 
examples of targeting pathways/genes via miRNAs is becoming more prevalent (Fischer et al., 2013) 
in order to increase CHO cell specific productivity. Overexpression of myc in CHO cells have been 




productivity (Kuystermans & Al-Rubeai, 2009).  
 
Engineered CHO cells overexpressing XBP1s have enabled a significant enhancement in protein 
productivity due to an improvement of the secretory capacity of cells, although, there were not any 
improvement of recombinant protein production. Here, we target lipid biosynthesis pathway where 
a cascade of regulatory genes interplay which regulate the TM7SF2 and DHCR7 signal levels are 
functional. Another reason for the increased recombinant EPO and etanercept transient expression 
may depend on high transcription levels of the genes of interest.  It must be noted however, that 
depending on the cell type being used for overexpression, expression levels may vary. Additionally, 
productivity can easily be improved by increasing the gene copy number of the gene of interest 
independent of the promoter system used (Vassileva et al., 2001). 
 
Sometimes, there may be a decline in productivity upon increasing the copy number and this might 
be a limitation in protein folding and secretion (Hohenblum et al., 2004).   We monitored the culture 
behaviour shown by the TM7SF2 and DHCR7 overexpressing clones transiently expressing EPO and 
etanercept during this project where we compared data to stable GFP and pcDNA3.1hygro controls, 
although only over a period of 3 days (Figure 4.7). Our findings showed improved growth pattern for 
lipid engineered cells transiently transfected with EPO and etanercept ultimately translating into 
improved yield of both types of recombinant protein products in stable producer lines.  
 
As the greatest increase in recombinant protein productivity was seen in cells overexpressing TM7SF2 
pool B and DHCR7 pool A as well as the high producer clones, it is imperative to establish an overall 
consequences of TM7SF2 and DHCR7 overexpression on the phenotype of the cell with reference to 
cell productivity. Our analysis of extracellular protein expression of EPO and etanercept showed a 
direct positive impact of recombinant protein levels (Figure 4.7) (Figure 5.6) with increased TM7SF2 
and DHCR7 overexpression levels of engineered cells.  
 
However, conclusions drawn from the findings would require further work as there were no loading 
controls to ascertain equal loading of sample materials of GFP and pcDNA3.1Hygro as well as YFP-
TM7S2 pools and YFP-DHCT7A pool investigated in this study. Subject to further work, it is safe to 




of lipid engineered CHO-S was investigated with control cells using western blots technique, following 
the equal amount of samples loaded, resulting in the direct positive impact, here reported. 
 
6.8      Quantification of recombinant proteins for relevance to commercial value 
Sensitive analytical methods for the quantification of protein concentration in solution are important 
in biological laboratories (You et al., 1997). However, the available methods have limitations in many 
respects, such as sensitivity, protein-to-protein variability and dynamic range (Pihlasalo, 2011). When 
EPO and etanercept secretory amounts were expressed, the hypothesis that the engineering of the 
CHO-S secretory machinery would result in the enhancement recombinant protein production, 
would not have been ascertained without a means to accurately quantify how much of these 
products were secreted in the lipid engineered cells , in relation to control. Absolute values of protein 
expression levels in cells are crucial information for understanding cellular biological systems (Narumi 
et al., 2016). Generally, for the purpose of analysis, western blotting was used to assay for proteins.  
 
When transient transfection was carried out over a 2 day period, YFP-TM7SF2 (Figure 3.9) and YFP-
DHCR7 (Figure 3.10) were probed with GFP control and the predicted molecular weights investigated 
on western blots. For stably expressing cells, western blots were used to investigate whether the 
genes of interest had been successfully integrated into the chromosome of CHO-S cells (Figure 3.16). 
However this methodology is not without its limitations such as error during loading and poor 
migration of proteins. Densitometry data generated for western blots are commonly used to 
compare protein abundance between samples ((Butler et al., 2019).  
 
We have quantified EPO and etanercept expression level using Densitometry, Data generated on 
densitometry analysis were obtained from western blots. For instance, densitometry data of Figure 
3.12 had analysed the western blots obtained in Figure 3.10 for the quantification of YFP-TM7SF2 
lysates as well as GFP transiently produced on different days, post transfection (day 1, day 2 and day 
3). While western blots confirmed the presence and sizes of these proteins, it was not certain how 
much of these endogenously secreting proteins was recovered each day. However by densitometry 
analysis, the number of folds per expression could be determined. For YFP-TM7SF2 assay, western 
blots of Figures 4.5, 4.7 and 4.10 were analysed using densitometry in Figures 4.6, 4.9 and 4.11 




were quantified in Figures 5.4 and 5.7 respectively. Bennati et al., (2006) by densitometry analysis of 
lipids separated by TLC, quantified cholesterol in plasma and liver microsomal membranes. Prabhu 
et al., (2016) quantified the effects of various sterols on DHCR7 protein stability using densitometry. 
 
Zwerger et al., (2010) had quantified protein concentrations of the lysates using the method of 
Bradford (Bradford, 1976) using the Bio-Rad Protein Assay (Bio-Rad #500-0006) and bovine serum 
albumin (BSA) as a standard, a method also used in this work. Lysates expressed on western blots 
were first analysed for respective concentration and calculations for equal loading up to 20 µg across 
each well was done. Several studies have used Bradford as a means to quantifying the concentration 
of proteins. Kim et al., (2004) quantified proteins (Carbamoyl Phosphate Synthetase I and Ornithine 
Transcarbamylase) using a Coomassie brilliant blue binding assay according to Bradford while EPO 
was measured by an ELISA for the enhancement of Erythropoietin Production from CHO Cells using 
Urea Cycle Enzymes, Carbamoyl Phosphate Synthetase I and Ornithine Transcarbamylase. 
 
Several other methods have been used to quantify proteins. These include the ultraviolet 
absorbance methods which are based on the absorption of ultraviolet (UV) light by proteins in 
solution. With a peak of approximately 280 nm, resulting from the amino acids phenylalanine, 
tryptophan, histidine, tyrosine, cysteine, and cysteine-containing aromatic rings, and at 
approximately 200 nm, primarily from peptide bonds and secondarily from tryptophan and tyrosine 
(Albani, 2004).  
 
Analysis using Enzyme-linked immunosorbent assay (ELISA) is also very useful for scaling Proteins. 
This method is based on the concept of antigen–antibody reactions, representing the chemical 
interaction between antibodies produced by the B cells of leukocytes and antigens. Hence, by 
exploiting this reaction, ELISA permits the highly sensitive and selective quantitative/qualitative 
analysis of antigens, including proteins, peptides, nucleic acids, hormones, herbicides, and plant 
secondary metabolites (Sakamoto et al., 2018). The Biuret method is known to be the oldest 
method for the quantification of proteins and is still commercially available. It involves only one 
reagent addition and a single incubation of 20 min. The divalent copper ion in the reagent forms a 
complex with the amide groups of the protein and is reduced to a monovalent ion under alkaline 
conditions. The purple complex formed absorbs at 550 nm and the absorbance is directly 




6.9      Content Analysis in relation to Zwerger et al., (2010) reference paper 
The present study reviews our findings as against the findings of the publication that informed this 
work. Although many of the assays and methodologies differ as well as certain findings, a common 
ground lie in the influence generated when TM7SF2, DHCR7 and LBR were over-expressed. Zwerger 
et al (2010) extensively reported on LBR and introduced the relationship of LBR with the two sterol 
reductase (TM7SF2 and DHCR7); its C-terminal domain being 58% identical to TM7SF2 and 37% 
identical to DHCR7. It is important to note, that Zwerger et al., (2010) investigated their work using 
several human cell lines, such as skin (A431), ovary (HeLa), breast (MCF7), liver (PLC), bone (U2OS), 
and brain (T98G), except CHO-S - the platform for this work.  
 
When Zwerger et al., (2010) investigated the nuclear compaction and vacuolization observed in 
U2OS cells, both intact YFP-TM7SF2/YFP-DHCR7 and C-terminally truncated TM7SF2/DHCR7 were 
transfected and over-expressed in U2OS cells. They observed that, not only did the C-terminally 
truncated TM7SF2/DHCR7 induce comparable effects, similar to the LBR truncations already 
observed, but even the wild type YFP-TM7SF2/YFP-DHCR7 caused a compaction of the U2OS cells 
nuclei as well as dilation of the Perinuclear space and even the endoplasmic lumen. We have over-
expressed the wild type YFP-TM7SF2/YFP-DHCR7 (samples kindly provided by Monika Zwerger) in 
CHO-S and have observed that the YFP reporter signal of these sterol reductases was traced to the 
portion around the nuclei of CHO-S believed to be the ER lumen. Further assay to confirm whether 
expression observed was from the ER, was done by co-expressing YFP-TM7SF2 and YFP-DHCR7 with 
calnexin a molecular chaperone in the ER lumen to investigate co-localization.  
 
Data from this work corroborates the findings, by the Zwerger et al., (2010) on the localisation of 
these sterol reductases and where the influence was going on (Figure 5.9). However, whether the 
influence on the ER led to some vacuolization was not confirmed in this work. However, with the 
generation of clones having observed variation in expression levels of the YFP-tagged sterol 
reductases, we generated nine clones (in total) between the two sterol reductases, considered to 
be high expresser in CHO-S cells (Figure 4.2) (Figure 5.2), a different approach to the Zwerger et al 





While Zwerger et al., (2010) reported a comparable phenotype upon overexpression in the related 
sterol reductases, we have reported a comparable phenotype among clones over-expressing YFP-
TM7SF2 and YFP-DHCR7 which might not be unconnected to their functional role at the molecular 
level. For instance, when we observed that TM7SF2 clone 7 showed a similar phenotype to TM7SF2 
clone 11. We have also observed how TM7SF2 clone 3 presents a layered cellular formation similar 
to TM7SF2 clone 10 (Figure 4.3). The implications of these phenotypic conformations would need 
to be further investigated, going toward. 
 
Zwerger et al., (2010) extensively reported on Lamin B receptor (LBR) protein. We have only briefly 
investigated this protein. However LBR has been reported as a dual function protein with functional 
activities occurring both in the Nucleus and also in the cytoplasm (ER Lumen). When Zwerger et al., 
(2010) investigated the impact of LBR mutant variants on the integrity of the lumenal compartment, 
they had hypothesized, as published, an effect on this compartment consisting of the ER and the 
Perinuclear space (PNS) mainly due to the relation of TM7SF2 and DHCR7, which had induced a 
comparable phenotype according to their submission.  
 
Their findings however reveal a correlation with the loss of nuclear size and an increase in nucleus-
associated vacuole NAV volume. When we studied the localisation of LBR, we monitored the 
mCherry-tagged protein (kindly supplied by Monika Zwerger) using transient fluorescent microscopy 
techniques. 24 h after transfection, the CHO-S cells were fixed with paraformaldehyde and analysed. 
With control cells having DAPI, the nuclei were marked and cells expressed mCherry signal, in a region 
around the nuclei suggesting the presence of LBR in the Perinuclear space (PNS) where it is believed 
to localise to the ER lumen. The carboxy-terminal domain has enzymatic activity, that is, it is a sterol 
reductase acting at a distinct step of the cholesterol biosynthesis pathway (Herrmann & Zwerger, 
2010). Subramanian et al.,(2012) had reported that Lamin B receptor (LBR) is a bifunctional nuclear 
membrane protein with N-terminal lamin B and chromatin-binding domains plus a C-terminal sterol 
D14 reductase domain, hence its exhibition of 3β-hydroxysterol Δ14-reductase activity (Bennati et 
al., 2006). While the focus on this work was on TM7SF2 and DHCR7, the molecular implications of 
the over-expression of these sterol reductases may as well be influencing the C-terminal enzymatic 






An important aspect to this work was to gain an understanding of the impact, as to whether positive 
or negative, induced on the mammalian cell lines as a result of the phenotypic characteristics 
observed when mCherry-LBR, YFP-TM7SF2 and YFP-DHCR7 was over-expressed. Again, Zwerger et 
al., (2010) investigated whether the nuclear compaction, NAV and CV formation observed were not 
due to ER stress, a condition known to trigger the unfolded protein response (UPR) to maintain ER 
homeostasis. Analysis of xbp1 mRNA has a stress marker and an autophagy marker protein to probe 
the impact of LBR and the sterol reductases on U2OS cells led to the conclusion that the increased 
vacuolisation observed do not interfere with cellular processes as autophagy pathway was not 
present as observed. We have also looked at the influence of over-expression on CHO-S cells. The 
generation of the stable cell lines over-expressing these sterol reductases in pcDNA3.1Hygro allowed 
for the generating on an empty cassette vector (pcDNA3.1Hygro) as a negative control channel.  
 
Unlike Zwerger et al., (2010), a GFP control was also generated as control. GFP and YFP only differ in 
a few amino acids and the plasmid was readily available for use. A growth profile assay carried out 
on culture for a 10 day period showed a sustained growth pattern for the engineered cells as 
compared to controls (Figure 3.20). When cells where further investigated, we confirmed that there 
was indeed an heterogeneous population and not all cells were over-expressing YFP-TM7SF2 and 
YFP-DHCR7 using flow cytometry and western blots (Figure 3.19) (Figure 4.1) profiling of the growth 
behaviour of clones agreed with submissions of Zwerger et al., (2010) as there were no tendencies 
for apoptosis and engineered cells were clearly not undergoing autophagy. Despite these findings, 
the statistical inference drawn at a probability less than 0.05 (p˂0.05) showed there was no 
significant difference in growth pattern.  
 
On the molecular implications of these findings, Zwerger et al., (2010) discussed that while they had 
observed a remarkable membrane extension, which did not activate ER stress, nor resulted in 
autophagy nor apoptosis, the molecular mechanism involved remained elusive. To understand what 
might be going on at the molecular level, we looked that  a novel approach to attempt to influence 
cholesterol biosynthesis, a pathway that takes place in the ER lumen. While Zwerger et al., (2010) did 
exclude the possibility that minor changes in cholesterol concentration of ER and NE membranes or 
the presence of low amounts of intermediate sterol, the bulk of the activities is vested upon the 
capacity of the ER lumen to synthesize proteins. Cholesterol regulates HMG-CoA reductase activity 




called separator of regulatory element-binding proteins (SREBP) and when intracellular cholesterol 
levels are high, SREBP are inactive; if cholesterol decreases, the N-terminal domain of SREBP is 
cleaved by hydrolysis. In future, it assays to quantify cholesterol and lipid amounts will be beneficial 
if the molecular implications of the influence and positive phenotypic impact of overexpressing LBR, 
TM7SF2 and DHCR7 is to be unravelled.  
 
 
6.10       Overexpression Engineering strategies in some other cell expression system 
In December 1983, a seminal paper appeared on the overexpression of human IFN-b in insect cells 
with a genetically engineered baculovirus (Oers et al., 2015). Overexpression first gained prominence 
as a screening tool in the molecular genetics era shortly after the development of yeast 
transformation techniques and the construction of genomic libraries in vectors derived from the 
endogenous 2 µ plasmid, which are maintained at 10 – 30 copies per cell (Prelich, 2012). Since its 
inception, several studies have continue to manipulate this molecular technique for therapeutic 
purposes. For instance, Zeng et al., (2014) observed the overexpression of Bmal1 gene inhibited 
colorectal cancer cell proliferation and increased colorectal cancer sensitivity to oxaliplatin in three 
colorectal cancer cell lines and HCT116 cells model in vivo. Lee et al., (2009) showed that the 
overexpression of Heat Shock Proteins (HSP27 and HSP70), either individually or in combination, can 
delay the onset of apoptosis in CHO cell cultures and thus extend culture lifespan and improve 
recombinant protein production in fed-batch cultures. By overexpressing engineering, (Wilkens & 
Gerdtzen, 2015) showed that PYC2 in CHO cells were able to improve their exponential growth rate 
and cells transfected with the fructose transporter gene were able to increase cell density and reach 
the same volumetric protein production as parental CHO cells in glucose, to state but a few. However, 
lessons learned from overexpression studies have several implications for human health, either 
positive or negative, impacting our understanding of the causes and treatment of diseases, as there 
are numerous human diseases directly caused by increased gene expression (Prelich, 2012).Till date, 








6.11        Impact of overexpression of YFP-TM7SF2 and YFP-DHCR7 sterol reductases on the 
manufacturing processes and the downstream processing 
When commercial scale biopharmaceutical manufacturing began in the middle of the 1980’s, the 
average titre started out at 0.5 g/l (McAuliffe, 2018). As at 2015, however the average reported 
titre was averaging at greater than 3g/l, with top end values reaching 7 & 10g/l, while average yields 
being reported at 70% (Rader & Langer, 2015). A typical bioprocess is split into two sections, 
upstream processing where the cell line is grown and the product synthesised and downstream 
processing where the cell mass and other contaminants are removed and the product is captured 
in a pure form (Mclachlan, 2017).  
 
The upstream process is due to advances in culture media and its optimisation, in expression 
systems, genetic engineering and in cell line development as advances in process development have 
come in the genetic engineering and modification of cell lines, rather than the equipment 
(McAuliffe, 2018). Hence, there has been a significant progress in the optimisation of upstream 
processing  in the last two decades and this is largely because Upstream titres depend mostly on 
biological limits (for example, cell line or media optimisation) and can be raised without an increase 
in costs whereas downstream capacity always scales at least linearly with costs due to its physical 
principles for separation (Gronemeyer et al., 2014). It is expected, that the genetic engineering of 
CHO-S secretory machinery by overexpression of sterol reductases (TM7SF2 and DHCR7) ordinarily 
will reduce the cost on downstream purification which should be beneficial for production 
processes.  
 
This may explain why the biopharmaceutical industry continues to change rapidly as the production 
portfolio steadily expands for new biologically active molecules resulting in the need for fast and 
reliable process development and optimisation tools (Baumann & Hubbuch, 2017). In addressing 
the need for a scale up for commercial manufacturing, there is a need to look into omics-based 
approaches, such as transcriptomics, proteomics and metabolomics, which have been used in the 
whole process of developing recombinant CHO cell-based production in both upstream and 
downstream processes (Kim et al., 2012) and these range from clone selection, cell engineering, 
culture media and culture environments in the upstream process, to protein purification and 




Without doubt, demands for high quality biologics will continue to increase in the coming decades 
whereby, the boundary conditions will change substantially with regards to the amounts to be 
produced such that the number of products will increase (Gronemeyer et al., 2014). One area of 
interest in biopharmaceutical manufacturing is the invention of new designs for downstream 
processes, namely, the protein separations. Such a development, if successful, would be a major shift 
in the way that biopharmaceuticals are manufactured (Hong et al., 2018) and as the downstream is 
an integral part of the entire production process and is influenced by many factors, downstream 
equipment which at present, has been designed with the intent of lower cell titres of the previously 
mentioned 0.5 to 3 g/l range, resulting in this equipment reaching is physical limits (McAuliffe, 2018), 
would need to be reviewed.  
 
Meanwhile, as recombinant therapeutic proteins are usually produced by genetically-engineered 
prokaryotic or eukaryotic host cells using fermentation/cell culture technology (Li, 2017), the genetic 
engineering of YFP-TM7SF2 and YFP-DHCR7 sterol reductases in CHO-S cells for the production of 
recombinant therapeutic proteins, for instance, would require a more robust downstream processes 
in order to meet the increased challenges. 
 
 
6.12 Molecular mechanism involved in cholesterol (lipid) biosynthesis which may be used to 
enhance secretory productivity of CHO-S cells 
The big question which defines the aim of this research is whether cholesterol biosynthesis 
manipulation can be used to control and channel increased productivity in CHO-S secretory 
machinery.  
Firstly, to address this curiosity, we review the role of cholesterol/lipid biosynthesis in membrane 
secretion and unravel how some key players of the biosynthesis pathway modulate signalling within 
the ER to achieve biochemical conformation of their functions.  The secretion of proteins by 
mammalian cells is a complex pathway involving an initial polypeptide translocation from the cytosol 
into the lumen of the endoplasmic reticulum (ER), where folding and assembling happen before being 
targeted to their final destination. Fourn et al., (2014 ) had reported, that for cells to reach a 
consistent and high-yield production of recombinant proteins, there is the need to identify the 




translational protein processing and secretion machineries. Although recent studies have reported 
that the bioengineering of host cell lines may improve the modification or the secretion of 
heterologous proteins and of other therapeutics, the molecular mechanisms by which these ER 
proteins may improve protein secretion and their ability to act on various recombinant proteins have 
not been studied systematically (Fourn et al., 2014).  
 
A review by Fagone & Jackowski, (2009) reported on the role the ER, which together with the Golgi 
apparatus, is a major site of de-novo bulk membrane lipid synthesis and how they constitute the 
endomembrane compartment, which is a major site of lipid biosynthesis in eukaryotic cells. Lipid 
(including cholesterol) biosynthesis is highly conserved in all the eukaryotes and is needed to build 
new membranes and maintain active signalling.  TM7SF2/DHCR7 genes transcribe for C14-SR, 
involved in cholesterol biosynthesis. By overexpressing these sterol reductases, what we have done, 
was to alter key players of the cholesterol biosynthesis pathway, exploiting its over-expression 
capacity, such that it would lead to an expansion of the ER membrane capacity which is speculated, 
to result, in turn, to an increased cell growth and productivity. According to Snapp et al., (2003), high 
abundance of transmembrane proteins in the ER can induce extensive membrane growth, whereas 
low expression does not alter ER morphology.  
 
From the literature an awareness into the functional role of TM7SF2 and DHCR7 had been 
established. Zwerger et al., (2010) had suggested from its findings that the presence of wild-type 
TM7SF2 and DHCR7 as well as mutant LBR might alter certain membrane properties as the 
overexpression of the wild-type forms of TM7SF2 and DHCR7 was observed to have mimicked the 
phenotype observed for mutant LBR. They had found, that even fully functional proteins can critically 
affect the ER and NE morphology. However, the molecular mechanism that leads to the remarkable 
membrane extension, as reported, remains elusive. LBR, which was the main focus in the previously 
reported study, is not an SREBP-2 target gene unlike TM7SF2 and DHCR7.   
 
Some studies have suggested that this may be due to LBR being constitutive, whereas TM7SF2 
encodes the inducible sterol Delta (14)-reductase activity. Further, the molecular mechanism of 
TM7SF2 and DHCR7 overexpression may be observed in the SREBP cascade signalling mechanism 
during cholesterol biosynthesis. SREBPs are weak activators and require additional transcription 




to up regulate cholesterol synthesis genes, SREBP-1c is responsible for the regulation of genes 
involved in FA and TG synthesis pathways (Horton et al., 2002). SREBP-2 however is the main 
transcription factor responsible for regulating the cholesterol biosynthetic pathways (Sato 2010). 
TM7SF2 is responsible for cholesterol biosynthesis and is regulated by SREBP-2 (Schiavoni et al., 
2010).  
 
Therefore, cholesterol metabolism are controlled in a coordinated manner by SREBP. A review by 
Sharpe and Brown (2013), reported that although nearly all the genes encoding cholesterol synthesis 
enzymes are SREBP targets, a notable exception is the LBR, a protein of the inner nuclear membrane 
mainly involved in heterochromatin organisation, but also possessing sterol Delta (14)-reductase 
activity. It is interesting how regulating cholesterol synthesis in cells underpins cholesterol 
homeostasis of the whole organism, and forms the basis of successful therapies for treating human 
disease. As such, investigation of the SREBP control and interaction with DHCR7 and TM7SF2 should 


















6.13 Future work and Directions 
 
Although the outcome from this work suggests that the overexpression of either YFP-TM7SF2 or YFP-
DHCR7 protein can result in the generation of CHO cells that give transient enhanced yields of bio 
therapeutic proteins, much further work needs to be undertaken to confirm this and determine the 
mechanism(s) by which this effect is impacted on the cell. It is clear that there are many opportunities 
that could be explored in this area while improving on current engineering strategies by engineering 
different parts of the protein secretion pathway through knowledge of the flux through the secretory 
pathway for improvement of heterologous protein production. For instance comparative analysis of 
‘omics data gathered under specific physiological conditions has revealed differentially regulated 
molecular mechanisms responsible for desirable phenotypes in isogenic clone populations and 
guided the design of improved cell factories (Ley et al., 2015). 
 
Literature reports show that the process of clonal cell line generation has inherent pitfalls as random 
integration of the experimental vector/transgene can result in various genetic phenotypes such as 
intensity of expression potentially due to insertional mutagenesis and/or copy number variation 
(Griffith 2015).  While absolute care was used during the generation of the clonal cells, further 
investigation may be carried out to get a better and clearer understanding on the cellular machinery 
of clones, such as clone 10, 11 and 7 of TM7SF2 engineered cells and determine if selective pressure 
in identifying clones resulted in their isolation while also carrying out further studies on the influence 
of transient expression of recombinant proteins such as EPO and etanercept on the clonal cell lines. 
Further work determining the locus of integration, the transcript and protein amounts of TM7SF2 in 
the different cell lines and the half-life of these, how the amounts changes throughout culture and 
with extended passage number (the stability) and obtaining a more precise measurement on the 
volume and amount of ER could be investigated. 
 
It would also be of interest to investigate the influence of the over-expression of these molecules on 
general metabolism and lipid metabolism of the CHO cells to see how each clone impacts growth by 
studies that involve the molecular mechanisms of genome dynamics with reference to cell 
proliferation. Growth being a dynamic process results from cells accumulating mass. While the 
growth rates of clones investigated are related and proportional to their respective RNA and protein 




and clones. Heterogeneous protein production has been reported to often result in a decrease in the 
maximal specific growth rate while stating that it is obvious to expect some changes in heterologous 
protein production during prolonged growth (Krogh, 2009).            
 
While this study has demonstrated recombinant protein productivity and biomass-influenced 
generation using stable batch cultures of engineered CHO-S cells, it would be interesting to 
investigate whether the specific effect of engineering the cells is maintained at large scale production 
in the fermenters and during fed-batch culture. We have showed that by overexpressing TM7SF2 and 
DHCR7 more EPO and etanercept could be generated (as determined by western blot) when 
compared to stable GFP and the ocDNA3.1Hygro control cells.  However, questions such as whether 
these are reproducible in large scale batch and fed-batch fermenters remain, as it is known that some 
choices of cell type may also have influences on the subsequent downstream processing (Hansen et 
al., 2017). The makeup of the CHO-S model may have also contributed to the expression profiles 
observed for both parental pools and clones of TM7SF2 and DHCR7 engineered cells. Going forward 
therefore, it would be interesting to analyse other CHO cell lines as reported in literature, that they 
respond differentially to process platforms further downstream (media, feeding strategy, bioreactor 
conditions, purification, etc).  
 
A future direction for this project would be the genetic manipulation of the host cell lines by co-
overexpression of gene(s) which promote protein secretion, for example co-expressing TM7SF2, 
DHCR7, TMS1, a J domain protein, localized in ER lumen and is induced by heat stress Sterol C5 
desaturase (SC5D) while down-regulating processes that hinder production, for example, Follicle 
Stimulating Hormone (FSH), Cholesterol 7α-hydroxylase (CYP7A1). During the project there was not 
enough time to generate an inducible multi-gene vector cassette system, an aspect of great interest. 
With the manipulation of multiple genes simultaneously using either constructive or regulatable 
promoters, we can control the expression of exogenous gene and investigate cells during gene 
silencing by transient knockdown of gene expression while also expressing the DHCR7 and TM7SF2 
genes.  
 
The role or impacts of the proteins over-expressed in this study on lipid biosynthesis and in driving 
ER expansion and changes to the lipid nature of the ER and other membranous structures was not 




signalling pathways in response to ER expansion (Madeline et al., 2018). Therefore, it would be 
important to look into the influence that engineering of the two proteins investigated here have on 
lipid biosynthesis by determining any impact on the lipids present in the cell upon over-expression 
using methods to determine lipids and the study of lipidomics. A study investigating CHO cell lipids 
has been reported and used mass spectrometry to determine the lipid profile of industrially relevant 
CHO cells. Whether any ER expansion actually does occur upon overexpression of the target proteins 
could then be related to impacts on lipid biosynthesis.  
 
Data from this research suggests that the overexpression of the two proteins influences recombinant 
protein production, the mechanism by which this occurs, as described above, was not determined. 
In addition to determining if the ER had expanded, investigation of the contents of the ER could be 
investigated. For example, if the ER was expanded, was this just the total ER membrane space or was 
there also an increase in the total amount of ER machinery (e.g all the chaperones and proteins within 
the ER were also increased in amounts) or was any impact restricted to just the membrane 
component of the ER. A further level of investigation could be to investigate if there was any impact 
on vesicle transport or other organelles in the secretory pathway, including the Golgi. As part of this, 
it would be interesting to determine if there was any impact on post-translational glycosylation of 
recombinant proteins and the recombinant product characteristics across different engineered cells. 
 
There are limitations identified in this work. For validation studies, the need to analyse recombinant 
protein secretion levels along with a loading control is crucial. Although protein samples were 
quantified using Bradford assay for equal loading on SDS PAGE gel, a loading controls generally 
conveys numerous benefits particularly in relation to quality. Issues such as edge effect when 
proteins in outer lanes drift towards the centre can be removed through the use of a loading control. 
Loading controls can also be used to minimize the impact of erratic protein expression levels. In any 
situation in which proteins may be affected by either loading or protein transfer errors. Therefore ,it 
is of essence that this is considered for future work In future, loading controls such as Beta-actin 
Tubulins (Alpha tubulin and Beta tubulin), Lamin B1, Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) among others may be considered for use. Also enzyme quantification assays used in this 
work can be improved. Apart from western blots, Bradford assay and densitometry, it might be quite 
useful to investigate protein concentration using ELISA (enzyme-linked immunosorbent assay), in 




an enzyme. This research could equally benefit from other quantification methods for EPO and 
etanercept, and these include measurement of Ultraviolet (UV) absorbance at 280 nm, Bicinchoninic 

























6.14   General Conclusions 
Overall, findings from this project demonstrate how TM7SF2 and DHCR7 overexpression in CHO-S 
cells can be beneficial in the specific productivity capacity of recombinant proteins and therapeutic 
agents. By overexpressing TM7SF2 and DHCR7, two sterol reductases of cholesterol biosynthesis 
with altered signal expression levels, we have maintained an unusual expression levels of these 
proteins as they influence CHO-S cellular growth when expressed with GFP and pcDNA3.1Hygro 
stably expressing cells and although densitometry data for western blots suggest there might have 
been some  increase in EPO and etanercept expression levels in lipid engineered CHO-S cells, these 
are not considered statistically significant at a set probability value less 0.05 (p ˂ 0.05). Given all 
functional validation and cytological analysis, it is not known whether, coordinated lipid 
biosynthesis has actually resulted in an expansive ER membrane system. Generation of different 
clones with beneficial phenotype suggests that the effect of overexpression of TM7SF2 and DHCR7 
may be influential towards ER expansion.  
 
This project has shown that: 
1. Transient and stable overexpression of TM7SF2 and DHCR7 tagged with YFP were achieved in 
the commercial CHO-S host cell line.  
YFP reporter gene tagged to the N-terminal of TM7SF2 and DHCR7 allowed for the cellular 
monitoring of YFP signal of proteins both transiently and stably. However, the localization 
studies of TM7SF2 and DHCR7 was not confirmed to be confined to the ER. Although in the 
literature which informed this research, Zwerger et al., (2010) had hypothesized that the related 
sterol reductases TM7SF2 and DHCR7 induce a comparable phenotype and that two proteins 
are predicted to reside in the cytoplasm. 
 
2. Fluorescence microscopy of both transiently and stably expressing TM7SF2 and DHCR7 YFP CHO-
S cells suggests that both proteins are mainly localised to the ER. 
Functional validation studies showed that clones exhibit different phenotypic expression levels 
such as cell viability, cell densities which was observed when growth profiling was carried out 
on cells while protein yield was confirmed using western blotting techniques, when assayed for, 
along with GFP and pcDNA3.1Hygro stable cells as positive and negative channels respectively. 




clones generated for TM7SF2, clones 3, 4, 7, 8, 10 and 11 were selected as top expressers of 
TM7SF2 whereas of seven generated DHCR7 clones, clones 4, 6 and 7 were selected as top 
expressers of DHCR7. Data could have benefitted from a loading control on western bots images 
to confirm equal amounts of proteins were loaded, although all western blots of lysates were 
first quantified by Bradford assay for the purpose of equal loading for western analysis. 
 
 
3. Overexpression of these cholesterol biosynthesis proteins (TM7SF2 and DHCR7) did not 
negatively impact upon CHO-S cell growth or culture viability although no very high expressing 
pools or clones were isolated.  
Stable overexpression of TM7SF2 and DHCR7 in CHO-S cells favours beneficial phenotypes as 
increase in cellular growth and recombinant protein yield was observed. These findings have 
been observed at culture temperature at 37°C and may not be same in event of a temperature 
shift. Therefore, stable over-expression of TM7SF2 and DHCR7 have shown increased 
proliferation and expression levels of recombinant proteins when cultured by 37°C. 
 
4. A TM7SF2 pool (pool B) with higher expression levels than other pools gave increased transient 
expression of EPO and etanercept amounts compared to a pool with lower expression (pool A). 
On productivity, pools and clones showed various amount of EPO and etanercept expression 
levels as there was a significant out performance, in many cases, over pcDNA3.1Hygro. 
Interestingly, high expresser clones maintained a similar pattern of recombinant EPO and 
etanercept expresser levels according to their secretory capacity as confirmed by the TM7SF2 
expression levels. TM7SF2 Clone 11 remained the highest expresser of EPO and etanercept 
whereas DHCR7 Clone 7 expressed highest amount of EPO and etanercept. However, data could 
have benefitted from more quantification methods to ascertain how much of recombinant 
protein materials were generated in relation to controls. 
 
5. Clones of YFP-DHCR7 showed more ‘even’ expression between cells and variable EPO and 
etanercept expression.  
It is not clear if cells with increased recombinant protein expression do so because of over-
expression of DHCR7 or is due to clonal variation although there appears to be some relationship 





6. Further work should be undertaken to determine if overexpression of these proteins impacts 
cholesterol biosynthesis and the secretory capacity of CHO-S cells as well as explore more 
quantification assays to establish these findings. 
 
6.15.1      Concluding Remarks 
Advances in systems and synthetic biology applications have made it possible to undertake findings 
that cut across use for industrial and academic applications. The scope of this work has highlighted 
the possibility of engineering the protein secretory pathway of the ER to improve heterologous 
protein production by controlled manipulation of desired pathways. The most promising direction 
for this work is the genetic manipulation of host cell lines, re-engineering its secretory system. The 
data reported here provide a better understanding of the effects of overexpression of TM7SF2 and 
DHCR7 on CHO-S cells. Our findings suggest that the overexpression of proteins that impact upon 
cholesterol biosynthesis can be manipulated for the expansion CHO secretory capacity. By stably 
overexpressing TM7SF2 and DHCR7, we generated the parental pools of TM7SF2 engineered cells 
as well as DHCR7 engineered cells. Due to the highly reported heterogeneity of CHO cells, we 
carefully identified the high clonal producers of TM7SF2 and DHCR7. Clones 3, 4, 7,8,10 and 11 as 
the top expressers of TM7SF2 while clones 4, 6 and 7 were considered top producers. When we 
monitored the growth rate and viability of the engineered cells over a 10 day period, with control, 
the clones showed increased growth rates and higher viabilities and do not show any toxicity to the 
cells when compared to controls. Each clone displayed adjudged peculiarity in presentation of 
nucleus during confocal imaging suggesting that they differ in phenotypes variation that exist 
among the clones. Therefore we have confirmed that CHO-S cells exhibit functional heterogeneity 
and high heritability. It has been successfully demonstrated that by engineering the secretory 
processes of the CHO cell machinery, we produced more transient recombinant EPO and 
etanercept-a difficult-to-express TNFα fusion protein. Interestingly, amounts secreted from the 
extracellular channel correlated with the expression levels of engineered TM7SF2 and DHCR7 cells. 
When the clones were transfected transiently, they produced EPO and etanercept accordingly to 
their expression level. It has been noted, that there were no loading controls presented with 
western blots data and this serve as a limitation to findings. Also, data could have benefitted from 




did not impact upon cell growth behaviour, however transient expression of two model 
recombinant proteins (EPO and etanercept – a TNFR-Fc fusion protein) that are difficult to express 



























7.1 Schematics of commercial vectors used in the cloning and expression of 
Transmembrane7superfamily member 2 (TM7SF2) and 7-DeHydroCholesterol 
Reductase (DHCR7) 
                   
  
 
       
Schematic 7.1        Vectors used in the transient and stable expression of TM7SF2 and DHCR7  
(A)  Vector   map of pcDNA3.1Hygro used in the stable expression of TM7SF2 and DHCR7. 






7.2      YFP-Tagged Sequence for TM7SF2 and DHCR7                                                                                                                      
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